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Abbreviations 
AMR Antimicrobial Resistance 
ARG 
AST 
Antimicrobial Resistance Gene 
Antibiotic Susceptibility Testing 
BCB Blood Culture Bottle 
BD Becton Dickinson 
CA-MRSA Community-acquired MRSA  
CCs Clonal Complexes 
CFU Colony-Forming Unit 
CgMLST Core genome MLST  
CoNS Coagulase Negative Staphylococci 
EBJIS European bone and joint infection society 
ESR Erythrocyte Sedimentation Level 
FDA Food and Drug Administration 
HA-MRSA Healthcare-acquired MRSA 
HGT Horizontal Gene Transfer  
IDSA Infectious Diseases Society of America  
LA-MRSA Livestock-associated MRSA  
MALDI-TOF Matrix-assisted laser desorption/ionization-time of flight mass spectrometer  
MGEs Mobile Genetic Elements  
MLST Multilocus Sequence Typing  
mNGS Metagenomics-Next Generation Sequencing 
MRSA Methicillin resistant Staphylococcus aureus 
MSIS Musculoskeletal Infection Society 
MSSA Methicillin susceptible Staphylococcus aureus 
NGS Next Generation Sequencing 
PCR Polymerase Chain Reaction 
PFGE Pulsed-Field Gel Electrophoresis 
RPM Revolutions Per Minute 
SaPIs Staphylococcal Pathogenicity Islands  
SCC Staphylococcal Cassette Chromosome  
SMg Shotgun-Metagenomics 
STs Sequence Types  
THA Total Hip Arthroplasties 
TKA Total Knee Arthroplasty  
TNF-α Tumor Necrosis Alpha Factor 
TTD Time to Detection 
VFDB Virulence Factor Database  
VFs Virulence Factors  
WBC White Blood Cells 
wgMLST Whole-genome MLST  
WGS Whole Genome sequencing 
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  V 
Summary 
Shotgun-metagenomics (SMg) has a huge potential, particularly in areas where conventional diagnostic 
methods have limitations such as in prosthetic joint infection (PJI). However, the application of 
metagenomic sequencing on periprosthetic joint tissue (PJT) specimens is often challenged by the low 
bacterial load in addition to a high level of inhibitor and contaminant host DNA, limiting the potential 
that this emerging approach can offer in clinical diagnostics. The main objective of this Ph.D. project 
was to explore the use of SMg in clinical diagnostics of PJI directly from blood culture bottles (BCBs) 
inoculated with PJT specimens. 
 
In paper I, we assessed the use of a BacT/Alert® Virtuo blood culture system for culturing periprosthetic 
tissue (PJT) specimens. We showed that the blood culture bottle (BCB) method was found to detect a 
wider range of bacteria more rapidly than the conventional microbiological method. Our findings show 
that the use of BCB is a convenient approach to be used in the routine in the clinics for diagnosis of the 
PJI cases. 
 
In paper II, we developed a proof of concept study with the aim of evaluating the use of SMg on BCBs 
inoculated with PJT for pathogen identification for diagnosis of PJI. For this purpose, we developed a 
method for the preparation of high-quality bacterial DNA from PJT for downstream SMg, established a 
bioinformatics pipeline, and compared SMg results with conventional culture method results. Our DNA 
preparation method resulted in high quality microbial DNA from all samples, both with and without 
human DNA depletion allowing downstream SMg. All bacteria identified by the culture method were 
also identified by SMg. We obtained an acceptable high number of bacterial reads, genome coverage 
and genome sequencing depth for identification of PJI pathogens 
 
In paper III, we explored further applications of SMg, beyond pathogen identification. SMg from BCBs 
inoculated with PJT, allowed the identification of potential PJI pathogens, and strain-level typing of S. 
aureus. We obtained S. aureus antimicrobial resistance (AMR) and virulence gene profiles from both 
monomicrobial and polymicrobial samples. However, the use of this approach for the detection of AMR 
to help guide clinical antibiotic usage needs to be further elucidated, due to some disagreement between 
the AMR phenotype and genotype. Precise AMR prediction is required for the mainstream adoption of 
SMg into the clinical microbiology laboratory. 
 
In conclusion, these studies present an alternative approach for the application of SMg in PJI diagnosis, 
complementing the currently available tools. Our results might be useful in further validation and 









Infectious diseases remain the leading causes of morbidity and mortality worldwide. In order 
to reduce the burden of infectious diseases, an efficient and accurate diagnosis is important. 
Research into improving all aspects of culture-based methods and new alternative strategies to 
replace or support current microbiological methods is needed, especially when the first-line 
investigation tools present technical limitations, are time consuming and labor intensive. 
Currently, a large number of tests are available. Microbiological methods differ across 
countries, and within countries and institutions using varying criteria and protocols. The most 
efficient diagnostic strategy is likely formed by a combination of conventional and new 
diagnostic strategies.  
 
Basic scientific applied research and emerging genomic technologies have enabled us to start 
exploring the utility of Next-generation sequencing (NGS) into multiple areas in the field of 
diagnostics of infectious diseases. NGS is actively moving from research to the clinical 
setting and has been presented as a tool with the potential to complement or replace the current 
diagnostic methods. It has the potential to change the microbial diagnosis of infectious diseases, 
especially when detection and identification of pathogens can be challenging, such as prosthetic 
joint infection (PJI) diagnosis. The application of NGS and Shotgun metagenomics (SMg) on 
PJI specimens is often challenged by the low bacterial load in addition to high inhibitor and 
contaminant host DNA limiting pathogen recovery.  
 
This project investigates if SMg performed directly from blood culture bottles (BCBs) 
inoculated with periprosthetic joint tissue (PJT) specimens may be a convenient approach for 
overcoming these obstacles. We first established a method for culturing PJT on BCBs, 
continuing with establishing and evaluating a method for the preparation of bacterial DNA 
suitable for SMg directly from BCBs inoculated with PJT specimens and assessed their 
potential for identifying potential causative pathogens. Additionally, the potential of SMg for 
prediction of virulence factors (VFs) and antimicrobial resistance (AMR) determinants in 
Staphylococcus aureus on BCBs with PJT was assessed.  
 
A general introduction is presented as follows: (1) The application of NGS methods for the 
analysis of clinical specimens that can be used for the identification of microorganisms and 
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detection of AMR and VFs in the clinical microbiology laboratory. (2) The microbiological 
diagnosis of PJI since it is the infectious disease model selected for this study. 
1 NGS technology in the clinical microbiology laboratory 
Over the last two decades, advances in sequencing technologies have revolutionized the ability 
to sequence nucleic acids. NGS also known as high-throughput sequencing is the term used to 
describe a number of different modern sequencing technologies whereby billions of nucleic 
acid fragments can be simultaneously and independently sequenced1. These technologies allow 
for sequencing of nucleic acids much more quickly and cheaper than the previously used Sanger 
sequencing, which have led to introducing this emerging technology as a tool in the clinical 
settings with the potential of revolutionizing the clinical laboratory by simplifying and 
improving the clinical diagnostic testing2.  
 
NGS is rapidly finding a variety of applications in both clinical and research laboratories. NGS 
has previously been used in clinical settings as a research tool and currently, it has begun to be 
an affordable alternative to be used in the clinical microbiology laboratory for the diagnosis of 
infectious disease3–5. However, despite the remarkable progress of NGS for improving the 
diagnoses of infectious diseases, the translational gap between NGS and clinical 
implementation remains. There are several challenges to overcome before NGS can deliver its 
potential in the clinical laboratory for patients, clinicians, and society. Therefore, further efforts 
need to be addressed.   
 
1.1 NGS technologies 
There are several NGS technologies commercially available, which are continuously evolving 
and improving. They differ substantially in terms of protocols (engineering and sequencing 
chemistry), output (length of reads, number of sequences), accuracy, and cost6. The unique 
combination of specific technical details differentiates one technology from another and 
determines the type of data produced from each platform. 
 
NGS includes second generation and third generation sequencing methods defined as short-
read (50-400 bp) and long-read (1-100 kb) technologies, respectively7. The most used short 
reads platforms include Illumina (San Diego, CA) and Ion Torrent (Waltham, MA) while for 
long- reads platforms are the single molecule real time sequencing (Pacific Biosciences) and 
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Oxford nanopore sequencing (Oxford, United Kingdom)6,8,9 (Table 1). Choosing among 
available methods depends on the sequencing objectives and involves tradeoffs in accuracy, 
efficiency, and cost 6. Due to differences in methodology and technology between the NGS 
platforms each platform has advantages and disadvantages that should be considered when 
choosing the technology to use in specific sequencing projects and for analyzing sequence data, 
both own and publicly available data10.  
 
Table 1. Comparison of the most used NGS platforms (Modified from6,11) 
Abbreviations: Gb, Gigabytes; bp, base pairs; SE, single-end reads; PE, Pair-end reads; PGM, 
Ion Personal Genome Machine. 
1.1.1 Short-reads sequencing  
In general, the short-read technologies produce billions of nucleotide sequences during each 
run, where each genome is sequenced multiple times in small random pieces to generate very 
large data sets6. Short read sequencing can be divided further into two categories, based on the 
sequencing methodology used, as sequencing by ligation and sequencing by synthesis.  
Sequencing by ligation is a method that uses the mismatch sensitivity of the DNA ligase to 
determine the identity of nucleotides in a given DNA sequence12. Currently, the only 
sequencing by ligation method commercially available is the BGIseq platform, which has been 
developed by the Beijing Genomics Institute (BGI) and has been into the market since 201613. 
This platform uses DNA nanoball technology by cloning single DNA molecules locally on a 
flow cell that produces clonal DNA nanoballs that then undergo sequencing by synthesis14. This 
Sequencing 
generation
Platform Instrument Throughput 
range (Gb) 
Read length (bp)
MiniSeq 1.7–7.5 75 SE/PE - 150 PE
MiSeq 3.3–15 75 - 300 PE
NextSeq 10–120 75 - 150 PE
HiSeq (2500/3000/4000) 10–1500 50 SE/PE - 150 PE
NovaSeq 5000/6000 134-3000 50 -150 PE
PGM 0.08–2 Up to 400
S5 0.6–15 Up to 400
Proton 10–15 Up to 200
PacBio RSII 0.5–1 Up to 60 Kb


















platform has already been used for clinical applications, in reference gene catalog–based human 
gut metagenome studies15. 
 
Sequencing by synthesis includes a group of methodologies that make use of a DNA 
polymerase enzyme to incorporate a single nucleotide or short oligonucleotides (provided either 
one at a time or fluorescently labeled), containing a reversible terminator14. It is the most widely 
adopted NGS technology, with Illumina dominating the sequencing market.  
Illumina sequencing by synthesis 
Illumina has several platforms in the market including iSeq, MiSeq, MiniSeq, NextSeq, HiSeq, 
and NovaSeq. Depending on the specific Illumina platform it may be partitioned into 1 (miSeq), 
2 (HiSeq2500), or 8 (HiSeq2000, HiSeq2500) separate sequencing lanes16. All of them use a 
strategy of bridge amplification on the surface of a flow cell17. Illumina NGS workflows include 
three basic steps: Library preparation, cluster generation, and sequencing. Briefly explained, 
following library preparation (the process that generates a collection of DNA fragments of 
uniform size ready to be sequenced), the DNA templates are hybridized (attached) to a glass 
slide (flow cell) that has patterned clusters of complementary adaptors and then the fragments 
are PCR amplified locally from one end only (single-end read) or from both ends (paired-end 
reads), producing millions to billions of clusters of clonal template DNA fragments that can be 
sequenced simultaneously1. This is followed by sequencing by synthesis which as mentioned 
before, utilizes DNA polymerase to build the complementary DNA utilizing modified 
deoxyribose nucleoside triphosphates (dNTPs) actin as chain terminators (one nucleotide per 
cycle), and then a readout of fluorescently labeled nucleotides determines the nucleotide 
identity1. This process is repeated for the length of the read to generate the sequence output, 
where read lengths are now typically between 75 to 350 bp (see Table 1). 
 
Overall, all second-generation sequencing platforms have the disadvantages inherent to short-
read sequencing platforms. They tend to generate relatively fragmented genome assemblies, 
causing an inability to resolve e.g. repetitive regions and making some types of genetic variants 
challenging to identify. The need for amplification is time consuming and could introduce 
laboratory bias, such as over/underrepresenting certain regions. Therefore, longer reads are 
desired in order to generate closed reference genomes particularly useful when sequencing 
through complex genomic regions such as repeats and phages (very common in bacterial 
genomes). To meet this demand, the so-called third-generation sequencing platforms have been 
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introduced. Third-generation methods are under development and generally are not clinically 
available. 
1.1.2 Long-reads sequencing technology 
New sequencing instruments are currently available for research use, that provide longer 
sequencing reads and are able to read the sequence of a single molecule rather than amplified 
DNA as a template: the PacBio SMRT (single molecule real time) (Menlo Park, California) and 
the Oxford Nanopore (Oxford, United Kingdom).  
Oxford nanopore sequencing 
Oxford Nanopore Technologies (Oxford, United Kingdom) includes the MinION (1 flow cell), 
GridION (5 flow cell capacity), and PromethION (48 flow cell capacity)18. The Oxford 
Nanopore uses a protein pore inserted into a membrane. A current is applied and flows through 
the pore between the 2 sides of the membrane. As the structure (DNA or RNA strand) passes 
through the pore, the current changes and the degree of change correlates with the individual 
base (A, C, G, or T) and also correlates with the methylation status of C; therefore, methylation 
and hydroxymethylation can be detected. Notably, for infectious disease diagnostics, nanopore 
DNA sequencing is orders of magnitude faster than other strategies that use sequence-by-
synthesis methods (used by Illumina). Nanopore sequencing also does not require prior PCR 
amplification, although often this is still performed due to the high baseline sample input 
requirement (>500 ng).  
 
Real-time nanopore sequencing enables real-time analyses, which is particularly interesting for 
the diagnosis of acute infectious diseases since timely diagnostics is essential when treating 
patients. The nanopore approach currently has more sequencing errors, lower throughput, and 
higher per-read costs than other NGS platforms, which may limit its utility1. The clinical 
adoption of these devices has been limited by the rapid pace of improvements to the platform, 
which can delay clinical validation efforts requiring standardized instruments and locked-down 
protocols19. Overall, long-read approaches currently tend to have lower throughput and higher 
total costs, limiting their widespread implementation. For these reasons, short-read 
technologies are more frequently used. 
1.2 NGS basic workflow 
Regardless of the differences in NGS methods and in the application, all NGS technologies are 
based on the same general process. Conceptually, this approach involves a series of steps 
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including the work carried out in the microbiology laboratory (wet lab) and in the computational 
laboratory (dry lab) (Figure 1). Wet lab analyses involve clinical sample processing including 
DNA isolation (and/or RNA, followed by reverse transcription), library preparation, and 
sequencing steps. It is followed by the dry lab consisting of the bioinformatic data analysis, 
where the sequences are analyzed commonly in the context of a reference database, to 




Figure 1. Next generation sequencing basic workflow. 
1.2.1 Sample collection 
Potential samples for NGS analysis include clinical specimens such as e.g. tissue, body fluids, 
and swabs1. Sample collection and preservation protocols can affect both the quality and 
accuracy of the NGS data. Protocols for sample collection and storage must be optimized and 
internally validated for different sample types. The length of time between sample collection 
and freezing for storage, as well as the freeze-thaw cycles used until DNA extraction, can affect 
the sample microbiological composition21.  
1.2.2 DNA extraction 
DNA extraction is a crucial step during the NGS workflow to obtain reliable and quality results. 
The DNA extraction protocol used is highly dependent on the sample type1. DNA extraction is 
a procedure used to isolate DNA from cell membranes, proteins, and other cellular components 
by using physical and/or chemical methods22. The main features that are required in DNA 
extraction methods include good quantity and quality of DNA, removal of impurities and 
inhibitors, such as RNA and proteins, and high–throughput processing 23. DNA extraction 
involves lysing the cells and solubilizing DNA, followed by chemical or enzymatic methods to 
















based on their purification strategies: organic extraction (phenol-chloroform method), 
nonorganic method (salting out and proteinase K treatment), solid-phase DNA extraction 
methods (silica-gel membrane), and ionic chelating resins (Chelex). Different strategies have 
been developed using some of these basic DNA isolation principles (or a combination of them) 
depending on the type of sample source. Currently, there are manual methods as well as 
commercially available kits that are used for DNA extraction22.  
 
Assessing the quality and yield of DNA 
Estimating nucleic acid quality for library preparation is indispensable for the success of next-
generation sequencing (NGS) applications. A broad variety of DNA sample types and 
extraction methods may introduce inhibitors that can negatively affect the sequencing process. 
Therefore, the quality and yield of DNA have to be assessed after the DNA extraction process, 
to avoid poor sequencing performance due to degradation, fragmentation, or contamination. 
 
The origin of the sample, from which DNA is extracted, might influence the quantity and 
quality of the nucleic acid. Input DNA concentrations for SMg can be <100 pg or up to six 
orders of magnitude higher1. Commonly, the quality and yield of DNA are assessed by 
spectrophotometry or by gel electrophoresis. Illumina recommends UV spectrophotometry for 
purity assessment and fluorometric based methods such as Qubit or Pico/RiboGreen for nucleic 
acid quantitation. (http://www.illumina.com). Gel electrophoresis shows the DNA integrity, 
e.g. a ladder or smear below a band of interest may indicate sheared or degraded DNA. 
Furthermore, contaminating RNA can be detected on an agarose gel (since RNA has a lower 
molecular weight than genomic DNA). Other impurities, such as detergents or proteins, can be 
also be detected (smearing of DNA bands)24. 
1.2.3 Library preparation 
After DNA extraction, the library preparation is the first step of the sequencing process. This 
prepares the DNA to be sequenced into a form that is compatible with the sequencing system 
to be used, using specific protocols. Libraries allow optimal use of the output capacity of high-
throughput sequencers and increase the number of samples that can be analyzed in a single 
sequencing run by adding an additional molecular barcode sequence to the adapters 
(multiplexing)20. There are several library preparation kits available commercially from 




A library is a collection of DNA fragments of uniform size ready to be sequenced. Library 
preparation is performed by tagmentation (DNA recombination) of sequencing adapters to 
DNA (e.g., Illumina’s Nextera preparation)26 or ligation of the adapter to sheared DNA27 (used 
for the rest of Illumina preparations different to Nextera)1. Libraries are tagged with a library-
specific DNA sequence (barcode) allowing multiple libraries to be pooled together and 
sequenced simultaneously. The library preparation process usually includes DNA shearing into 
fragments of ~500bp or less, either mechanically or enzymatically, followed by ligation of 
DNA fragments to platform specific oligonucleotide adapters and barcodes/indexes, and library 
amplification1,6. Depending on the platform, the amplification method can vary. There are two 




Figure 2. Schematic presentation of the workflow of library preparation. 
 
The basic principle in EmPCR is dilution and compartmentalization of template molecules in a 
reaction mixture consisting of oil-aqueous droplets. PCR is performed within these droplets to 
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create beads with copies of the same template sequence. The beads are attached to a glass 
slide28. This type of amplification method is used by Ion Torrent platforms. On the other hand, 
Illumina platforms rely on a unique isothermal bridge amplification reaction, that occurs on the 
surface of the flow cell (Immobilized template) with immediately adjacent primers to form 
clusters (Figure 2). 
1.2.4 Sequencing 
After the library preparation, the sequencing follows, using one of the sequencing technologies 
described above. Then the reads obtained can be sorted by barcodes to get read data for each 
sample individually. Illumina reads are commonly 25-250 nucleotides long. Reads can be 
separated, known as single reads (SE), which involves sequencing DNA from only one end or 




Figure 3. Single-end and pair-end reads. 
1.2.5 Bioinformatic analyses 
Bioinformatic analyses focus on the application of concepts, methods, tools, and software to 
analyze, integrate, and interpret biological data. Regardless of the NGS platform and the 
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application, the overall goal of each analysis is the same, therefore there are a few common 
steps for all the NGS approaches. However, each platform has its particularities and 
specificities29. Overall, all the bioinformatic workflows start with the preprocessing and quality 
assessment of the raw reads which is common for all the NGS applications, followed by the 
data analysis and interpretation, which can be directed onto many different paths depending on 
the needs of the user. The most common tools used for NGS analyses are listed in Table 2. 
 




































Identification of bacteria at the species or 
clonal level.
Prediction of plasmid sequences.
Data quality Check
Application 
Phylogenetic trees can be used to analyze 
and visualize SNP differences between 
Virulence
Resistance
Prediction of  resistance genes in WGS 
data.
Prediction of virulence factors in bacteria.
Annotation
Genome annotation includes identification 
of open reading frames and matching the 
identified segment to a database of known 
Assembly
Consist on using computer algorithms to 
align WGS reads to form longer DNA 
sequences known as contigs, and order the 
contigs into longer sequences called 
Phylogeny
Adapter sequences should be removed 
from reads because they interfer with 
downstream analysis.
Read mapping is the process of aligning 
reads to a reference genome.
Trimming
Alignment and read mapping
Quality of the raw sequencing reads is 
evaluated, to remove, correct or trim the 
reads not meeting the standards.
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1.3 Application of NGS in clinical microbiology 
The field of clinical microbiology comprises both diagnostic microbiology (identification of 
pathogens from clinical samples to species level and identification of their AMR patterns) and 
public health microbiology (surveillance and monitoring of infectious disease outbreaks in the 
community)1. NGS is rapidly finding a variety of applications in both clinical laboratories and 
research and it has been transitioning from research tools to diagnostic methods becoming more 
integrated into clinical microbiology laboratories.  
 
The most common NGS approaches used in clinical microbiology include: whole-genome 
sequencing (WGS), targeted NGS methods (including amplification or probe hybridization), 
and metagenomic next generation sequencing (mNGS)30,31. The application of NGS in clinical 
settings is tremendous. They have successfully been used in a numerous range of clinical 
applications such as the diagnosis of infectious diseases4, outbreak tracking and management32–
35, characterization and surveillance of pathogens36,37, rapid identification of bacteria using the 
16S-23S rRNA region, taxonomy11,38,39, pathogen discovery40, tracking the transmission of 
zoonotic microorganisms, microbiome studies, and metagenomics approaches on clinical 
samples among many others11. 
 
Whole genome sequencing analyses from cultured isolates have been extensively used for the 
characterization of pathogens, including species, strain type, antibiotic resistance, virulence, 
and other information for outbreak and case management41. However, this culture-isolate 
dependent approach is out of the scope of this study. Several reviews describe the different 
applications of the NGS in clinical microbiology in more detail11,42. 
1.3.1 Metagenomic approaches 
Metagenomic approaches characterize all nucleic acid (DNA/RNA) present in a sample, which 
may contain mixed populations of microorganisms, and assigning these to their reference 
genomes to understand which microbes are present and in what proportions. The ability to 
sequence and identify nucleic acids from multiple different taxa for metagenomic analysis 
makes this a powerful new platform that can simultaneously identify genetic material from 
entirely different kingdoms of organisms. This approach has been used for characterizing 
several niches, from the environment to the microbiome. In the clinics, the study of 
metagenomics primarily was incorporated into the study of infectious disease diagnostics, 
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microbiome analysis, and oncological applications19. Nowadays, in clinical microbiology 
laboratories, these methods have a huge potential especially for the identification of 
microorganisms.  
 
There are two general classes of metagenomic approaches that can be used for the identification 
of microorganisms in the clinical microbiology laboratory: targeted amplicon sequencing, 
usually based on amplification and sequencing of a phylogenetic marker and shotgun 
metagenomics (SMg), sequencing the genetic material present within a sample directly without 
amplification43. When applied to clinical samples, these approaches have been referred to as 
“metagenomic sequencing” or Metagenomic Next Generation sequencing (mNGS)9,44. 
However, not all sources define the amplicon sequencing approach as metagenomics, as many 
researchers prefer to use these terms for the shotgun sequencing approaches44 since they 
consider that even universal or broad-range PCR methods are not sufficiently broad to be 








Targeted amplicon sequencing is a widely used approach that provides only taxonomical 
classification for a broad range of pathogens. DNA is extracted from a clinical sample and 
subjected to PCR amplification using an appropriate set of PCR primers that targets a 
taxonomically informative gene such as the ribosomal RNA (rRNA) genes that are universally 
conserved among bacteria (16S or 23S rRNA) or fungi and parasites (18S rRNA, 28S rRNA or 
internal transcribed spacer (ITS). The other alternative is the use of other sets of primers that 
can be designed to target a defined set of pathogens and/or genes and used for multiplex reverse 
transcription PCR or PCR (multiplexed amplicon PCR). Amplicons from separate samples are 
then given molecular barcodes, pooled together, and sequenced. Following sequencing, raw 
data is analyzed with bioinformatics tools which include trimming, error correction, and 
comparison to a reference database. Subsequently, the reads are assigned to a phylogenetic 
rank, a taxonomy profile can be generated, by the alignment of consensus sequences to an 
appropriate reference database45, enable to determine which microorganisms are present in the 
sample and their relative abundance allowing that pathogen(s) may be identified to the genus 
or species level.  
 
The 16S rRNA gene is the most widely used taxonomically informative gene used in NGS 
methods. This gene is approximately 1500 base pairs (bp) in size and its genetic structure 
comprises nine highly conserved and nine hypervariable regions (V1–V9). The conserved 
regions can serve as universal primer binding sites for the PCR amplification of gene fragments, 
whereas the hypervariable regions contain considerable sequence diversity, useful for 
prokaryotic identification purpose46. By comparing these hypervariable regions to 16S rRNA 
gene sequences of designated prokaryotic type strains available on large public databases, 
researchers can generate accurate identification of the prokaryotic taxa present within clinical 
samples.  
 
The benefits of targeted methods over SMg include: (i) increased sensitivity for the 
microorganism of interest since it has inherent an amplification step9. (ii) Decreased cost due 
to the possibility of extensive multiplexing of samples, which allows researchers to process 
hundreds of samples and analyze millions of PCR amplicons in a single NGS-run. (ii) Since 
sequencing is restricted only to the region of interest of a single gene, lower sequencing depths 





Among the limitations for using targeted amplicon metagenomics are: (i) it does not provide 
genetic information beyond species identification, such as the presence of AMR genes or VF 
genes unless these regions are specifically included in the targeted sequencing reaction3,44. (ii) 
This approach also requires a hypothesis about which organism group (bacterial or fungal) is 
suspected to ensure that appropriate amplification targets are chosen44. (iii) Universal primers 
used to target the 16S rRNA gene for polymicrobial may also be a problem. If polymicrobial 
populations are present when using 16S sequencing, multiple base-calls will be made per 
nucleotide, producing a mixed nucleotide chromatogram that cannot be interpreted. (iv) PCR 
amplification bias can cause preferential amplification of some targets, which may affect the 
proportions of the taxa identified in the clinical specimen44. 
1.3.2 SMg in clinical microbiology 
The application of WGS on infectious agents in clinical samples to obtain the complete genome 
sequences are emerging and are currently known as Shotgun-Metagenomics (SMg)47. When 
SMg is directly applied to  the clinical specimens it is known as “clinical metagenomics”47.  
It is an alternative approach to characterizing microbial communities, where all nucleic acids 
present in a specimen, including those derived from host and from any microorganism(s), are 
extracted and sheared into small fragments that are independently sequenced in parallel47,48, 
producing relative abundance information for all genes detected. This method may not only 
identify microorganisms but also provides information on the types of genes presents within a 
clinical sample, eventually inferring functional characterization.  
 
Currently, there are four main potential applications of SMg for pathogen characterization in 
the diagnostic microbiology laboratory: identification, molecular typing, antimicrobial 
resistance detection, and virulence gene detection. SMg has the possibility to be used as a single 
and rapid comprehensive test for potential pathogens49; has the advantage of not being limited 
to certain pathogens50. It is a promising approach to opening huge opportunities for detecting, 
identifying, and characterizing all potential pathogens in a sample, even if the sample present 
more than one bacterium (polymicrobial) 50,51.  
 
Kumeren et al.52 describe a systematic review and meta-analysis  including  studies that use 
metagenomic sequencing as a clinical diagnostic tool for infectious diseases. To date, several 
studies have provided evidence of the potential and successful applications of SMg as a 
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diagnostic tool for infectious diseases in a variety of clinical specimens, including urine4,5,53, 
blood samples54–56, respiratory secretions, spiked and clinical samples for bacterial (e.g. 
Mycobacterium tuberculosis and viral pathogens57–60, Cerebrospinal fluid59,61, intraocular fluid 
62,63, cerebrospinal fluid59,61,64, orthopedic device, sonication fluid65–71 and bone and joint65–72. 
Several reviews have summarized the advances, limitations, and challenges in the field19,31,73,74.  
1.3.2.1 Detection of AMR and virulence-associated genes  
The sequencing data provided by SMg may provide clinically useful information beyond the 
identification of a potential pathogen75.  If the SMg depth of coverage of the microorganism is 
sufficiently high, valuable functional information such as antibiotic resistance and virulence-
associated genes can be revealed63. SMg can identify previously described and potentially novel 
antimicrobial resistance determinants, although determinants on mobile genetic elements 
including plasmids are considered a greater challenge. 
 
SMg-based detection of AMR can be further applied to predict phenotypic antimicrobial 
susceptibility testing (AST). There are two prediction models used to correlate AMR detection 
with AST phenotype: (i) rule-based approaches using databases of AMR loci and (ii) model 
based approaches using machine learning and/or statistical models76. The rule-based approach 
is based on the detection of antimicrobial resistance genes or k-mers (small portions of genes). 
Detection can be done using either raw reads or assembled genomes. It is done using software 
that searches databases of AMR. Resistance profiles from raw reads obviate the need for 
assembly and can, therefore, reduce the time to results. However, because of sequencing errors 
present in individual reads or DNA contamination from other organisms, false positives may 
be introduced77. In the model-based approaches, the classifier is trained based on a set of 
genomes with known phenotypes without linking individual AMR genes. The models can use 
k-mers, raw reads, contigs, or assemblies to predict phenotypic results. Most of the studies 
predicting AST from NGS have used Illumina platforms and  the rule-based approach76. 
 
The other main potential use of SMg for organism characterization is the detection of genetic 
markers of virulence78. The pathogenesis of bacterial pathogens is determined by the virulence 
factors (VFs) that enable them to cause infection. The potential horizontal transfer of VFs 
between different strains or species of bacteria makes the emergence of new pathotypes of 
bacteria almost inevitable. Comprehensive characterization of the VFs carried by the new 
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pathotypes of emerging bacterial pathogens is critical for the effective prevention and control 
of infectious diseases.  
 
Databases for ARGs and VFs play an essential role in studying the resistome and the virulome 
from (a) microorganism(s) in clinical samples. A critical first step in many such approaches is 
the construction and curation of databases. There are several AMR databases that have been 
developed, among them: ResFinder79, the Comprehensive Antimicrobial Resistance Database 
(CARD)80,81, Basic Local Alignment Search Tool (BLAST), Antibiotic Resistance Gene-
ANNOTation, short read sequencing typing, and National Center for Biotechnology 
Information’s (NCBI) National Database of Antibiotic Resistant Organisms82. However, they 
were not developed for clinical purposes and therefore they have a certain degree of restriction 
in clinical diagnosis. Similarly, there are comprehensive databases available to predict the VFs 
present in bacteria, such as VirulentPred 83, Virulent-GO84, and the virulence factor database 
(VFDB)85,86, which provide knowledge of VFs and serve as a comprehensive repository of 
bacterial pathogenesis knowledge for the scientific community86.  
1.3.2.2 Implementation of SMg in the microbiology laboratory 
The use of any diagnostic test in the clinical laboratory requires analytical and clinical 
validation, as well as the careful monitoring and documentation of quality control and 
proficiency testing87. Currently, the FDA has provided general guidelines for clinical validation 
of NGS infectious disease testing19. However, so far, there are no FDA-approved SMg 
approaches for diagnosing infectious diseases. For SMg to be extensively implemented in the 
clinical microbiology laboratory, further work is needed in terms of quality control and 
validation. The base is to apply what is learned from the application of NGS in other areas and 
adapt that knowledge to the microbiological diagnosis, which present unique challenges, such 
as highly variable specimen complexity and quality, and the broad genetic diversity of 
microorganisms, among others. 
 
Among the requirements suggested for NGS test establishment in clinical laboratory87, the 
following aspects are included: test validation, quality control procedures (to assure and 
maintain accurate test results), independent assessment of test performance through proficiency 
testing or alternative approaches, and reference materials88. To date, most published studies are 
retrospective analyses of curated samples normally in sample sizes that are not optimal for test 
validation (case studies). They have been done using individualized laboratory-developed 
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workflows that are highly dependent on the type of infection and the type of sample74. 
Workflows vary regarding methods, tools, and interpretation, making it difficult to compare 
and assess the variability of the results. Therefore, rigorous and extensive validation must be 
performed. 
 
Prior to clinical implementation, all laboratory test protocols must be optimized and validated. 
Assay validation is the procedure to establish analytical performance specifications for certain 
performance characteristics, to ensure the analytical validity of test results prior to clinical 
testing. Analytical performance specifications include accuracy, precision, analytical 
sensitivity and specificity, reproducibility, and reportable range (limit of detection)89.  
So far, it has been reported just one developed and validated mNGS assay for clinical diagnosis 
of infectious causes of meningitis and encephalitis from cerebrospinal fluid (CSF) in a 
microbiology laboratory59,61. In fact, it is expected, that the application range of this approach 
will be limited to small targeted assays that are validated90. 
1.3.2.3 Quality assessment 
Standardization of protocols and quality metrics for both the wet and dry laboratory (including 
sample preparations, reagent selection, sequencing process, bioinformatic pipeline, 
interpretation, and report) is critical to ensure the validity of the test result91. Quality control 
metrics specific for NGS should be established, including depth of coverage and quality scores 
as part of standard operating procedures. Additionally, it is important to establish clinical 
validity, to ensure that the test is appropriate for the intended clinical use88,90. 
 
The development of reference materials is important to support mNGS assay validation, 
performance assessment, and quality control. Reference standards materials are also important 
to be used as standard metrics suitable for comparison among laboratories92. Among them, 
characterized nucleic acids, whole microbes, spiked matrices (mock community), and data set, 
can be used as controls for assay validation and quality control90.  
 
Quality control is essential for reliable and valid metagenomic results and will be essential for 
regulatory approval for clinical applications. Both positive and negative controls must be run 
with the clinical samples through the entire process. Positive and internal controls mitigate the 
risk of a false negative result. Positive controls in mNGS assays consist of a negative matrix 
with a spiked-in microorganism(s) that are known74. External controls can be developed using 
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well characterized mock microbial communities to establish detection limits for mNGS19. 
Positive controls enable the detection of performance failures in several steps in the workflow. 
On the other hand, negative controls are required to detect contamination and avoid false 
positive results. Negative controls are samples that do not contain any possible pathogens. 
Negative controls enable the detection of contamination from the reagents or other sources, or 
it may indicate a problem in any of the workflow steps74. Previous studies have used elution 
buffer from the nucleic acid extraction kit72, DNA extractions (blank) control63, transport 
medium93, water, and non-infectious samples as negative controls94.  
 
In addition to positive and negative controls, there are other controls during the process that 
must be considered for quality assurance for mNGS. Among them: (i) Process control and 
checkpoints that can ensure the quality of material before going to the next step in the workflow 
(e.g. quantification of DNA before library preparation). (ii) Contamination control since 
contamination may be introduced in every step of the workflow, for instance from laboratory 
reagents, cross-contamination from other samples. (iii) Database quality control, because 
databases may not be curated or updated, affecting sensitivity. Therefore, databases may require 
re-validation and version control, as they impact the accuracy of the results, and (iv) 
bioinformatics quality control, when for instance changes in the pipeline includes software 
updates, input parameters, algorithms, or databases. All of these changes must be documented 
and added to the standard operational procedures1. 
 
Proficiency testing is another important component of the quality assurance assessment that is 
required to verify the accuracy and reliability of laboratory testing (like in any clinical 
laboratory test). However, for mNGS, it is very challenging since there is not a well 
characterized reference material on the market. Therefore, the design of suitable alternative 
testing materials should be used, e.g. leftovers from clinical samples, previously analyzed and 
confirmed using traditional methods, that then may be compared to evaluate the consistency of 
the results74.  
2 Prosthetic joint infection (PJI) 
2.1 Prosthetic joint replacement 
Joint replacement surgery is the major procedure to alleviate pain, improve mobility in patients 
with destructed joints95. It is one of the most successful surgeries performed currently with the 
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significant patient and health economics benefits. Currently, there are arthroplasties available 
for hips, knees, shoulder, elbow, and ankle; where hip and knee arthroplasties are among the 
most commonly performed procedures96. Joint replacements are referred to as either primary 
or revision arthroplasty, according to the number of times that a given joint is replaced. Primary 
arthroplasty is the first time that a native joint is replaced; revision arthroplasty is a second or 
subsequent surgical procedure performed when a joint replacement fails and some or all parts 
of the original prosthesis need to be removed or replaced. 
 
Globally, the number of joint arthroplasty surgeries performed each year is increasing and it is 
expected that as the need for primary arthroplasties increases so will the need for revision 
arthroplasties. In the United States, until 2014, approximately 4.7 and 2.5 million have 
undergone total knee arthroplasty (TKA) and total hip arthroplasties (THA) respectively97. The 
number of hip and knee replacements in most European countries has also increased in recent 
years, although rates between countries vary considerably. Data collected from 24 European 
joint replacement registries (most of them of national coverage), showed that until 2018, over 
3.1 and 2.5 millions of Europeans have undergone primary THA and TKA respectively98.  
According to the Norwegian Arthroplasty register99,  233 142 and 97 022 THA and TKA cases 
during the period between 1994 – 2018 were reported, respectively, with approximately 9000 
primary hip arthroplasties and 6 900 primary knee operations performed in 2018 in Norwegian 
hospitals.  
 
While the majority of joint arthroplasties are generally successful, postoperative complications 
commonly occur and will require additional surgery at some point during the life of the device. 
Among the complications of prosthetic joint surgeries are instability, fracture, dislocation, 
aseptic loosening, and infections of the prosthesis100,101. Aseptic loosening is nowadays the 
major cause of arthroplasty failure102. However, infections related to joint prostheses occur less 
frequently than aseptic failures but represent the most devasting complication103. 
2.2 PJI definition  
Prosthetic joint infection (PJI), also referred to as periprosthetic infection, is defined as an 
infection involving the joint implant and adjacent tissue104. It is a devastating complication of 
total joint arthroplasty which appears in 0.5-4 % of all the cases103,105 , and may exceed 10 % 
in revision surgery or patients with specific risk factors e.g. diabetes, systemic infections or 
immunocompromise106. PJI is associated with high morbidity, need for complex treatment 
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including the need for prolonged hospitalization, repeat surgery, antibiotic exposure, and 
societal costs (recent estimated costs of 20,000–40,000 dollars per infection107). PJI can lead to 
an unsatisfactory functional results or even permanent disability, including arthrodesis or leg 
amputation. 
There is no standard definition of PJI. However, there are several consensus guidelines, such 
as those produced by the Infectious Diseases Society of American (IDSA)108 and the 
Musculoskeletal infection society (MSIS)109, that have attempted to provide a uniform, 
evidence-informed approach to the management of PJI. Among the most recently proposed, 
there is the one that has been presented at the annual meeting of the European Bone and Joint 
Infection Society (EBJIS) 2018 in Helsinki, Finland (Table 3)110, which has been shown to offer 
better sensitivity for diagnosing PJI111,112. 
 
Table 3. Definition of PJI proposed by EBJIS, 2018110. 
Abbreviations: CFU, Colony Forming Unit. 
2.3 Diagnosis of PJI  
2.3.1 Diagnostic criteria 
The conventional diagnostic strategy to diagnose PJI is usually simple. Infection is suspected 
based on clinical findings (local pain, erythema, edema, fever and wound secretion) then 
confirmed by examination of samples obtained by simple aspiration (synovial fluid) or biopsy 
(periprosthetic tissue), which identifies the causative organism(s), thus defining the 
pharmacological and surgical treatment strategy113. However, the clinical presentation of 
prosthetic joint infection is variable and sometimes difficult to distinguish from that of aseptic 
implant failure114 in addition to several interconnected issues that make the diagnosis of PJIs a 
challenging aspect of management for these infections, among them: the lack of a standard 
Organization Definition
PJI is present  when at least one of the 4 criteria are fulfilled
Sinus tract or visible purulence
Acute inflammation in periprosthetic tissue
Elevated synovial leukocyte count (>2000/µL)
Elevated synovial granulocytes (>70%)
Microbiology
Synovial fluid or tissue samples or sonication fluid (≥ 50 CFU/mL)
Microbial culture in ≥ 2 Positive samples
For highly virulent organisms already one positive sample confirms infection.
Under antibiotics and for anaerobes, <50 colony-forming unit (CFU)/mL can be significant
The European Bone 




definition of PJI109,115, the lack of a perfect diagnostic reference standard, the presence of 
biofilm and challenges differentiating pathogens from contaminants. 
Currently, there is an array of laboratory methods available that aim to improve the diagnosis 
of PJI (Table 4). However, none of these diagnostic methods has achieved satisfactory 
specificity or sensitivity in common practice and it is currently recognized that the complex 
management of these cases implies a multidisciplinary approach. One key part is the 
microbiology, especially due to the importance of diagnosis107,113,116–118. 
 
Table 4. Conventional PJI diagnosis test. Modified from 116. 
Abbreviations: WBC, White Blood Cells; ESR, Erythrocyte Sedimentation Level; CRP, C-
reactive protein level; IL, Interleukin; TNF-α, Tumor Necrosis Alpha Factor; LE, Leukocyte 
esterase. 
 
Microbiological diagnosis of PJI  
Microbiological assessment is considered an important criterion for diagnosis of PJI playing a 
central role in infection confirmation, and it is also critical for determining antimicrobial 
susceptibility of the pathogen(s) to guide antimicrobial treatment. Although multiple definitions 
of PJI have been proposed, all of them include identification of pathogen(s) as a key component. 
The microbiological diagnosis of infection generally depends upon the isolation of a pathogen 
from a clinical specimen  by conventional inoculation onto solid and/or liquid media under 







Periprosthetic tissue Histopathology; Gram stain and culture 
Explanted prosthesis Culture
Fluorine-18 fluorodeoxyglucose (F-18 FDG) positron emission tomography
Intra-operative assessment
Description of the diagnostic test
Serological tests 
White blood cells (WBC) count and differential; Erythrocyte sedimentation rate
(ESR); Serum C-reactive protein level (CRP); Serum biomarkers for detecting PJI:
Serum IL-6, procalcitonin, TNF-α, among others.
Synovial fluid aspiration
Radiographic imaging
Radionuclide bone scanning Scintigraphy using a number of isotopes including: Technetium 99m, Gallium-67 
citrate, or Indium-111-labeled leukocyte or immunoglobulin scan.
WBC count and differential; Gram stain and culture; PCR; leucocyte esterase (LE); 
Synovial CRP; synovial biomarkers: α-defensin, Interleukin (IL)-1β, IL-6, IL-8, 
IL17, TNF-α, among others.
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recommend strategies for identifying the organism(s) causing PJI from both pre-operative and 
at the time of surgery108,120. 
Among the microbiological definitions of PJI, is the isolation of two or more identical isolates 
from multiple specimens, or the isolation of one highly virulent organism from a single sample. 
Notably, single positive tissue or synovial fluid cultures, especially for organisms that may be 
contaminants (e.g. coagulase-negative staphylococci (CoNS), Cutibacterium acnes), should 
not be considered evidence of definite PJI120. The specimens commonly recommended for 
diagnosis of PJI are: synovial fluid, periprosthetic joint tissue (PJT) and sonication fluid for 
removed implant101. Two or more intraoperative cultures or a combination of preoperative 
aspiration and intraoperative cultures that yield the same organism is considered definite 
evidence of PJI.  
The “usual suspects’’ causing PJI 
A wide range of microorganisms can cause PJI. They include Gram-positive bacteria, Gram-
negative bacteria and, although less common also fungi. The majority of PJIs reported are 
caused by a single microorganism (~85%), but polymicrobial PJI is also possible121. Frequency 
of microorganisms causing PJI can vary significantly by time after implantation and the site of 
the joint prosthesis, among others96. Table 5 contains a list of the most common causes of 
prosthetic joint infection and the range reported in several studies from different countries and 
a study made in Norway in total hip arthroplasties (THAs)122. In Norway, in a nationwide study, 
based on 278 revisions of infected THA, staphylococci were the most common bacteria in THA 
revision for infection. S. aureus was more common in acute postoperative infections and CoNS 













Table 5. Common causes of PJI. 
 
Data from: aInternational data96,121,131,132,123–130, bNorwegian data122. 
Polymicrobial PJI tends to occur more frequently after implantation than monomicrobial PJI. 
There has been little research about polymicrobial PJI, including the frequency of the different 
bacteria involved. Existing studies have reported a prevalence of polymicrobial PJI infections 
in the range between 10-15%. Differences in the distribution of bacterial species between 
monomicrobial and polymicrobial have been observed, probably due to the fact that certain 
types of microorganisms may be more likely to grow together than separately. In a recent study 
by Flurin et al. 2019121, Staphylococcus epidermidis and other CoNS were commonly found in 
polymicrobial PJIs. S. epidermidis was found in 60% of polymicrobial PJI and it was found at 
a higher rate in polymicrobial than monomicrobial infections. The most common co-pathogen 
found with S. epidermidis was E. faecalis. In addition to CoNS and enterococci, 
Corynebacterium sp. and Finegoldia magna are common in polymicrobial infections121,127. S. 
aureus, aerobic gram-negative bacilli, including Pseudomonas aeruginosa are also within the 
most isolated bacteria. In Norway, the incidence of the different bacteria is mostly unchanged 
throughout the study period. There is a trend towards more polymicrobial infection and the 
combination of CoNS and Corynebacterium sp. is most common122.  
 
International data Norwegian data
Aerobic Gram-positive cocci >50 60
Staphylococcus aureus 12-28 19
Coagulase-negative Staphylococci (CoNS) 13-40 41
Staphylococcus epidermidis 23 16
Streptococcus  sp. 8-10 11
Streptococcus agalactiae 2.8 -
Enterococcus  sp. 3-10 9
Aerobic Gram-negative bacilli 10-42 6
Enterobacteriaceae 20 -
Escherichia coli 9 -
Anaerobic bacteria 3-24 -
Cutibacterium acnes 0.9-19 -
Polymicrobial 10-15 10





The prime suspect in PJI: Staphylococcus aureus 
Staphylococcus aureus is regularly reported to be the most common pathogen in PJIs (12-
27%)96,123–125,128. For most healthy individuals, colonization is unproblematic. However, if S. 
aureus contaminates a breach in the skin or mucous membranes, it can go on to infiltrate the 
underlying tissue causing an infection. There is evidence that support that  S. aureus from nose 
and PJI isolates of S. aureus in arthroplasty patients are genetically indistinguishable, 
suggesting that commensal S. aureus clones are capable of causing PJI 133. 
S. aureus taxonomy and general features 
S. aureus was first described in 1880 by the Scottish surgeon Sir Alexander Ogston, from a pus 
sample originated from a surgical abscess in a knee joint. The Staphylococcus name comes 
from the Greek staphyle (bunch of grapes) and kokkos (berry), due to its spherical shape 
(cocci), which cluster together into colonies that look like grapes, when observed under the 
microscope. Then, in 1884, Friedrich Julius Rosenbach named the bacteria S. aureus due the 
color of the colonies, S. aureus from the Latin aurum, gold134. 
 
S. aureus belongs to the phylum Firmicutes, class Bacilli, order Bacillales, family 
Staphylococcaceae, genus Staphylococcus. Today, there are 54 and 22 validated species and 
subspecies of Staphylococcus respectively (according to (https://lpsn.dsmz.de/), accessed June 
07/2020)135,136. S. aureus in contrast to other Staphylococci members, form fairly large 
yellowish pigmentation on their colonies due to the production of staphyloxantin137. By testing 
the coagulation of rabbit serum, S. aureus can be readily distinguished from other 
Staphylococcus species, which are coagulase negative. They are Gram-positive bacteria, 
facultative anaerobes, catalase positive, oxidase negative, coagulase positive, and non-spore 
forming organisms. They can cause hemolysis in blood agar plates due to the secretion of 
several toxins (α, β, δ, ϒ). 
S. aureus colonizer and pathogen 
S. aureus is considered both a commensal colonizing different human body parts and a pathogen 
that causes a wide range of clinical infections138. Humans are constantly exposed to S. aureus 
in the environment, and the bacteria are well adapted to colonize multiple body sites which 
provide several niches for this species. S. aureus colonizes skin and mucous membranes in 
humans but also in several animal species. The nares, throat, and perineum are the most 
prevalent sites for carriage in the general adult population. In the human body, S. aureus is 
considered part of the human microbiota139. It has been estimated that around 20-30 % of the 
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healthy adult population are asymptomatically carriers with 20 % and 60% being colonized 
permanently or temporarily, respectively140. Colonization is considered an important risk factor 
for the development of S. aureus infection and nosocomial infections140. 
 
S. aureus is an opportunistic pathogen that has the potential to cause many different diseases. 
Among these, both healthcare- and community-associated bloodstream infections, skin, and 
soft tissue infections, endocarditis, septic arthritis, osteomyelitis, and infections of prostheses. 
The success of S. aureus reflects an array of abilities, for instance, its capacity to adapt to 
different environments, which can vary widely within the host, such as pH, nutrient availability, 
or oxygen tension; inducing the bacterium to express a variety of different phenotypes139.  
S. aureus genome evolution and molecular typing 
Bacteria retain most of their genetic information from generation to generation. However, they 
also need to develop strategies that allow them to acquire new genetic material in their genomes 
to adapt and survive in an environment that changes continually. Genomes of more closely 
related bacteria are more conserved, but the genome variability exists within different genera 
and among different isolates of a single bacterial species. The mains mechanisms that contribute 
to the plasticity of the bacterial genome are the acquisition of DNA (gene gain), and the loss of 
genetic information (gene loss)141. The sequencing of S. aureus has provided valuable 
information to the understanding of this pathogen. Approximately 554 complete genomes 
assembly has been registered in the NCBI database to this day. The S. aureus genomes are 
about 2.83686 Mb in size (median total length), with approx. 2800 coding sequences and a 
median G+C content about 32.7% (NCBI accessed 07/06/2020).  
 
The bacterial pan-genome is divided into the core and accessory genome. The core genome 
refers to the stable regions with relatively low mutational capacity containing the genes present 
in all strains. The core comprises ~75% of the 2.8 Mb genome of S. aureus and is highly 
conserved among strains. The accessory genome refers to genes not present in all strains of a 
species and it is where more of the genetic diversity of pathogenic bacteria occurs. The 
accessory genome comprises ~25% of the total S. aureus genome142. Mediators of virulence, 
immune evasion, and antibiotic resistance are commonly found in the accessory genome. 
Including, mobile genetic elements (MGEs) such as S. aureus pathogenicity islands (SaPIs), 
bacteriophages, staphylococcal cassette chromosomes (SCC), transposons and plasmids, which 
are acquired by horizontal gene transfer (HGT)143. Therefore, the accessory genome provides a 
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considerable resource for bacterial flexibility to improve their fitness and, potentially, 
pathogenicity, and virulence 144. The success of S. aureus as both a colonizer and a pathogen 
is mostly because it has the ability to adapt to different environments due to the acquisition 
of new DNA by HGT and to spread clonally.  
 
Molecular characterization of S. aureus populations is an important component in the study of 
clonal relatedness, evolutionary pathways, the genetic diversity of the pathogen, and tracking 
the spread of S. aureus infections145. Various typing techniques have been used for 
discriminating bacterial isolates and characterizing S. aureus populations, e.g. Pulsed-Field gel 
electrophoresis (PFGE), multilocus sequence typing (MLST), and spa typing (Staphylococcal 
protein A)146.  
 
MLST directly measures the DNA sequence variations in a set of housekeeping genes and 
characterizes strains by their unique allelic profiles, with the resulting data made publicly 
available online. Seven housekeeping genes are used in S. aureus MLST typing including 
carbamate kinase (arcC), shikimate dehydrogenase (aroE), glycerol kinase (glpF), guanylate 
kinase (gmk), phosphate acetyltransferase (pta), triosephosphate isomerase (tpi) and acetyl 
coenzyme A acetyltransferase (yqiL), as specified by the MLST website 
(http://saureus.mlst.net)147. The analyzed isolates are then assigned to a specific sequence type 
(ST). The comparison of different isolates and their STs has allowed the comparison of different 
isolates. MLST has become an important and reliable technique for epidemiological analysis. 
For instance, it has been found that methicillin-resistant S. aureus (MRSA) strains, including 
healthcare-acquired MRSA (HA-MRSA), community-acquired MRSA (CA-MRSA), and 
livestock-associated MRSA (LA-MRSA) strains have produced different STs, which help to 
identify them148.  
 
Based on typing, STs can be clustered together into clonal complexes (CCs). A clonal complex 
(CC) is defined as groups of STs in which every ST shares at least six out of seven identical 
alleles. The associated clonal complex (CC) is calculated using the eBURST algorithm 
(http://saureus.mlst.net.eburst)149, which is used to cluster related STs149. S. aureus has a highly 





Now there is an extended MLST, which analyses the alleles of several hundred or even 
thousands of genes (core genome MLST (CgMLST) or Whole-genome MLST (wgMLST)) and 
consequently has a high discriminative power allowing the comparison of genetic relatedness 
between bacteria even on a sub-species level151. In principle, wgMLST can provide a higher 
resolution as the distance matrix is computed on a larger set of loci. However, some studies 
have demonstrated that results derived from wgMLST and cgMLST approaches are often quite 
similar152. Studies have confirmed that WGS is a suitable strain characterization and typing 
method for S. aureus153. 
S. aureus antibiotic resistance and virulence factors 
Many factors seem to contribute to the success of S. aureus as a pathogen, such as (i) its ability 
to persist as a commensal, (ii) its acquired resistance to multiple antimicrobial agents, and (iii) 
the diverse repertoire of virulence factors (VFs) that facilitate its ability to invade the host, 




Table 6. Factors contributing to the success of S. aureus.  Modified from143 
 
 
Abbreviations: rRNA, ribosomal RNA; SaPI, Staphylococcus aureus pathogenicity 
island. aNot a comprehensive list.  
Category Gene	name Gene	product Function Location
aur Aureolysin Tissue	destruction Core
capA 	and	capP Capsular	polysaccharide	biosynthesis	proteins Immune	evasion Core
chp Chemotaxis	inhibitory	protein Immune	evasion Bacteriophage
clfA 	and	clfB Fibrinogen	binding	proteins Adhesion Core
coa Staphylocoagulase Coagulation Core
ebhA 	and	ebhaB Extracellular	matrix-binding	proteins Adhesion Core
eta Exfoliative	toxin	A Scalded	skin	syndrome Plasmid
etb Exfoliative	toxin	B Scalded	skin	syndrome Bacteriophage
etd Exfoliative	toxin	D Scalded	skin	syndrome vSAγ
geh Lipase Lipid	degradation Core
hld δ-Haemolysin Haemolysis Core
hlgA,hlgB 	and	hlgC γ-Haemolysin	components Haemolysis Core
hysA Hyaluronidase Tissue	invasion vSaβ
lukD 	and	lukE Leukotoxins Immune	evasion SaPI
lukS-PV 	and	lukF-PV Panton–Valentine	leukocidin Leukotoxin Bacteriophage
sak Staphylokinase	(protease	III) Clot	dissolution Bacteriophage
sea Enterotoxin	A	superantigen Food	poisoning Bacteriophage
seb 	and	sec Enterotoxin	B	and	enterotoxin	C	(superantigens) Food	poisoning SaPI
seq2 	and	sek2 Enteroxin	and	superantigen Food	poisoning SaPI
sep Enteroxin	P Food	poisoning Bacteriophage
spa Immunoglobulin	G-binding	protein	A Immune	evasion Core
sspA Serine	protease Tissue	destruction Core
sspB Cysteine	protease Tissue	destruction Core
tst Toxic	shock	syndrome	toxin	1 Superantigen SaPI
aacA –aphD Bifunctional	AAC–APH	protein Aminoglycoside	resistance Transposon
aadD Aminoglycoside	adenyltransferase Aminoglycoside	resistance Plasmid
ant (9) O -nucleotidyltransferase(9) Aminoglycoside	resistance Transposon
cat Chloramphenicol	acetyltransferase Chloramphenicol	resistance Plasmid
dfrA 	and	dfrK Dihydrofolate	reductase Trimethoprim	resistance Plasmid




ileS Isoleucyl-tRNA	synthetase Mupirocin	resistance Plasmid
mecA Penicillin-binding	protein	2 Methicillin	resistance SCCmec
tetK Tetracycline	resistance	protein Tetracycline	resistance Plasmid
tetM Tetracycline	resistance	protein Tetracycline	resistance Transposon
Virulence	
factorsa












Methicillin-resistant S. aureus (MRSA) is a major public health concern154. In Europe, MRSA 
proportions were reported to be around16.4% in 2018 (EARSS Annual Report. 2018). From S. 
aureus causing PJI (12-27%), around 50% are MRSA. They are considered one of the most 
challenging organisms causing PJI and can compromise the success of surgical treatment and 
result in much higher costs. It has acquired resistance to all the antibiotics that have entered the 
clinic to date155, and the World Health Organization defined it as a high-priority pathogen for 
research and development of new antibiotics156. 
 
Methicillin resistance is due to the acquisition of a new gene, mecA, that codes for a novel 
penicillin-binding protein (PBP), designated PBP2a that makes the strain resistant to all beta-
lactam antibiotics, including penicillins, cephalosporins, and carbapenems. The mecA gene is 
carried on a mobile genetic element designated Staphylococcal cassette chromosome 
(SCC) mec that is chromosomally integrated. Acquisition of mecA initiated the successful 
spread of MRSA, one of the most important multidrug-resistant (MDR) nosocomial pathogens. 
Some MRSA clones are spread globally while others are restricted to specific geographical 
regions, that are usually dominated by a single subclone, with different subclones present in 
different regions157.  MRSA infection trend to occur in waves of infection, characterized by the 
emergence of predominant strains158. 
 
The prevalence of MRSA varies according to the geographical area. In some areas of the world, 
MRSA prevalence is very high, for example, in Latin American countries prevalence is 
estimated to be >80 % and in India proportions of 41– 80% were observed in 2008–2012159. In 
the United States and Canada, the prevalence of MRSA is 15 % to 45 % while it is generally 
lower in northern Europe and higher in the south and south-east Europe. In the Nordic countries, 
the incidence of MRSA is very low. In fact, Norway has one of the lowest prevalence of MRSA, 
with 0.8 % prevalence reported in the NORM surveillance system in 2018160. The most 
common spa types in 2018 were t002, t304 (CC6), t008 (CC8), t127 (CC1), t223 (CC22), t019 
(CC30), t437 (CC59), t034 (CC398), t044 (CC80) and t105 (CC5)160. In a study, including PJI 
samples collected from different Swiss and French hospitals, S. aureus isolates were typed 
by agr (accessory gene regulator) group and the spa type. Results reported that the most 
common CCs were CC1, CC5, CC8, CC30, CC45, and CC59161.  
 
On the other hand, virulence factors contributing to S. aureus pathogenicity in PJI are involved 
in processes such as the invasion of host tissues, evasion of the immune system, adhesion to 
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surfaces, and biofilm formation138. Cell surface components, enzymes, and exotoxins are 
important virulence factors for invasion, evasion, and propagation 162. By persisting in biofilm, 
bacteria evade neutrophil killing and display decreased susceptibility to antibiotics, which 
creates significant challenges, e.g. in the treatment of PJIs133.  
Clinical specimens for microbiological diagnosis of PJI 
Needle aspiration of synovial fluid or a biopsy sample of intraoperative tissue provides the most 
accurate specimens for detecting the etiology of PJI103. Identifying the causative organism is 
crucial and requires the collection of high-quality clinical specimens from deep sites in contact 
with the prosthetic material and collected under aseptic conditions. The results of the culture of 
intraoperative specimens (fluids and/or tissue) are usually considered the gold standard for 
detecting the infecting organism(s)163. 
 
Analysis of synovial fluid culture is considered one of the main analyses to perform PJI 
diagnosis in patients with underlying inflammation, especially because the result from the test 
is independent of the presence of underlying inflammatory disease allowing the identification 
and susceptibility testing of microorganisms 164. Needle aspiration can be performed routinely 
before surgery or samples are collected only during surgery 113. Synovial fluid can be inoculated 
onto solid and/or liquid media. Culture sensitivity range between 82–94% and specificity of 
94–97%. However, the use of antimicrobials  prior to aspiration increases the number of false-
negative in synovial fluid cultures 165. As a solution for that, more recent studies have inoculated 
synovial fluid into blood culture bottles (BCB) 166–168. It has been found that when combining 
both methods (agar plate vs BCB) while sampling joint fluid adds sensitivity (0.61 vs. 0.5) 
while reducing specificity (0.89 vs. 0.95) 169.  
 
The microbiological culture of PJT is considered one of the most important criteria for the 
diagnosis of PJI. PJT provides the most accurate specimens for detecting the infecting 
microorganism(s)103. Previous studies have used various criteria for the microbiological 
diagnosis of infection, ranging from the isolation of organisms from one direct culture, or two 
or more broth enrichment cultures requiring even five of five specimens to yield the same 
organism. Multiple intraoperative tissue specimens should be submitted to the microbiology 
laboratory for aerobic and anaerobic culture to optimize culture yield, increase sensitivity, and 
because cultures may be falsely positive due to contamination introduced e.g. in the operating 
room, during specimen transport, or in the microbiology laboratory 120,170. The Infectious 
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Diseases Society of America (IDSA) and the American Society of Microbiology 
recommendations suggest the use of at least three, but optimally six tissue specimens as the 
number of samples that should be obtained. A specification is done according to the culture 
method used for analyzing the samples. If the conventional plate and broth cultures are used, 
four samples are suggested, while if aerobic and anaerobic blood culture bottles are used, three 
samples are recommended as optimal numbers of tissue specimens for diagnosis of PJI68,120. 
Although the need to culture multiple samples is considered good practice in order to increase 
sensitivity and to overcome the problem of contamination, a standardized method has been 
neither defined nor validated.  
 
Currently, there is a discussion about which specimen is superior for the PJI diagnosis. 
Sonication has been found in multiple studies to improve the yield of culture-based 
diagnostics171–173. Some studies suggest that sonication is more sensitive than tissue sample 
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Objectives of the study 
The main objective was to explore the use of shotgun-metagenomics (SMg) in clinical 
diagnostics of prosthetic joint infection (PJI) for the identification of potential pathogens and 
prediction of antimicrobial resistance (AMR) and virulence determinants directly from blood 
culture bottles (BCBs) inoculated with periprosthetic tissue (PJT) specimens. 
 
Paper I 
Hypothesis: Use of the BacT/Alert® Virtuo blood culture system for culturing PJT specimens 
improves the microbiological diagnosis of PJI. 
Specific objectives: 
• Evaluate and optimize the use of the BacT/Alert® Virtuo BCB system for culturing PJT  




Hypothesis: SMg can be performed directly on PJT from BCBs for pathogen identification. 
Specific objectives: 
• Establish a protocol for the preparation of high-quality gDNA from BCBs inoculated 
with PJT specimens for downstream SMg application. 
• Optimize an SMg bioinformatics analysis pipeline for analyzing the SMg results for 
identification of potential pathogen(s) 
• Compare the SMg results with the results from the conventional method and the BCB 
method for pathogen identification. 
 
Paper III 
Hypothesis: Typing and prediction of AMR and virulence determinants in S. aureus, can be 
performed with high accuracy by SMg from BCBs containing PJT.  
 Specific Objectives: 
• Assess the use of SMg for typing, prediction of antimicrobial resistance genes (ARG) 
and virulence profiling of S. aureus from BCBs inoculated with PJT. 
• Compare the genotypes predicted from the SMg data and AMR phenotypical results. 
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• Analyze and evaluate the sequencing data using reads-based and contigs-based 
approaches for taxonomic classification and prediction of ARD.
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Choice of Methods 
A detailed description of the methods is presented in papers I, II, and III. The following sections 
aim to present a brief description of the methods used in this study and the rationale for choosing 
them.    
1 Sample collection 
Currently, there are not well characterized reference materials intended for SMg assays or 
guidance for developing specific procedures to assess SMg1. Therefore, appropriate alternatives 
materials and assessment procedures were designed in this study. Three different types of BCB 
samples were obtained to get a comprehensive overview: BCB inoculated with PJT specimens 
from patients with suspicion of PJI, BCB inoculated with bacterial species common causes of 
PJI and a negative control which was prepared by inoculating sterilized tissue into a BCB. The 
choice was based on SMg workflows from different published studies, and they were adapted 
to the SMg approach from BCBs workflow. An overall description of the samples used in this 
study, discriminated by paper is listed in Table 7. 
 
Table 7. Description of samples used in this study discriminated by paper. 
 
 
Abbreviations: MNS, manuscript; FA, Bact/Alert® BCB FA Plus for aerobic bacteria; FN, 
Bact/Alert® BCB FN Plus for anaerobic bacteria; NC, negative control. 







No. of spiked BCBs (n=)                   
and strains spiked-in 
NC   
(n=)








Escherichia coli ATCC 25922
Staphylococcus aureus ATCC 25923
Enterococcus faecalis ATCC 29212
Staphylococcus epidermidis ATCC 12228
Bacteroides fragilis ATCC 25285
Cutibacterium acnes (Clinical isolate)
2












(13 new samples + 
6 from paper II)
18 SMg sequencing 






S. aureus  ATCC 25923
II 3 FA 
E. coli ATCC 25922
S. aureus  ATCC 25923
C. acnes  + S. aureus  ATCC 25923
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Samples to be analyzed are obtained through collection techniques that vary in their level of 
invasiveness and risk to the patient175. In this project, the type of clinical samples used were all 
types of PJT specimens submitted on a routine basis to the Department of Microbiology and 
Infection Control (AMS) at the University Hospital in North Norway (UNN), comprising any 
type of PJT from e.g. hip, knee, elbow, and shoulder. Only residual PJT samples, also analyzed 
by the conventional routine method, were used as testing material in this study. Consequently, 
the samples used may be of lower volume and quality that would be the case if the method were 
used routinely. Samples were collected continuously over 28 months (August 2017–December 
2019), anonymized, de-identified and stored at 4°C until processed. 
 
PJT specimens used for paper I were randomly collected, while samples from paper II were 
selected based on the presence of bacteria (monomicrobial) reported as common cause of PJI. 
For paper III, samples were selected on the bases of being positive for S. aureus by the 
laboratory methods (conventional and BCB). Samples contained just S. aureus 
(monomicrobial, n= 17) or S. aureus and other bacterial species (polymicrobial, n=2). In total 
22 BCBs inoculated with PJT samples were SMg sequenced (Paper II, n=9 and Paper III, n=19). 
All the BCB samples sequenced were taken from aerobic bottles, to facilitate the comparison 
between samples. Bacterial strains for spiking experiments were selected based on the criteria 
of covering a range of different bacteria (Gram-negative, Gram-positive, aerobic, and anaerobic 
bacteria) known as common causes of PJI.  
2 Thesis workflow 
The general workflow of the methods used in this study is summarized in Figure 5. The results 
from the conventional routine method were used for comparison with the BCB and/or the SMg 
methods, to validate the findings obtained. 
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Figure 5. General workflow of methods used in this study. 
 
2.1 Sample preparation 
2.1.1 Tissue sample homogenization 
Tissue samples need to be liquified to get access to the bacteria. Currently, mechanical 
disruption techniques are used on specimens to increase the sensitivity113. Bead mill processing 
using ceramic or glass beads and sonication of prosthetic material before inoculation onto solid 
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and/or liquid media are among the most used mechanical techniques in the clinical diagnosis 
of PJI176. In this project, sample homogenization included a bead-beating technique. It was done 
by adding an aliquot of the tissue samples (≈1 cm3) to 15 ml tubes with glucose broth and 
ceramic beads. Then, the mixture was homogenized using a FastPrep-24 instrument (MP 
Biomedicals, France). This homogenized solution was used to inoculate the BCBs. 
2.1.2 Sterilization of tissue material for spiking and negative control 
The biological material used for mimicking infected tissue (spiked) and for the negative control 
were obtained from excess material of a native femoral head and surrounding tissue from an 
anonymous donor. The sample was crushed, sterilized, aliquoted, and frozen at -20˚C until use. 
Each time an aliquot was taken from the freezer, it was checked for contamination by plating 
on blood agar media. 
 
Tissue sterilization was done using Gamma irradiation. Gamma radiation has several 
advantages and is the most suitable method for sterilization of biological tissues which has been 
used to assure adequate sterilization of tissue and bone allografts before transplantation 
procedures177. There are other sterilization techniques that may been use for tissue sterilization, 
among them: ethylene oxide gas, thermal treatment with moist heat, beta-propiolactone, 
chemical processing, and antibiotic soaks. Most current sterilization procedures have inherent 
disadvantages affecting biological properties of the tissue. Therefore, Gamma radiation offers 
a better alternative for sterilizing tissues177. Radiation sterilization at a dose of 25 kGy provides 
a high safety factor for sterility. Gamma radiation dose is measured in kilogray (kGy) units. 
One gray is the absorption of one joule of radiation energy by one kilogram of matter (one kGy 
= one joule/gram). 25 kGy was selected as the dose for sterilization as it is 40% above the 
minimum dose required to kill the microorganisms. Accordingly, 25 kGy is the minimum 
irradiation dose established for sterilization177.  
2.1.3 Horse blood as a BCB supplement 
Defibrinated horse blood was used as enrichment supplement for the BCBs. This has previously 
been shown to produce high positivity rates and shortening of time to detection when testing 
simulated sterile body fluids other than blood models178. The use of horse blood does not 
significantly influence the performance of blood culture systems178,179. Horse blood is one of 
the most widely used animal blood products in culture media. BioMerieux has recommended 
the use of horse blood as a supplement in BacT/Alert FA blood culture bottles. In this study, 
  Choice of Methods 
 37 
the BCB were inoculated with 4 mL of defibrinated horse blood (TCS Biosciences Ltd) as 
enrichment supplement.  
2.1.4 Spiking tissue samples  
Spiked samples were designed to evaluate the performance of the BacT/ ALERT® (BioMeriux) 
blood culture bottles system for culturing periprosthetic tissue samples (Paper I) and to create 
positive controls for the SMg experiments (Paper II and III), since positive controls mitigate 
the risk of false-positive results. A spiked sample is a negative matrix inoculated with a 
microorganism(s) that is known74.  It is also known that positive controls are part of the quality 
control practices. It must be run with the clinical samples through the entire process to mitigate 
the risk of false-negative results and to enable the detection of performance failures in several 
steps in the workflow74. The design of this type of material is important to support the SMg 
assay validation, performance assessment, and quality control. 
 
An important factor to consider when designing spiked samples is the bacterial inoculums 
concentration used to spike the negative matrix (in this project, the sterilized samples). The 
concentration of bacteria in spiked samples must be close to the inoculum of microorganisms 
needed to establish infection in real PJI samples. The size of the inoculum needed for bacteria 
to cause a PJI is a factor that depends in part on the type of microorganism that is causing the 
infection. Some microorganisms are highly pathogenic, and a relatively small number are 
capable of causing disease e.g. S. aureus, while others, e.g. S. epidermidis, require special 
settings or a relatively high bacterial inoculum, being more common in the delayed onset of PJI 
infections.  
 
Commonly, in PJI, a low inoculum of microorganisms is needed to establish infection in the 
presence of the prosthetic material96. In fact, a low inoculum of infection is a factor that plays 
a role in making the diagnosis of PJI difficult180. Commonly, PJI are initiated through the 
introduction of microorganisms at the time of surgery and the infections occurs within 1 year 
of surgery. In a rabbit model, it was reported that lower inoculum concentration was needed to 
stablish infection (<102) if inoculated at the time of hip arthroplasty, compared with when no 
implant is present (104 CFU)181. In this project, to simulate PJI samples, bacterial inoculums 
were prepared and added to the glucose broth containing a piece of the sterilized tissue (≈1 cm3) 
to get an inoculum concentration of ≈500 CFU on the glucose broth.  
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2.1.5 Negative control 
Negative controls (NCs) are samples that do not contain any possible microbes and that follow 
the same entire process as the clinical samples. They are an essential part of the method of 
quality control for reliable and valid results of assays that are aimed for clinical applications52. 
NCs must be included in SMg assays to enable discriminating true pathogens from 
contaminants (external, reagent, and cross-sample contamination) and avoid false-positive 
results74. SMg studies have used as a variety of negative controls among them: elution buffer 
from the nucleic acid extraction kit72, DNA extractions (blank) control63, transport medium93, 
water, and non-infectious samples94. In this study, a negative control sample was designed by 
inoculating a BCB with sterilized infection-negative tissue from a donor with no suspicion of 
infection.  
2.2 Blood culture bottles (BCB) 
Optimization of culture techniques for rapid isolation and detection of the infectious agent(s) 
from clinical specimens is desired. There are a number of changes in modern microbiological 
diagnoses and automated systems have become an integral part of many clinical 
microbiological laboratories. One such optimized culture technique is the inoculation of BCBs 
with clinical specimens. It is often used in the clinical microbiology laboratories for the 
detection of microorganisms, mainly from the blood where it is regarded as the “gold standard”, 
but also for other body fluids and clinical specimens. 
 
A blood culture is a laboratory test in which clinical specimens are inoculated into sets of bottles 
containing culture media to determine whether infection-causing microorganisms (bacteria or 
fungi) are present in the patient’s sample. A set includes an aerobic and an anaerobic bottle.  
The most common BCB systems used worldwide are BD BACTEC (Becton Dickinson 
Instrument Systems, Sparks, MD) and BacT/Alert® (bioMérieux, Marcy l’Etoile, France)182–
184. BioMerieux launched a new version of the blood culture system to the market in 2014, the 
BacT/Alert Virtuo system which comes with automatic loading and unloading, and improved 
detection algorithm and temperature stability179,185. With colorimetric detection, 
BacT/ALERT® culture media use advanced technology including specialized Liquid Emulsion 
Sensors (LES) at the bottom of each culture bottle that visibly change color when the pH 
changes due to the rise in CO2 as it is produced by microorganisms. BacT/ALERT VirtuO 
instruments measure the color changes every ten minutes and analyze the 
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changes. Sophisticated algorithms, including a unique “threshold” algorithm, ensure early 
detection of microorganisms from various sample types. Furthermore, the BacT/ALERT® FA 
Plus and FN Plus BCB series contains absorbent antibiotic-binding polymeric beads that 
neutralize the antibiotic effect optimizing the recovery of microorganisms for samples from 
patients on prior antimicrobial therapy, in addition to adsorbing inhibitory compounds183. 
BacT/ALERT® FA Plus medium composition contains peptones, yeast extracts, supplements, 
and absorbent resins. BacT/ALERT® FN Plus (anaerobic) media differ in their composition as 
well as their relative contents of two polymeric resins designed for neutralizing antibiotics and 
additional inhibitory substances. The anaerobic formulation includes a complex amino acid 
component not contained in the aerobic formulation186. 
 
The traditional approach for identifying pathogen(s) from positive blood culture bottles starts 
with Gram staining to confirm the presence of microbes and to determine the morphotype. The 
Gram staining allows disclosure of the presence of polymicrobial infections. Then the pathogen 
identification can be achieved by (i) subsequent steps of subculture on agar plates which 
requires 18-48 hours of additional time for subculture until colonies are present on the agar 
plates. Among them, Matrix-assisted laser desorption/ionization-time of flight mass 
spectrometer (MALDI-TOF) which is a spectrophotometry system that performs protein 
analysis of microorganisms for the identification or the Vitek 2 XL (BioMerieux)187. (ii) using 
molecular methods directly from positive BCBs that significantly reduce the time to results. 
These methods may be based on MALDI-TOF MS (on positive blood-culture pellet), PCR, and 
fluorescent nucleic acid probes188.  
2.3 Evaluation of the BacT/Alert Virtuo b system for culturing 
periprosthetic tissue 
In order to ensure laboratory quality practice in the clinical microbiology laboratory, test 
validation and verification are needed. The terms verification and validation are often used 
interchangeably. However, each refers to a separate step in assuring that a test is performing as 
expected. Verification is the one-time process completed before a new test (or a modification 
of an existing test) is used for patient testing. In contrast, validation is the ongoing 
documentation that a test, which has already been verified, is repeatedly giving the expected 
results as the test is performed over a period of time189. Validation, verification, and evaluation 
of the performance of microbiological diagnostic tests are challenging. It is mainly because 
living microorganisms represent an extra source of uncontrollable variation and because the 
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test methods are the sum of sequential and conditional sub-processes that can affect the 
results189–191.   
 
One of the most important aims when trying a new application of an existing test is determining 
whether the sample to be examined has any inherent interfering properties and whether the 
incubation and growth conditions can recover microorganism to an acceptable level192. In this 
study, we present an evaluation of the use of the BacT/Alert® Virtuo blood culture system for 
microbiological analyses of periprosthetic tissue specimens as a tool that can be beneficially 
used for improving and accelerating the diagnosis of PJI (Paper I). Our analyses included spiked 
and clinical samples, as well as a comparison of the BCB method with the local routine 
diagnostic method, for time to detection (TTD) and bacterium (monomicrobial) or bacteria 
(polymicrobial) identified. A workflow summarizing the BCB evaluation process is presented 
in Figure 6. The translation of this test system into the clinical application at the local level was 
the main goal (paper I). 
 
The use of BCBs is currently the standard diagnostic method for the diagnosis of blood 
infections193.  They are approved by the FDA and they have been validated by the 
manufacturers for the detection of microorganisms from blood and other normally sterile body 
fluids (e.g. cerebrospinal fluid, ascites)193. When users practice a sub-process that differs from 
guidelines and for which the level of evidence in the literature does not ensure enough 
confidence for safe patient management, this particular sub-process needs an additional 
validation191.  
 
Previous studies have demonstrated the potential of BCB systems for microbiological detection 
from PJI specimens, including PJT174,193–195. The method has already been implemented in 
some clinical laboratories replacing the conventional diagnostic method. Multiple studies have 
validated BCB systems for their use with tissue preparations193. However, most studies are 
mainly using the BD BACTEC BCB system. 
 
There are procedures suggested for evaluating the ability of a BCB system to support the growth 
and detection of typical clinical pathogens, allowing the validation to be performed with seeded 
suspensions versus patient specimens, in addition to a parallel comparison with a reference 
method189. Seeded suspensions refer to the inoculation of BCB using spiked materials that 
mimic patient specimens and that contain a known number of bacteria, preferably using 
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reference strains to verify that the analytic process is under control by detecting proper bacterial 
growth, positive bottle detection and time to detection. The use of this approach has been 
suggested for certain local accreditation committees and suppliers to meet the ISO 15189 
standards for medical laboratories with respect to quality controls191. The parallel comparison 
approach, on the other hand, is important since the BCB method intended to replace another 
method, invariably requiring a level of comparison189. However, BCBs represent a particular 
process with very few equivalents in laboratory tests in many aspects, as for instance the volume 
of sample inoculated into the BCB, and this sample volume critically determines disease 
detection. In this study, the BCB method was based on, and modified from, similar methods 
used in the previous studies194,196,197, while the conventional method was an already validated 
in-house method.  
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Figure 6. Overview of the process followed for evaluating the use of the BacT/Alert® Virtuo 
blood culture system for culturing periprosthetic tissue specimens. Abbreviations: O/N, 
overnight culture; CFU, Colony forming unit; MALDI-TOF MS, Matrix-assisted laser 
desorption/ionization-time of flight mass spectrometer; BCB, blood culture bottle. 
2.4 SMg from positive BCBs 
The workflow typically includes DNA extraction, library preparation, sequencing libraries, 
assembly of contigs, binning, and in silico analysis of the metadata. 
2.4.1 DNA Sample preparation for SMg from BCB  
The success of SMg is highly dependent on the quality and quantity of DNA extracted from a 
given specimen59. Therefore, for using SMg on clinical specimens in the microbiology 
laboratory, protocols must be tested, adapted, and validated according to the type of specimen. 
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Each specimen present unique and specific challenges reflecting their matrix and 
concentrations of the target pathogen and resident microflora. E.g. bacterial load will be not the 
same in specimens from normally sterile sites such as joint spaces or periprosthetic tissue, 
compared to specimens taken from sites with colonizing flora, such as the throat or surgical 
wounds 113,198.  
DNA amplification inhibitors commonly found in BCBs include blood-derived heme 
compounds, heparin, EDTA, polyacetal sulfonate contained in the culture media, in addition to 
human DNA. Since the extraction method is from  BCB media inoculated with PJT, a feasible 
sample preparation method must involve not only the removal of potent inhibitors but also 
efficient cell wall disruption and subsequent recovery of microbial DNA, of a diverse range 
of microorganisms that potentially may cause PJI (Table 8)199.   
 
Currently, it is possible to find products that deplete host DNA and simultaneously extracts 
enriched microbial DNA in one kit e.g. the Ultra-Deep Microbiome Prep or the Complete5 
DNA extraction kit (Molzym GmbH, Bremen, Germany). There are also kits for the depletion 
of host DNA and microbial DNA enrichment that can be combined with any microbial DNA 
isolation kit. E.g. MolYsis Basic5 kit (Molzym, Bremen, Germany).  Host DNA depletion and 
microbial DNA enrichment using Molzym kits are performed before DNA isolation. However, 
e.g. NEBNext Microbiome DNA Enrichment Kit (New England BioLabs, Ipswich, MA) do it 
after DNA isolation. Other methods have also been reported but are not available as commercial 
products, such as host cell lysis with detergents200 or ox bile201, among others65. 
 
Separation of bacterial DNA from host DNA in clinical samples may have an important impact 
on downstream applications, involving microbial diagnostic systems. The host genome 
interferes with the detection and diagnosis of pathogens resulting in decreased sensitivity19. The 
majority of sequencing reads produced during SMg are identified as human, which is on 
average 1000 times larger than the average bacterial genome. While bioinformatics tools can 
remove human reads, greater sequencing depth (which leads to an increase in cost) is required 
to obtain enough pathogen reads for the identification of a causative agent and obtain 
information regarding resistance or strain type. 
 
Methodologies focusing on depleting host cells from the original specimen by exploiting 
differences in cell surface structure between human cells and bacteria for selective lysis of host 
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cells have been developed. One of these methodologies is the MolYsis basic kit from Molzym. 
The MolYsis kit works based on the principle that human cells are first selectively lysed by the 
use of chaotropic reagents. Then the released host DNA is degraded by a MolDNase (which is 
active in the presence of chaotropes in the lysis buffer) prior to the extraction of DNA 
from microorganisms. Bacteria present in the specimen are then sedimented, washed, and 
subjected to DNA extraction (Figure 7). 
 
 
Figure 7. MolYsis kit Protocol for the depletion of host and horse DNA followed by DNA 
extraction. Modified from the source:(https://www.molzym.com/technology). 
 
The MolYsis5 kit has been successfully used for direct sequencing from different types of 
specimens such as subgingival paque202, sonicate fluid65, and urine5, among others. However, 
it is important to be aware of potential limitations that should be taken into consideration when 
using MolYsis in clinical diagnostics.  For this study, total gDNA was extracted from the BCBs 
using the QIAamp BiOstic Bacteremia DNA Kit (Qiagen, Hilden, Germany). Samples were 
pre-treated using the MolYsisTM Basic5 kit (Molzym, Bremen, Germany) to deplete human 
DNA from the samples before DNA extraction. In order to find the most suitable procedure for 
extracting DNA from BCBs, DNA was extracted with or without pretreatment with the 
MolYsis5 kit (Figure 8).  
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Figure 8. BCB DNA sample preparation methods tested in this project 
2.4.2 Library preparation  
The main objective when preparing a sequencing library is to create as little bias as possible25. 
Library preparation in SMg is possibly the most unbiased approach because the library covers 
all the genomes in the sample according to their frequency. However, the sequencing depth is 
minimized1. There are a variety of library preparation kits and sequencing platforms available 
that can be used for SMg. The selection depends on the cost, the number of samples, the 
availability of materials, and services203. The main concern about library preparation for SMg 
is related to amplification. The sequencing process requires a representative source of the 
genome(s) under investigation25 and certain types of samples yield small amounts of DNA, 
sometimes requiring amplification during library preparation which may generate 
representation biases in the original DNA content1.  
 
In our study, DNA was prepared as a standard Illumina library using the ThruPLEX DNA-seq 
DNA-sequencing Kit (Rubicon). This library preparation kit has high multiplexing capability 
with improved performance for Illumina Next Generation Sequencing (NGS) Platforms. 
ThruPLEX DNA-seq DNA-sequencing Kit from Rubicon Genomics is compatible with the 
Illumina platforms for whole genome sequencing or for target enrichment workflows204. 
ThruPLEX™ kit enables library preparation from 0.05 to 50 ng of DNA distinct to other NGS 
library preparation kits, which are based on ligation of Y-adapters, ThruPLEX uses stem-loop 
adapters to construct high quality libraries in a fast (two hours) and efficient workflow. In fact, 
ThruPLEX is considered the fastest and most sensitive library prep kit available205, with lower 
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duplication rates when compared with the Nextera, with less bias in the coverage (i.e fewer 
dropout regions and fewer regions with unnecessary deep coverage), easy for controlling the 
size of the library inserts, which has benefits for sample-sample yield and also increase the 
chances of success with the run. All of these features make ThruPLEX especially useful for 
clinical samples. 
2.4.3 SMg Sequencing 
One of the most commonly used methods in SMg studies is Illumina sequencing-by-synthesis 
(San Diego, CA), due to its high sequence throughput, low error rate, and low sequencing cost 
per base. It is important to note that this technology has the disadvantage of barcode index 
switching, in which high-frequency indices, that are designed to uniquely identify multiplexed 
samples may be misassigned during scanning of the flow cell. For SMg, this can lead to 
microbial reads from one sample containing a high titer pathogen cross-contaminating other 
samples on the same run, thus generating false-positive detections. This problem is intensified 
in the higher throughput HiSeq and NovaSeq sequencers due to the new chemistry techniques1. 
 
In this project, sequencing was performed using a MiSeq sequencer (Illumina) with v2 
chemistry and 500 cycles for 250 bp paired-end sequencing. The criteria selection for using this 
platform was based on the number of samples sequenced (small sample size), previous reports 
in clinical metagenomic studies, and the availability of the sequencing center.  
2.4.4 Bioinformatics Pipeline 
The bioinformatic pipeline is a fundamental component of the SMg workflow. Particularly for 
clinical diagnosis, SMg bioinformatic pipelines use a number of different algorithms and tools 
developed for research on microbiome or environmental metagenome. Therefore, it is 
important to make custom optimization and modifications for the tools used but also to the 
reference databases used during the analyses for the purpose of clinical validation206. An SMg 
bioinformatic pipeline consists of a series of steps where the raw data (FASTQ files) generated 
from the sequencer can be processed through several different computational analysis tools. 
The typical NGS bioinformatic pipeline consists of three steps: reads preprocessing, data 
analyses, and interpretation. The workflow and the bioinformatic tools used during this study 
are summarized in Figure 9. In paper II, the analysis ends with the taxonomical assignment of 
the reads, while in paper III, the whole pipeline was followed. 
 




Figure 8. Bioinformatic pipeline followed during this project. Abbreviations: AMR, 
antimicrobial resistance; cgMLST, core genome multi-locus sequence typing; wgMLST, whole 
genome multi-locus sequence typing. 
 
2.4.5 Data preprocessing and quality assessment 
Sequencing data is often provided as raw reads which are preprocessed prior to data analysis. 
Reads preprocessing consists of the trimming of adaptors, low quality reads, and complex 
sequences filtering, followed by the data subtraction of reads mapped to background genomes, 
e.g. human genome, the PhiX phage and the horse genomes in the case of this project.  
 
Errors such as base calling errors, poor quality reads, etc. occur during sequencing29. Therefore, 
it is important to assess the quality of the reads before starting to analyze the data generated. In 
this step, the quality of the raw reads is evaluated, to remove the reads that are not meeting the 
standards. Commonly, raw data are provided in FastQ files. They are an ASCII-based format 
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containing all the raw sequencing reads, the filenames and their ASCII-coded quality score for 
every single base207. Quality scores are based on the Phred score, a logarithmic error 
probability. In order to assess the quality of the raw sequencing reads, several bioinformatic 
tools have been developed, such as FastQC, NGS QC toolkit, and QC-Chain. One of the most 
used preprocessing procedures is read trimming. This procedure removes low quality portions 
of the reads while preserving the longest high-quality part of an NGS read. Then, adapter 
sequences used for the library preparation should be removed from the reads because they interfere 
with downstream analyses. Trimming is performed at the ends of each read to remove adapter 
sequences, which contain the sequencing primer binding sites, the index sequences, and the sites 
that allow library fragments to attach to the flow cell. The trimming step, although reducing the 
overall number and the length of reads, raises quality to acceptable levels. Several tools have 
been developed to perform trimming of Illumina data, such as Trimmonatic, Cutadapt, BBtools, 
and AdapterRemoval, among others208. The choice of the tool is highly dependent on the 
dataset, downstream analysis, and parameters used. 
 
In the diagnostics of infectious diseases, it is important to detect and resolve DNA 
contamination from known sources. Common sources of contamination with foreign DNA 
include e.g. carry-over from samples previously loaded onto a sequencing machine or libraries 
from genomes of other species added intentionally for quality control or the host DNA209. For 
instance, Illumina offers PhiX libraries from the PhiX bacteriophage genome to provide 
quality control. If PhiX is used during library preparation, these libraries should be removed 
to avoid integration into the target genome(s)210. The raw reads produced need to be aligned 
to the reference genomes of the contamination sources in order to be detected and then 
filtered. The aim of aligning a read to the reference genome (mapping) is to find the 
chromosomal position the read is most likely coming from. If only perfect matching positions 
are sought for a reference sequence, no variation can be found. Several tools are currently 
available to map reads against pre-specified genomes, among them: BWA211, Deconseq212, 
Bowtie213, BBMap214, and fastqScreen209. 
2.4.6 Data analyses  
Data analyses are considered one of the biggest challenges concerning the introduction of NGS 
in the clinical microbiology laboratory215. Depending on the analytic approach, the remaining 
reads can go directly to taxonomic classification and assignment of appropriate phylogenetic 
groups by comparing them to a genomic database, or they can be assembled into longer 
  Choice of Methods 
 49 
sequences called contigs. Contigs can be grouped by species into discrete units, referred to as 
bins for taxonomic identification to the lowest taxonomical level and downstream analyses for 
pathogen identification19,20.  
 
Though it is possible to analyze sequence data without assembly, most analyses can be 
improved by constructing longer contiguous sequences (contigs)216 through an assembly 
process. Metagenomic assembly is a computational process with the aim of reconstructing 
genes and genomes from metagenomic samples by combining the short reads to build larger 
stretches of DNA217. An assembly algorithm is then implemented, to compile reads into contigs. 
Several assembly tools have been published for short-read metagenomics, as Illumina reads. 
Among the assemblers using paired-end reads are MEGAHIT218, SPAdes219, and Omega220, 
among others221.   
 
Metagenomics classifiers tools match sequences, typically reads or assembled contigs against 
a database of microbial genomes to identify the taxon of each sequence222. Some programs 
return an assignment of every read, while others only provide the overall composition of the 
sample. Methods for the analysis of metagenomic datasets can be classified into three classes: 
First, kmer-based read classifiers. This class includes tools like Kraken. Second, alignment-
based methods, for complete genomes or marker genes only or translating the DNA and 
aligning to protein sequences. This category includes tools like MetaPhlan223 and MG-RAST. 
Third, Bayesian or EM-based estimators. This class includes Bracken224. 
 
Kraken225 is a fast taxonomic classifier using in-memory k-mer search of metagenomics reads 
against a database built from multiple genomes by using an algorithm that relies on exact k-
mer matches, replacing alignment with a simple table lookup. Kraken constructs a database that 
stores, with every k-mer in every genome, the species identifier (taxonomy ID) for that k-mer. 
When a k-mer is found in two or more taxa, Kraken stores the lowest-common ancestor (LCA) 
of those taxa with that k-mer. This works on reads or contigs of a metagenomics data set. 
Kraken maps reads to the taxonomic tree, not to a specific level such as species or genus. 
Bracken226 is an extension of Kraken that estimates species- or genus-level abundance based 
on a Bayesian probability algorithm222.  
 
Resistance genes and virulence factors databases play an essential role in studying the resistome 
and the virulome from microorganism(s) in clinical samples. A critical first step in many such 
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approaches is the construction and curation of databases. There are several AMR databases that 
have been developed, including CARD80,81, ARDB82, ARG-annot, and ResFinder79. However, 
they were not developed for clinical purposes and therefore they have a certain degree of 
restriction in clinical diagnosis. On the other hand, the virulence factor database (VFDB)85,86 
provides knowledge of VFs from various bacterial pathogens and serves as a comprehensive 
warehouse of bacterial pathogenesis knowledge for the scientific community86. 
2.4.7 Molecular typing 
The genetic relationship between isolates can be investigated. There are two approaches using 
a multi-locus sequencing typing (MLST) approach that can be applied to SMg data: Core 
genome multi-locus sequence typing (cgMLST) and the whole genome multi-locus sequence 
typing (wgMLST)11. 
 
By cgMLST, the conserved core genome is analysed via Sanger sequencing, unlike the 
conventional MLST, which only looks at seven gene regions. cgMLST schemes interrogate 
thousands of gene regions or alleles. The allelic pattern (i.e. the identity of the sequence at each 
allele) is compared across isolates and an allelic distance number is calculated (i.e. the number 
of alleles that are different between 2 isolates). This number is used to define the relatedness of 
the isolates227. On the other hand, wgMLST, which includes a set of variable accessory genes. 
Several software packages, such as SeqSphere (Ridom) and BioNumerics (Applied Maths, 
Biomérieux), or online tools, such as EnteroBase and BIGSdb (Bacterial Isolate Genome 
Sequence Database, can be used for this approach228. Each approach has a source of bias and 
associated limitations227. 
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Summary of Results 
PAPER I: Culturing periprosthetic tissue in BacT/Alert® Virtuo blood culture system leads 
to improved and faster detection of prosthetic joint infections 
 
• We showed that the BacT/Alert® Virtuo blood culture system effectively detected 
relevant bacteria from PJT specimens in both spiked and clinical samples, and the 
method was reproducible  
• The BCB method was found to be as sensitive (79 %) as the conventional method (76 
%) (p = 0.844) during analyses of clinical samples.  
• The BCB method yielded positive results much faster than the conventional method: 
89% versus 27% detection within 24 h, respectively.  
• More than 80% of the bacteria were detected in less than 20 h using BCBs, compared 
with the five days needed to obtain a similar percentage by the conventional method.  
• The median detection time was 11.1h for the BCB method (12 h and 11 h for aerobic 
and anaerobic BCBs, respectively.  
 
PAPER II: Shotgun-Metagenomics on Positive Blood Culture Bottles Inoculated with 
Prosthetic Joint Tissue: A Proof of Concept Study 
 
•  Our DNA preparation method resulted in high quality microbial DNA from all samples, 
both with and without human DNA depletion, allowing downstream SMg.  
• By SMg we were able to identify relevant PJI pathogens, and all bacteria identified by 
the culture methods were also identified through SMg.  
• The use of MolYsis resulted in a higher proportion of bacterial reads compared with 
untreated samples (96 % versus 87 %).  
• Only 0.07 % of the reads were classified as humans in the clinical sample, and in the 
negative control 1.4 % human reads.  
• We obtained a high enough sequencing depth by using this SMg method indicating that 
it is possible to multiplex samples reducing costs considerably.  
• We show a high sequencing quality, low human DNA content (<1 %), a high number 
of bacterial reads, and complete genome coverage of sufficient depth (PC1, S. aureus: 
775x and PC2, E. coli: 209x). 
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PAPER III: Shotgun-metagenomics for typing and prediction of antibiotic resistance and 
virulence determinants in S. aureus from prosthetic joint tissue on blood culture bottles.  
 
• We obtained a high sequence quality, low human DNA content, a high number of 
bacterial reads, and complete genome coverage of sufficient depth for identification 
and typing of S. aureus and prediction of virulence and AMR profiles.  
• Reads-based data analysis was found to be a better approach for pathogen identification, 
while for the AMR profiling the contigs-based approach gave a more complete picture.  
• AMR and virulence profiles for all the samples were generated. We detected 7 and 73 
different resistance and virulence genes in S. aureus, respectively, in the 20 samples 
analyzed (including the spiked sample).  
• The disagreement rate between the phenotype and the genotype was 25 % for S. aureus 
phenotypically resistance and genotypically susceptible to penicillin (false negatives). 
In the rest, phenotypes could be explained by the presence of AMR genes, e.g. fusB or 
fusE, for fusidic acid resistance, and bla- operon members for penicillin resistance. 
However, predicted resistance by genotype but susceptible phenotype (false positives) 
were found in some cases, e.g. presence of the tet(38) gene in all S. aureus isolates, but 
any expressed tetracycline resistance. 
• We identified genes encoding virulence factors known or proposed to play a role in PJI, 
among them aur, clfA, can, fnbA, hld, hlgA-C, sdrD-E, spa, sspA-C, hly/hla. 
• Typing from SMg data showed that S. aureus grouped into eight phylogenetically 
diverse MLST CCs.  
• Our work demonstrated that it is highly possible to perform identification, typing, and 





SMg has emerged as a promising approach for diagnosis from clinical samples50.  A single 
metagenomics analysis has the potential to detect all, common, rare and novel pathogens9, and 
provides information on all microorganisms  present in a sample, even if the sample contains a 
complex (polymicrobial) community54,229. SMg applied to clinical specimens has the potential 
for pathogen identification, outbreak investigation, and prediction of antimicrobial resistance 
(AMR) in clinical microbiology laboratories. In this thesis, we wanted to explore the use of this 
emerging approach for the microbiological diagnosis of PJI, since it is an interesting infectious 
model, recognized for being challenging, especially in the detection of the microorganism(s) 
causing the infection.  
 
Diagnosis of PJI is complicated by the wide array of pathogens implicated, potentially 
undetected polymicrobial infection, and the fact that most of the methods conventionally used 
to make microbiological diagnosis have low sensitivity and specificity, leading to 10-45% 
false-negative results96,196,230,231. Culture of peri-operative samples can be falsely negative 
because there are various factors that affect the microbiological results, such as previous 
antimicrobial therapy, a low inoculum of microorganism, the presence of microbial biofilm(s), 
low number of tissue specimens, inappropriate culture medium, inadequate culture incubation 
time, or prolonged time to transport the specimen to the laboratory. Despite the known low 
sensitivity, the culture of PJT specimens on agars and in broths is routine. However, a rapid, 
sensitive, and specific method is needed. 
 
In recent years, a variety of measures and tools have emerged to aid the diagnosis of PJI 
including the application of SMg, which despite its huge potential is still in its infancy. There 
are significant concerns regarding performance, validity, and clinical significance75. In fact, it 
is currently best positioned as a complementary technique to be used alongside culture and 
other traditional methods and may be of special interest, when both conventional and enhanced 
molecular testing fails9. These have encouraged us for further research on possible solutions to 






BCB, the base 
The use of BCB is one of the techniques proposed to improve the sensitivity of PJI sample 
cultures, including PJT194,196,197,232. There are several studies published about the inoculation of 
BCB with PJI specimens for microbiological diagnosis. Automated BCB systems have been 
used for culturing synovial fluid167–169,233–238, sonication fluids from explanted prostheses166,170–
172,174,239–241 and periprosthetic tissue specimens104,174,194–197,241–244. The focus has been mainly 
on the comparison between the use of the BCB method and the conventional culture. In 
addition, there are studies about the use of different BCB systems (BD BACTEC or 
BacT/Alert®), for a specific PJI specimen type and using the same BCB system with different 
PJI specimens. However, this approach has not been widely adopted and has been evaluated in 
a limited way196. To the best of our knowledge, most studies on PJI to date have used the BD 
BACTEC BCB system. Therefore, an evaluation of the BacT/Alert® Virtuo blood culture 
system for PJT was missed, despite being one of the most common BCB systems used 
worldwide. In the paper I, we evaluated the performance of this BCB system for this type of 
specimen (PJT).  
 
We found that the use of the BacT/Alert® Virtuo blood culture system was found to be as 
sensitive as the local conventional method (79 % vs 76 %, p = 0.844, respectively). Although 
other studies have reported higher sensitivities196,197,244, a meta-analysis evaluating the 
diagnostic accuracy of PJT culture in BCB reported that the pooled sensitivity of tissue culture 
in BCB was 70 % and the specificity 97 %, suggesting that BCBs may be of great value in PJI 
diagnosis239.  
 
Another important aspect of PJI diagnosis is the rapid detection of pathogens, the earlier the 
diagnosis, the better the outcome of subsequent treatment243. We found that the use of the 
BacT/Alert® Virtuo blood culture system yielded positive results much faster than the 
conventional method (89% against 27% detection within 24 h)245. This has been supported also 
by the previous studies194,196,245, e.g. Minassian et al. showed that PJT cultured in BCB resulted 
in the growth of most microorganisms within 3 to 5 days, in aerobic and anaerobic cultures, 
respectively, with detection rates of 95 % and 96 %, respectively. In addition, Peel et al. 
reported that aerobic and anaerobic BCB were positive within the first day of incubation194,196.  
 
Besides the culture of PJT samples, other PJI specimens have been inoculated into BCBs. 
However, when comparing the different PJI specimens, the culture of PJT into BCB improves 
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the diagnostic yield of microbiological culture and may approach or be superior to sonication 
culture170. We recommend the implementation of the BCB method for PJT samples in the 
laboratory if resources allow it. BCBs provide a semiautomated method for culturing PJI 
specimens that, incorporated into the routine lab, may provide many different significant 
advantages, among them:  
 
(i) BCBs may enhance the culture yield, allowing a sensitivity rate as compared with 
the conventional plate/broth culture system. This by neutralizing the effect of 
antibiotics (by diluting and binding resin)246, improving culture conditions (agitation 
and rich media composition)195,247, and because the sample volume inoculated into 
the bottle is larger than the one inoculated onto agar plates196,241.  
(ii) BCBs allow the identification of a broader spectrum of pathogens including slow-
growing bacteria248. 
(iii)  BCBs also provide partial automation of the workflow, mechanical loading and 
unloading of bottles, faster detection of microorganisms present in the samples, 
minimizing the risk of contamination, and reducing labor requirements in the 
clinical laboratory which minimizes human errors104,194,196,245. 
On the other hand, there are certain disadvantages using BCBs, for instance, the higher rate of 
false-positive results (in our study this was low 1.2 %), cost of BCBs, cost of waste disposal, 
and capacity problems in the laboratories170,232. Therefore, before implementation, laboratories 
adopting the protocol need to perform the appropriate validation, since BCB are not approved 
by the FDA for the culture of tissue specimens170. In fact, the translation of this test system into 
the clinical application at the local level was the main goal of this part of the project (Paper I). 
The combination of BCB and SMg  
First-line culture-based methods are powerful tools that usually are successful in establishing 
the diagnosis. However, they are looking for etiological agents that are associated with a 
specific disease and the results obtained may be incomplete when novel pathogens, 
uncultivable, strictly anaerobic, or very fastidious species are involved. When the first- line 
investigation tools fail to identify the causative pathogenic agent, it is important to have 
alternatives113. Currently, a large number of tests are available. Microbiological methods differ 
across institutions and have varying criteria and protocols. The most effective diagnostic 
strategy is likely formed by a combination of conventional and new diagnostic strategies for 
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PJI. Research into improving all aspects of culture-based methods and new alternative strategies 
to replace or support current microbiological methods is needed 249. Further research is needed 
to integrate many of the new techniques in the clinical laboratory routine. 
SMg may make a further contribution to the PJI diagnosis. To the best of our knowledge, there 
are no studies about SMg on BCBs inoculated with any specimens related to PJI. Although it 
is true that there are no real problems in identifying bacteria that grow in blood culture media, 
our study was conducted initially as a laboratory method development (Paper II), where the 
aim was to test the use of SMg directly on positive BCBs inoculated with PJT to try to solve 
the limitations observed when using SMg directly on PJI specimens (synovial fluid48,71, 
sonication fluid66,68,69,250, and tissue72). Those studies found that DNA extracted from PJI 
samples was contaminated with a high concentration of human DNA, while the bacterial DNA 
yield was very low. Special attention has to be paid to the sample preparation, background 
contamination, bioinformatic pipeline for the data analysis, and the data interpretation.  
Host DNA and bacterial DNA yield 
The presence of an overwhelming amount of host DNA is one of the most important problems 
to be addressed in SMg200. Host DNA removal should depend on appropriate host DNA 
removal methods in samples rather than bioinformatic analysis250. Reduction of host 
contamination may facilitate greater pathogen coverage and depth, especially when the 
bacterial cells in the PJI samples is low since the host DNA reduce the sequencing yield. Several 
methods have been developed for host DNA depletion and enrichment of bacterial DNA. They 
include two main different approaches: depletion of host DNA prior to DNA extraction, 
including centrifugation and the MolYsis kit65,198,200,251,252, or depletion of human DNA post-
extraction, e.g. NEBNext® Microbiome DNA Enrichment65.  For this purpose, in Paper II, we 
used a method which includes a sample pretreatment step using MolYsis. The rationale for 
using MolYsis was based on a higher proportion of bacterial reads obtained, compared with 
untreated samples. Previous studies have demonstrated the efficacy of MolYsis for selective 
lysis of human or eukaryotic cells from PJI samples. In synovial fluid spiked with S. aureus, the 
use of MolYsis Kit produced a higher fold of microbial reads compared to the 
NEBNext® Microbiome DNA Enrichment kit65. However, it is important to be aware of 
potential limitations when using MolYsis in clinical diagnostics. MolYsis provides a solution 
for the removal of host DNA and enrichment of intact microorganisms253, but this raises a 
question about which bacterial DNA is removed during the MolYsis treatment. It may create 
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decreased sensitivity for microorganisms without cell walls, such as Mycoplasma spp., 
Ureaplasma, Chlamydia, or parasites19,254,255.  
 
An effective sample preparation method is important for use of SMg for diagnosing infectious 
diseases since their quality will be reflected in the data produced, which will directly affect the 
accuracy of species and AMR prediction. A sufficient number of bacterial reads is needed from 
the sequencing process in order to give accurate results. Our results show that the sample 
preparation method used results in a high sequencing quality, low human DNA content (<1%), 
and a high number of bacterial reads (3,7 M, 98 %), in addition to a complete genome coverage 
of sufficient depth (775x), allowing us to explore SMg application further. These results show 
significant improvement since a current metadata study reports a median of 79 % of sequence 
data classified as human DNA in SMg studies, with a median of 89 % (range 76-98 %) when 
using samples related to PJI including sonication fluid and tissue samples52.  
 
Background contaminants or clinically significant species? 
A significant limitation for the use of SMg assays for infectious disease diagnostic is the 
possibility of false-positives due to contamination48,66,67,196. The spectrum of organisms defined 
as reportable by SMg assays should be defined, and organisms determined to be background 
contaminants or clinically insignificant should be described1. This is very complicated since 
the common contaminants also are among the common causes of PJI, making it difficult to 
discern based on identification alone48. We are aware that defining a contaminant is not clear 
for BCB in the laboratory and this presents a challenge for SMg256. However, this issue is not 
restricted to SMg testing; in fact, this is a recognized problem in the microbiology laboratory, 
especially for culture and molecular assays75. BCBs can lead to contamination and it will vary 
from batch to batch. In fact, contamination may be present not just from the BCB media but 
also from reagents, kits, environment, or labware. This is a common problem due to the 
sensitivity of shotgun metagenomics67,72, e.g. whole genome amplification kits are also sources 
of contamination.  
 
There are some recommendations that have been suggested as good practice for quality 
assurance and validation of SMg for pathogen detection, among them: documenting lot 
numbers, replacing material, and including controls. Various strategies have been employed to 
identify the true presence of a microorganism versus contamination. Most studies look at the 
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reads found in the controls and compare with reads in other samples66, others set a threshold56, 
and some use the reads, DNA quantity, and relative importance of the bacteria68. 
We validated our findings by comparison with conventional culturing methods, where we 
already knew the outcome, i.e. complete microbiological data from culturing were available for 
all samples (Paper II). Positive and negative controls were included, and all of this information 
allowed us to assess the true species present versus contamination. In our data analysis, we 
include several of the various strategies that may help in the discrimination between species 
presence versus contamination, among them: the proportion of reads assigned to the species 
present, higher depth and breadth coverage with respect to other species detected by the 
taxonomical classifier, and comparison with respect to the species, the proportions of reads 
found in the negative control and to set an appropriate threshold. In paper II, we show how 
the threshold set for taxonomical classification influences the results. Our experience is that it 
is difficult to create sequencing libraries from negative controls since sometimes sufficient 
DNA yield is not reached for library preparation protocols257. Since only positive BCBs are 
included in this project, the threshold of detection was not determined.  
SMg Sensitivity  
The application of SMg for detecting causal pathogens has been the most studied so far. In fact, 
SMg has actually performed well in detecting the causal agents. Previous studies have 
demonstrated the potential of SMg in the diagnosis of PJI and that this can be used as an 
effective tool for the identification of pathogens258,259. The studies were using both, 
Illumina48,66, and nanopore 69,71,72,260 sequencing platforms. In paper II, three negative samples 
by the conventional culture method reported as positive from the BCB method were included. 
All bacterial species identified from the BCB culture method were detected indicating that the 
BCB method and the SMg were consistent concerning bacterial species found and they were 
found to be the most abundant species present in the sample (mean rate, 97.9 %). In other 
previous studies, the sensitivity of species identification using SMg on PJI samples has been 
estimated to be 82 % (72 – 88 %)52. We detected 100 % of the species detected by BCB (Paper 







Beyond Species identification 
The use of SMg on clinical samples could potentially guide therapeutic treatment strategies. 
Currently, there are some examples of successful identification of drug resistance from a 
microorganism in samples analyzed by SMg37,72. So far, there are studies that attempt to predict 
drug susceptibility mainly by comparison with phenotype, WGS of isolates or no comparison 
is made52. We did not perform WGS on pure isolates for confirmation of the SMg results, but 
WGS data from the reference genome from the strain used in the positive control (Spiked 
sample) confirmed the AMR-profile, typing and virulence gene determinants from SMg. In a 
meta-analyses study by Kumeren et al.52, it was shown that agreement between the genotype 
and phenotype was 83 % (68-92 %), very major rates (prediction sensitive, phenotype resistant) 
was 9% (2-27 %) and major error (prediction resistant, phenotype sensitive) was 1 % (0-
20%). Correct antibiotic susceptibility could be predicted in 94 % and 76 % in monomicrobial 
and polymicrobial samples, respectively in samples of bone and joint infection72.  
 
In Paper III, AMR profiles were generated for S. aureus in all the samples containing this 
species, alone (monomicrobial) or accompanied by S. agalactiae (polymicrobial). Prediction of 
AMR by SMg showed that the S. aureus isolates in this study are not very resistant, which is in 
accordance with data from the NORM surveillance system in 2018160, where AMR in S. aureus 
is dominated by only beta-lactamase (69.8 %) in blood cultures, while for the rest of the 
antimicrobials tested were <5 %, with 3 % of the isolates, phenotypically resistant to fusidic 
acid (n=1,445 isolates)160. No MRSA isolates were observed, neither by phenotypical nor 
genotypical testing. This result is not surprising, since the prevalence of MRSA varies 
according to the geographical area and Norway has a  low prevalence of MRSA  (0.8 % 
prevalence reported in the NORM surveillance system in 2018160).  
 
When comparing genotype and phenotype, the disagreement rate was 25 % for S. aureus 
phenotypically resistance and genotypically susceptible to penicillin (false negatives). In the 
rest, phenotypes could be explained by the presence of ARGs, e.g. fusB or fusE, for fusidic acid 
resistance, and bla- operon members for penicillin resistance. However, predicted resistance by 
genotype but susceptible phenotype (false positives) were found in some cases, e.g. presence 
of the tet(38) gene in all S. aureus isolates, but any expressed tetracycline resistance. This 
confirms that detecting the presence of ARGs in the clinical specimen does not guarantee that 
a gene is expressed. One of the limitations when using short-reads sequencing technology is 
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that it is difficult to reliably determine if an ARG is derived from plasmids or chromosomes. 
Moreover, plasmid detection based on short-read sequences is error-prone and unreliable 
particularly when larger plasmids (>50 kb) are involved261.  
 
A factor that plays a vital role in identifying the ARGs from SMg, is the database used.  Analysis 
of SMg data relies on the ability of bioinformatics pipelines to classify reads or contigs using 
established databases. In papers II and III, we have explored available free tools for data 
analyses and a pipeline was assessed. SMg requires bioinformatics expertise for results 
interpretation. Caution must be taken about the fact that different pipelines use different 
microbial databases, which in turn have different degrees of curation, accuracy, and 
completeness, resulting in varying sensitivity and specificity at this level. In paper III, we use 
the NCBI databases to detect ARGs. It is essential that those implementing SMg in the clinical 
laboratory use standardized database resources. However, there are many limitations in this 
regard. Among them, the fact is that no databases have been qualified for clinical use. NCBI is 
used only for detection of acquired resistance, and CARD is limited to only known resistance 
genes, without considering other resistance mechanisms such as point mutations, gene 
expression changes, and posttranslational modifications262. The choice of data analysis 
approach clearly influences the results. We consider that further research is needed to explore 
which approach gives the most suitable results.  
 
To the best of our knowledge, this is the first study using SMg for the generation of virulence 
profiles from bacteria, directly on clinical samples (Paper III). The strategy for identifying 
virulence genes is very similar to the one aiming for identifying ARGs73.  We have generated 
virulence profiles of S. aureus in our samples. We identified some VFs that are known or 
proposed to play a role in S. aureus  PJI, e.g. genes involved in colonization and attachment of 
host tissues or implanted biomaterials such as the sdrD, coding for the serine aspartate repeat 
containing protein D (SdrD) that has been found to play an important role in adhesion to 
desmoglein in human cells263 and the adhesins clfA and fnbA encoding clumping factor A and 
the fibronectin-binding protein A, respectively264. Several studies have indicated that 
fibronectin is the most important protein in this process. Comprehensive characterization of the 
VFs carried by the new pathotypes of emerging bacterial pathogens is critical for the effective 




In addition, cgMLST was used for strain-level typing. We used a contig-based approach, which 
means that we had sufficient depth for metagenomic assembly. cgMLST demonstrated that S. 
aureus in the samples belonged to several lineages, CC15, CC22, CC30, CC45, and CC5. These 
have also been reported before as common CCs assigned to the S. aureus collection from The 
Tromsø Staph and Skin Study (TSSS)265. Interestingly, in a recent study, it was found that 
commensal nasal isolates belonged to the same CCs as the PJI isolates, including the CCs 
assigned to our PJT samples, which also displayed the same genetic determinants as the PJI 








Concluding remarks and future aspects 
 
Despite the initial interest, SMg has many challenges to overcome before being implemented 
as a diagnostic tool in clinical laboratories. This thesis explored the use of SMg in clinical 
diagnostics of PJI for the identification of potential pathogens, AMR genes, and virulence 
determinants directly from BCBs inoculated with PJT specimens.  
 
Overall, we have covered various potential applications of SMg for diagnosis and 
characterization of bacteria potentially causing PJI. However, we do not believe that SMg can 
replace conventional culturing today. Most likely, SMg can be a potential diagnostic tool in PJI 
under certain situations, for instance, to support conventional culture in cases when PJI 
diagnosis is challenging, e.g. when bacteria are not detected by the laboratory methods but there 
are still clinical signs of the presence of infection. It is still possible to extract DNA from a 
negative BCB and analyze if pathogenic bacteria are present. The results of SMg can also be 
valuable even when concordant with laboratory results, not only providing a guarantee that the 
laboratory diagnosis is correct, but also allowing extra information, e.g. detecting coinfections 
and/or predicting antimicrobial susceptibility. SMg will most likely be a good supplementary 
tool for complicated infection with AMR and long-term antibiotic treatment. It will certainly 
also play an important role in future clinical microbiology research.  
 
Our results can be useful for further validation, and standardization for the use of SMg on BCBs 
inoculated with clinical samples for routine diagnostics. However, it is too early to define its 
place in the clinical microbiology laboratory and PJI diagnosis. We do not know how useful it 
is at this point, but SMg is in continuous development.  There are still challenges that must be 
solved in order to be able to explore the full potential of SMg. Despite the high cost of SMg 
and the other current limitations, the role of SMg in the microbiology laboratories will increase 
during the next years. Our SMg approach presents an alternative tool in PJI diagnosis, 
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Culturing periprosthetic tissue in BacT/
Alert® Virtuo blood culture system leads to
improved and faster detection of prosthetic
joint infections
Adriana Sanabria1* , Merethe E. O. Røkeberg2, Mona Johannessen1, Johanna Ericson Sollid1,
Gunnar Skov Simonsen1,2 and Anne-Merethe Hanssen1
Abstract
Background: Blood culture bottles (BCBs) provide a semiautomated method for culturing periprosthetic tissue
specimens. A study evaluating BCBs for culturing clinical samples other than body fluids is needed before
implementation into clinical practice. Our objective was to evaluate use of the BacT/Alert® Virtuo blood culture
system for culturing periprosthetic tissue specimens.
Methods: The study was performed through the analysis of spiked (n = 36) and clinical (n = 158) periprosthetic
tissue samples. Clinical samples were analyzed by the BCB method and the results were compared to the
conventional microbiological culture-based method for time to detection and microorganisms identified.
Results: The BacT/Alert® Virtuo blood culture system detected relevant bacteria for prosthetic joint infection in both
spiked and clinical samples. The BCB method was found to be as sensitive (79%) as the conventional method (76%)
(p = 0.844) during the analyses of clinical samples. The BCB method yielded positive results much faster than the
conventional method: 89% against 27% detection within 24 h, respectively. The median detection time was 11.1 h
for the BCB method (12 h and 11 h for the aerobic and the anaerobic BCBs, correspondingly).
Conclusion: We recommend using the BacT/Alert® Virtuo blood culture system for analyzing prosthetic joint tissue,
since this detect efficiently and more rapidly a wider range of bacteria than the conventional microbiological method.
Keywords: BacT/Alert® Virtuo blood culture system, Blood culture bottle, Prosthetic joint infection,
Periprosthetic tissue specimens
Background
Prosthetic joint infection (PJI) is one of the most serious
complications in joint implantation, and if untreated, it
may lead to severe pain, persistent dislocation and death
[1]. Approximately 2 % of all patients undergoing joint re-
placement worldwide are affected by this complication
[2–4] and this number is expected to increase with the in-
creasing incidence of arthroplasty surgery [3, 5–7]. The
early diagnosis of PJI plays a key role in successful treat-
ment, however, the condition is difficult to diagnose [8, 9].
The diagnosis of PJI is not standardized [9]. The
scheme currently in use combines clinical findings and
laboratory results [10] where the microbiological assess-
ment of periprosthetic tissue is an important criterion
for diagnosis of PJI [4, 10, 11]. Most clinical microbiol-
ogy laboratory diagnostic methods for PJI are based on
culturing bacteria on agar plate and in enrichment broth.
These methods are labor intensive, involve subculturing
and require daily inspection of enrichment broths. Fur-
thermore, low sensitivity and lack of specificity leads to
10 to 30% false-negative results [3, 12]. These numbers
are not surprising. The accurate diagnosis of PJI is
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challenging due to various factors that affect culture re-
sults such as: low bacterial inoculum concentration, prior
antibiotic therapy, formation of biofilms, and presence of
fastidious slow-growing microorganisms [4, 13, 14].
Hence, improved methods for culturing periprosthetic tis-
sue for diagnosis of PJI are urgently needed.
Inoculation of blood culture bottles (BCBs) is often used
for detection of microorganisms. Clinical microbiology la-
boratories use this semiautomated system with continuous
monitoring for microbiological diagnosis, mainly from
blood and other body fluids [15]. Previous studies have
demonstrated the potential of microbiological detection
using BCBs for culturing specimens related to PJI, such as
synovial fluid [2, 16], sonication fluid [5, 17–19], and pros-
thetic joint tissue (PJT) [5, 20–22]. However, there is little
data on the culture of PJT samples on BCBs and more evi-
dence is needed for safe patient management before
method implementation into the clinical setting [12].
The most common BCB systems used worldwide are
BD BACTEC (Becton Dickinson Instrument Systems,
Sparks, MD) and BacT/Alert® (bioMérieux, Marcy
l’Etoile, France) [15, 23, 24]. The systems are similar as
they detect CO2 production and change in pH but differ
in culture media composition and additives. There are
many technical factors that could affect the sensitivity of
blood culture systems, such as the clinical sample type,
volume of blood required for culture, and timing of
blood culture media, among others. In order to ensure
laboratory quality practice, it is important to verify,
evaluate and optimize the use of each BCB system when
users practice a subprocess that differs from the manu-
facturer’s guidelines, such as the implementation of BCB
for clinical samples other than blood [20].
To the best of our knowledge, most studies on PJI to date
have used the BD BACTEC BCB system [5, 17, 19, 22].
Here, we evaluate use of the BacT/Alert® Virtuo BCB sys-
tem for culturing periprosthetic tissue specimens by the
analysis of spiked samples (i.e. simulated PJT specimens
with known bacteria) and clinical tissue samples. The use
of BCBs emerges as an attractive tool for accurate and
timely diagnosis of PJI, leading to improvement in outcome
for this challenging type of infection.
Methods
Study design and samples
A prospective laboratory study was conducted over a 11-
month period (August 2017–June 2018). Periprosthetic
tissue specimens from hip, knee, elbow, ankle and shoul-
der, belonging to patients with suspicion of PJI were rou-
tinely submitted to the Department of Microbiology and
Infection Control at the University Hospital of North
Norway (UNN), Tromsø, Norway.
Samples were processed using routine standard micro-
biological procedures. Excess tissue samples (n = 158)
from 62 patients were evaluated through the BacT/Alert®
Virtuo BCB system. The mean number of specimens re-
ceived per patient was 2.5 (mode 2, range 1–5).
The BCB method was based on, and modified from,
similar methods used in previous studies [12, 20, 21]
while the conventional method was an already validated
in-house method.
Ethics statement
The work was performed in compliance with the ethical
guidelines established by UiT- The Arctic University of
Norway. The project was evaluated by the Regional Com-
mittee for Medical and Health Research Ethics, Norway
(document no. 2016/1247/REK nord), concluding that
ethical approval was not required. There were no ethical
issues to consider due to use of anonymous clinical sam-
ples and development of methodological procedures.
Spiking experiments
Six bacterial species reported as common microbio-
logical causes of PJI were used for spiking experiments.
Escherichia coli ATCC 25922, Staphylococcus aureus
ATCC 25923, Enterococcus faecalis ATCC 29212,
Staphylococcus epidermidis ATCC 12228, Bacteroides
fragilis ATCC 25285 and Cutibacterium (formerly Propi-
onibacterium) acnes (clinical sample).
Excess material of a native femoral head and sur-
rounding tissue from an anonymous donor was crushed,
sterilized (irradiated to 25Gy) and tested for contamin-
ation by culturing on agar plates. Fresh bacterial cultures
were suspended in NaCl 0.85% or in tryptic soy broth
(TSB) for aerobic and anaerobic strains, respectively, to
a 0.5 McFarland density. These were further diluted to
bacterial suspensions of approximately 103 colony form-
ing units (CFU)/mL.
A piece of sterilized crushed native femoral head and
tissue (≈1 cm3), i.e. a simulated PJT sample, was trans-
ferred to a 15 mL tube containing four mL of glucose
broth and five ceramic beads. Five hundred microliters
of the bacterial suspension (≈500 CFU) was added to the
glucose broth containing the tissue. After two minutes,
the mixture was homogenized using a FastPrep-24 in-
strument (MP Biomedicals, France) to 6.0 M/sec (meters
per second) for 40 s.
Subsequently, a Bact/Alert® BCB (FA Plus for aerobic
or FN Plus for anaerobic bacteria, bioMérieux, Marcy
l’Etoile, France) was inoculated with one mL of the ho-
mogenized suspension containing approximately 90–
150 CFU/mL and four mL of horse blood (TCS Biosci-
ences Ltd), for a final bacterial concentration of approxi-
mately 100 CFU/bottle. BCBs were incubated in the
BacT/Alert® Virtuo Microbial Detection System until sig-
naling for positivity, or for a maximum of 12 days. Time
to positivity was recorded. When growth was detected,
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one drop (≈50 μl) of the BCB medium was subcultured
on suitable media to confirm pure culture. Spiking ex-
periments were performed in triplicates and two repeats
were done within a time period of one month.
In total, 36 BCBs were spiked, corresponding to 24
BacT/Alert FA plus and 12 BacT/Alert FN plus bottles.
Inoculum densities, viability, and purity were checked at
different time points during the process by standard
microbiological methods. Tissue sterility control was
performed for each bottle type by adding sterilized tissue
and horse blood and incubating the bottles for 12 days
as mentioned above. An overview of the process is pro-
vided in Fig. 1.
Analysis of clinical specimens by the conventional and
the BCB method
The BCB based method was run in parallel with the
conventional diagnostic method. For the conventional
method, several operators in the clinical microbio-
logical laboratory were involved in reading of broth
and agar plates as part of the routine procedures,
while in the BCB method, only one person was in-
volved in the experiments. For both methods, each
tissue specimen (≈1 cm3) inoculated in four mL of
glucose broth containing five ceramic beads, was ho-
mogenized in a FastPrep-24 instrument at 6.0 M/sec
(meters per second) for 40 s (Fig. 1).
In the conventional method, 0.1 mL of the previously
homogenized solution was inoculated onto a set of agar
plates: blood, lactose, chocolate, Sabouraud and anaer-
obic blood agar (Fig. 1). All agar plates (aerobic and an-
aerobic) and the remaining homogenized solution were
incubated for five days at 37 °C under aerobic condi-
tions, with the exception of the anaerobic blood agar
plates, which were incubated in an anaerobic jar system
(Anoxomat® Mark II). Aerobic agar plates and the
remaining broth were visually inspected daily, while the
anaerobic plates where inspected after five days of incu-
bation. The broth was inspected for opacity (almost al-
ways cloudy) and subcultured on aerobic agar for three
days at 37 °C. Time to detection (TTD) for the conven-
tional method was recorded (defined as the time until
growth is detected on the subsequent agar plate cul-
tures). Conventional microbiological methods for identi-
fication of bacteria and fungi were performed on
positive subcultures.
In the BCB method, a blood culture set, corresponding
to an aerobic bottle (BacT/Alert FA Plus) and an anaer-
obic bottle (BacT/Alert FN Plus) was inoculated with
one mL of the homogenized tissue specimen using a
sterile syringe. Inoculated BCBs were enriched with four
mL of horse blood and incubated in the Virtuo system
up to 12 days. TTD, defined as the time when the BacT/
Alert® Virtuo blood culture system signaled positive, was
recorded, and one drop from the bottle was subcultured
on the agar plate set mentioned above.
For both methods, the identification of bacteria was
done using matrix-assisted laser desorption ionization-
time of flight mass spectrometry (MALDI-TOF® MS
Bruker Daltonics - microflex™) and standard microbio-
logical procedures (Fig. 1).
Statistical analysis
Descriptive statistics for categorical variables were based
on percentages and frequencies, while continuous vari-
ables were based on means, standard deviations (SDs),
medians and interquartile ranges (IQRs). In addition, the
McNemar’s test was used to evaluate if the differences
between the methods were statistically significant. Data
were analyzed utilizing GraphPad software 7.0e (Graph-
Pad Software Inc., CA, US).
Fig. 1 Flowchart of study design. A and D are common processes through all the methods (i.e. spiking experiments, blood culture bottle (BCB)
method and conventional method). * spiked tissue was only tested using the BCB method. MALDI-TOF MS, matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry
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Results
BacT/Alert BCB system for detecting PJI pathogens -
spiking
The detection rate in spiked blood culture bottles was
100% (n = 36) for both blood culture bottle types. BacT/
Alert FA Plus bottles inoculated with aerobic bacteria
flagged positive for growth before 15 h (h). The mean time
to detection was 10.1 ± 2.2 h with a minimum of 7.9 h and
a maximum of 14.1 h. For the BacT/Alert FN Plus bottles
inoculated with anaerobic bacteria, there was a remarkable
difference in TTD between the two strains tested. C. acnes
was detected approximately nine hours later than B. fragi-
lis. The mean TTD for bottles inoculated with tissue
spiked with B. fragilis was 25.2 ± 1.1 h with a minimum
TTD of 24.4 h and a maximum of 26.7 h, while for C.
acnes, the mean TTD was 209.2 ± 18.1 h with a minimum
and maximum TTD of 175.2 h and 223.2 h, respectively.
No difference was observed between the two repeats per-
formed (SD 2.3–2.2), suggesting that the method is repro-
ducible (Additional file 1).
BacT/Alert BCB system effectively detected pathogens
from PJT specimens
After having confirmed that the BCB system can effect-
ively detect bacteria commonly found in PJI, we next
wanted to test the method on clinical specimens. Each
clinical specimen (n = 158) was inoculated into two bot-
tles. Therefore, 316 BCBs were included in total for the
study, comprising 158 bottles per blood culture type.
Eighty (25.3%) BCBs signaled positive for growth,
comprising 44 aerobic and 36 anaerobic bottles. Positive
BCBs belonged to 46 (29.1%) clinical tissue specimens
from 24 patients (38.70%). Two subcultures of positive
BCBs were negative after culturing on agar plates and
therefore classified as false positives. These were in-
cluded as negative samples during all analyses.
Organisms were identified from both bottles in 73.9%
of the cases, from the aerobic bottle only in 21.8%, and
from the anaerobic bottle only in 4.3%. For aerobic cul-
tures, 89% of the microorganisms were detected within
24 h and 100% within 40 h. For the anaerobic cultures,
97% of the microorganisms were detected within 24 h,
and 100% within 31 h.
The mean TTD for aerobic bottles was 13.9 ± 7.8 h
within a range of 3.8–39.3 h. For the anaerobic bottles,
the mean, minimum and maximum TTD was 11.3 ± 5.4
h, 4 h, and 30.9 h, respectively (Additional file 1).
BCB method yielded faster results compared with
conventional method
Use of BCB for analyzing clinical tissue samples from
patients with suspicion of PJI was compared with the
conventional method according to method sensitivity,
TTD and the bacterium (monomicrobial) or bacteria
(polymicrobial) identified. For these analyses, a sample
was considered positive by the BCB method when one
or two of the bottle types flagged positive.
In total, 158 periprosthetic tissue samples from 62 pa-
tients were analyzed (Table 1). By using BCBs, 112 sam-
ples were negative and 46 positive, belonging to 24
patients. By the conventional method, 114 samples were
negative and 44 positive corresponding to 23 patients
(Table 1).
Sensitivity was calculated without considering patient
clinical data (Additional file 2). The BCB method ap-
peared slightly more sensitive (79%) than the conven-
tional method (76%). A two-tailed P value of 0.844 was
obtained, which means that this difference is not statisti-
cally significant. There was an 84% agreement rate be-
tween the two methods (Table 2).
TTD was recorded for the conventional method
through daily visual inspection of agar plates and the
glucose broth for bacterial growth. Fifty-nine percent of
the bacteria were detected within the first 48 h, consist-
ing of 27 and 32% of bacteria detected on the first and
second day of incubation, respectively. The TTD was
significantly reduced using the BacT/Alert FA plus and
BacT/Alert FN Plus bottles compared to the conven-
tional method. More than 80% of the bacteria were de-
tected in less than 20 h using BCB, compared to the 5
days needed to obtain a similar percentage by the con-
ventional method (Fig. 2).
Microbiology
In total, 46 out of 158 prosthetic joint tissue (PJT) speci-
mens belonging to 24/62 (38.7%) patients had microor-
ganisms detected by BCBs (Table 1). Positive samples
were mostly monomicrobial (88.7%), with a low rate of
polymicrobial (11.3%). The two methods gave similar bac-
terial species in 89% of the positive samples, while 11% of
the samples gave different bacterial species. The most
prevalent microorganisms found using both methods,
were Staphylococcus aureus, Enterococcus faecalis,
Streptococcus mitis/oralis, Streptococcus dysgalactiae and
Staphylococcus epidermidis (Fig. 2, Additional file 3).
Discussion
Conventional microbiological culture remains the bench-
mark in PJI diagnosis, despite the longer time period associ-
ated with culture-based methods. Alternative approaches
that are both effective and practical should be considered
for use in the clinical routine setting [25].
Here, we present an evaluation of the use of the BacT/
Alert® Virtuo blood culture system for microbiological
analyses of periprosthetic tissue specimens as a tool that
can be beneficially used for improving and accelerating
the diagnosis of PJI. Our analyses included spiked and
clinical samples, as well as a comparison of the BCB
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method with the local routine diagnostic method, for
TTD and organism(s) identification. The translation of
this test system into clinical application at the local level
was the main goal of the project.
Currently, a microbiological definition of PJI is the isola-
tion of two or more identical isolates from multiple speci-
mens, or the isolation of one highly virulent organism
from a single sample [9]. During this study, we worked
with excess material from the clinical microbiology labora-
tory and the number of specimens accessible per patient
varied from 1 to 5 (mean of 2.5). Thus, we have sampled a
sub-optimal number of tissue specimens which may have
led to diminished sensitivity. According to Peel et al. [26]
three PJT specimens obtained and inoculated into BCBs
will give the greatest accuracy of PJI diagnosis. Alterna-
tively, four PJT specimens should be obtained and cul-
tured using standard plate and broth cultures. We only
evaluated the microbiological status of each sample re-
gardless of the clinical and histopathological requirements
needed to be catalogued as a true PJI.
In microbiological diagnostics, culture media and in-
cubation time might have a high influence on test sensi-
tivity. BCBs from different manufacturers have different
compositions which could influence their performance
[27]. Most of the studies using BCBs for diagnosis of PJI
have used the BD BACTEC BCB system [2, 16, 22, 25,
28]. For the BacT/Alert system, only evaluation of syn-
ovial fluid has been reported [17, 28]. To the best of our
knowledge, this is the first study evaluating the BacT/
Alert system for culturing PJT specimens. This is rele-
vant since there are many routine laboratories working
with the BacT/Alert system from bioMérieux that could
favorably implement this method into their routine
procedures.
The optimal BCB incubation time is a matter of debate
[29]. Commonly, most BCBs with samples obtained
from sterile sites are incubated for five days [30]. Some
studies suggest prolonging the incubation time up to 14
days, to increase the method sensitivity for anaerobes
and slow-growing bacteria [30, 31], while others report
that longer incubation time does not increase the
method sensitivity [32]. In our study, BCBs were incu-
bated for a period of up to 12 days. During our experi-
ments, most of the bacteria could be detected within the
first two days of incubation (Fig. 2), except for the spiked
C. acnes, which needed a mean time of 209 h (8.7 days)
to be detected. In the analysis of clinical specimens, just
one clinical sample contained C. acnes by the conven-
tional method (possible contamination) while there was
not a single sample positive for C. acnes or other anaer-
obic bacteria, using the BCB method.
Recent studies have reported that the BacT/Alert FN
Plus performed poorly with regard to TTD for anaerobic
bacteria including C. acnes [24, 33]. In our case, since
the spiked anaerobic bacteria C. acnes (clinical strain)
and B. fragilis (ATCC 25285) could be detected by the
BacT/Alert® Virtuo system, the possible lack of sensitiv-
ity for the BCB method was discarded. Instead, lack of
anaerobic bacteria in the clinical tissue samples may be
due to a low bacterial load, to the absence of bacteria in
the sample, or to inadequate sample storage and trans-
port (anaerobic device was not used). Overall, our results
suggest that BacT/Alert® Virtuo system is able to detect
relevant bacteria for PJI, including anaerobic bacteria,
and that longer incubation times beyond eight days may
increase the detection rate of C. acnes.
Despite the results mentioned above, at the general
clinical level, long incubation times are not convenient
in the routine clinical setting. Early results are significant
for the patient as well as for the clinician. C. acnes is
also a common contaminant of bacterial cultures and its
role in PJI is not well defined [30]. We conclude that
further research is needed before implementation of long
incubation times to increase the detection rate of low
prevalent slow-growing bacteria such as C. acnes.
In this study, we also compared the BCB method and
the local conventional method. Use of BCBs yielded fas-
ter results than the conventional method. Shorter time
to detection, when using a BCB system, has been re-
ported earlier for different sample types (body fluids and
Table 1 Results from culturing periprosthetic tissue samples using the blood culture bottle (BCB) method and the conventional method
Tissue
samples
BCB method Conventional method
No. of samples (%) No. of patients (%) No. of samples (%) No. of patients (%)
Positive 46 (29.1) 24 (38.7) 44 (27.8) 23 (37.1)
Negative 112 (70.9) 38 (61.3) 114 (72.2) 39 (62.9)
Total 158 (100) 62 (100) 158 (100) 62 (100)
Table 2 Concordance between culturing clinical tissue samples
using the blood culture bottle (BCB) method and the
conventional method
Method No. of tissue
samples (%)Conventional BCB
+ + 32 (20.2)
– – 100 (63.3)
+ – 12 (7.6)
– + 14 (8.9)
Total 158 (100)
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tissue) [20, 26, 34]. Peel et al. [12] compared a BCB sys-
tem with standard agar and thioglycolate broth culture,
yielding faster results using BCBs and showing a 47%
improvement of sensitivity.
Additionally, we have used horse blood as enrichment
supplement for the BCBs, which has previously been
shown to produce high positivity rates and shortening of
time to detection [35]. The use of horse blood does not
significantly influence the performance of blood culture
systems [33, 36].
Also, the BCB method was as specific as the use of
agar and broth. These findings are very interesting for
cases in which rapid diagnostic methods are applied dir-
ectly from positive BCBs, shortening the time for patho-
gen identification and to determine antimicrobial
susceptibility. The BCB method was shown to be repro-
ducible during spiking experiments, documented by the
fact that there were no differences observed in the TTD
from the repeats performed at different time points
(Additional file 1).
S. aureus, E. faecalis and coagulase-negative staphylo-
cocci are among the most common causes of PJI [3, 12],
findings that agree with our results. Less commonly rec-
ognized pathogens, such as S. pneumoniae and Candida
parapsilosis have also been confirmed to be associated
with PJI [37–39].
The BCB method and the conventional method
were concordant in most cases. However, in some
cases different microbiological agents were identified
comparing the two methods. This finding may indi-
cate a higher sensitivity of the BCB method for detec-
tion of polymicrobial samples, since a higher number
of species was found in samples sub-cultured from
positive BCBs (Additional file 3). This result is similar
to the report by Velay et al. [22] using the BACTEC
BCB system. In cases where the methods yielded dif-
ferent microorganism(s), discrepancies were analyzed
(when possible) by comparing the results obtained
from other samples belonging to the same patient
and/or by the presence of a virulent bacterium (e.g. S.
aureus). We conclude that in most of the cases, use
of the BCB method was more accurate.
There are certain disadvantages using BCBs, e.g.
cost of BCBs, cost of waste disposal and capacity
problems [6, 26]. There is also a contamination risk
when inoculating the homogenized material and horse
blood into the bottles, and careful manipulation
should be applied.
Our study had some technical limitations. (1) Low
total number of clinical samples collected (n = 158) and
limited number of samples per patient (mean 2.5); (2)
Limited clinical data about the patients making it diffi-
cult to define a sample selection criterion to distinguish
between true PJI and contaminations; (3) the inoculum
volume for the BCB (1 mL) was ten times higher than
that inoculated onto the agar plates (0,1 mL) which
could partially explain the faster detection rate observed
with the BCB method, and (4) As for the time of detec-
tion, comparative studies of this type contain a bias re-
lated to the reading frequency which differed between
the two methods. In the BCB method, reading was done
automatically every 10 min, whereas in the conventional
method, reading was performed manually only once
daily to comply with local laboratory practice. This con-
firms the utility and advantages of the BCB Virtuo sys-
tem, including automatization, mechanical loading and
unloading of bottles, faster detection of microorganisms
present in the samples, minimizing the risk of contamin-
ation, in addition to reduce labor requirements in the
clinical laboratory [23].
Fig. 2 Time to detection (TTD) and organisms identified by (a) blood culture bottle method and (b) conventional method
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Conclusion
In summary, we present a laboratory procedure that may
be an important tool in the diagnosis of PJI. We recom-
mend using the BacT/ALERT® BCB system for culturing
periprosthetic tissue as a laboratory procedure that can re-
liably and rapidly detect bacteria commonly found in PJI,
thus facilitating early clinical decision making.
Additional files
Additional file 1: Table S1. Analysis of Time to detection (TTD)
obtained from the spiking experiments. Figure S1. Boxplots from analysis
of Time to detection (TTD) obtained from the spiking experiments.
(DOCX 354 kb)
Additional file 2: Table S2. Conventional and BCB method sensitivity.
(DOCX 13 kb)
Additional file 3: Table S3. Organism(s) identified by the blood culture
bottle (BCB) method and the conventional method. (DOCX 96 kb)
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Additional file 1: Figure S1. Boxplots from the analysis of Time to detection (TTD) 




Figure S1: Boxplots from the analysis of Time to detection (TTD) obtained from the 
spiking experiments. a) Time to detection for the BacT/Alert FA Plus bottles 
inoculated with the aerobic bacteria; b) Time to detection for the BacT/Alert FN Plus 
bottles inoculated with B. fragilis; c) Time to detection for the BacT/Alert FN Plus 
bottles inoculated with P. acnes. 
Min 8 7,9 7,9 24,5 24,4 24,4 213,6 175,2 175,2
1st Quartile 8,6 8,42 8,42 24,6 24,45 24,5 218,4 186,9 206,4
Median 9,65 9,2 9,35 24,7 24,5 24,6 223,2 204 214,8
Mean 10,22 9,93 10,07 25,3 25,13 25,22 220 198,4 209,2
3rd Quartile 10,97 10,5 10,95 25,7 25,5 26,05 223,2 210 221,4
Max 14,1 14 14,1 26,7 26,5 26,7 223,2 216 223,2
SD 2,31 2,21 2,22 1,21 1,18 1,07 5,54 20,96 18,11
Setup 1 & 2   
(hrs)
Statistical parameter
Anaerobic strains in BacT/ALERT FA Plusb
Bacteroides fragilis P. acnes
Aerobic strains in BacT/ALERT FA Plusa
Setup 1 & 2     
(hrs)
Setup 1 & 2    
(hrs)
Setup 1      
(hrs)
Setup 2       
(hrs)
Setup 1       
(hrs)
Setup 2       
(hrs)
Setup 1       
(hrs)
Setup 2       
(hrs)
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Method True positives Sensitivity 
Conventional  (32+12) / (44+14) x100 75,86% 
BacT/Alert blood culture system (32+14) / (46+12) x100 79,31% 
 
Additional file 3: Table S3. Organism(s) identified by the blood culture bottle (BCB) method and the conventional method. 
 
 
*FA: Aerobic bottle BacT/Alert FA Plus, FN: Anaerobic bottle BacT/Alert FN Plus 
 
FA FN
Monomicrobial 43 74 90,24 40 22 95,00
Staphylococcus aureus 9 18 36 43,90 18 18 15 7 35,71
Enterococcus faecalis 2 5 9 10,98 4 5 4 2 9,52
Stretococcus oralis/mitis 2 4 7 8,54 4 3 3 1 7,14
Streptococcus dysgalactiae 1 3 6 7,32 3 3 3 1 7,14
Staphylococcus epidermidis 4 4 5 6,10 2 3 4 4 9,52
Staphylococcus caprae 1 2 4 4,88 2 2 2 1 4,76
Micrococcus luteus 3 3 3 3,66 3 0 0 0 0,00
Staphylococcus hominis 1 1 1 1,22 1 0 0 0 0,00
Streptococcus parasanguinis 1 1 1 1,22 0 1 0 0 0,00
Stretococcus pneumoniae 1 1 1 1,22 1 0 0 0 0,00
Candida parapsilosis 2 1 1 1,22 1 0 3 1 7,14
Staphylococcus capitis 0 0 0 0,00 0 0 3 2 7,14
Corynebacterium 0 0 0 0,00 0 0 1 1 2,38
Acinetobacter baumannii 0 0 0 0,00 0 0 2 1 4,76
Propionibacterium acnes 0 0 0 0,00 0 0 1 1 2,38
Polymicrobial 8 8 9,76 2 2 5,00
 Enterococcus faecalis + Pseudomonas aeruginosa + Dichelobacter nodosus  + Campylobacter jejuni 1 1 1 1,22 1 0 0 0 0,00
Enterococcus faecalis  + Serratia licuefaciens 1 1 1 1,22 0 1 0 0 0,00
Acinetobacter pittii  + S. epidermidis +  Dichelobacter nodosus 1 1 1 1,22 1 0 0 0 0,00
Staphylococcus condimenti  + Burkholderia phymatum 1 1 1 1,22 0 1 0 0 0,00
Enterococcus faecalis +  Acinetobacter pittii 1 1 1 1,22 1 0 0 0 0,00
Staphylococcus epidermidis + Staphylococcus hominis 1 1 1 1,22 1 0 0 0 0,00
Candida parapsilosis + Micrococcus luteus 1 1 1 1,22 1 0 0 0 0,00
Staphylococcus epidermidis  + Staphylococcus dysgalactiae 1 1 1 1,22 1 0 0 0 0,00
Enterococcus faecalis + Acinetobacter baumannii 0 0 0 0,00 0 0 1 1 2,38
Coagulase negative Staphylococcus + Streptococcus viridans 0 0 0 0,00 0 0 1 1 2,38
Indeterminate 2 0 0 0,00 1 1 0 0 0,00
Total 82 100,0 46 38 42 100,00
Organism (s)
Methods
Blood culture bottle method Conventional Method
No of patients
Total No. of  
positive  samples 
Total No. of 
positive BCBs 
%
Blood culture bottle type Total No. of  positive  
samples 
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Blood Culture Bottles Inoculated
With Prosthetic Joint Tissue: A Proof
of Concept Study
Adriana Sanabria1* , Erik Hjerde2, Mona Johannessen1, Johanna Ericson Sollid1,
Gunnar Skov Simonsen1,3 and Anne-Merethe Hanssen1
1 Research Group for Host-Microbe Interactions, Department of Medical Biology, Faculty of Health Sciences, UiT –
The Arctic University of Norway, Tromsø, Norway, 2 Department of Chemistry, Centre for Bioinformatics, UiT – The Arctic
University of Norway, Tromsø, Norway, 3 Department of Microbiology and Infection Control, University Hospital of North
Norway, Tromsø, Norway
Clinical metagenomics is actively moving from research to clinical laboratories. It has
the potential to change the microbial diagnosis of infectious diseases, especially when
detection and identification of pathogens can be challenging, such as in prosthetic
joint infection (PJI). The application of metagenomic sequencing to periprosthetic joint
tissue (PJT) specimens is often challenged by low bacterial load in addition to high
level of inhibitor and contaminant host DNA, limiting pathogen recovery. Shotgun-
metagenomics (SMg) performed directly on positive blood culture bottles (BCBs)
inoculated with PJT may be a convenient approach to overcome these obstacles. The
aim was to test if it is possible to perform SMg on PJT inoculated into BCBs for pathogen
identification in PJI diagnosis. Our study was conducted as a laboratory method
development. For this purpose, spiked samples (positive controls), negative control and
clinical tissue samples (positive BCBs) were included to get a comprehensive overview.
We developed a method for preparation of bacterial DNA directly from PJT inoculated in
BCBs. Samples were processed using MolYsis5 kit for removal of human DNA and DNA
extracted with BiOstic kit. High DNA quantity/quality was obtained, and no inhibition
was observed during the library preparation, allowing further sequencing process. DNA
sequencing reads obtained from the BCBs, presented a low proportion of human reads
(<1%) improving the sensitivity of bacterial detection. We detected a 19-fold increase in
the number of reads mapping to human in a sample untreated with MolYsis5. Taxonomic
classification of clinical samples identified a median of 96.08% (IQR, 93.85–97.07%;
range 85.7–98.6%) bacterial reads. Shotgun-metagenomics results were consistent
with the results from a conventional BCB culture method, validating our approach.
Overall, we demonstrated a proof of concept that it is possible to perform SMg directly
on BCBs inoculated with PJT, with potential of pathogen identification in PJI diagnosis.
We consider this a first step in research efforts needed to face the challenges presented
in PJI diagnoses.
Keywords: shotgun-metagenomics, clinical metagenomics, prosthetic joint infection, blood culture bottles,
prosthetic joint tissue
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INTRODUCTION
Metagenomic next-generation sequencing (mNGS) refers to
shotgun sequencing of all available DNA and/or RNA in
a sample followed by the precise taxonomic identification
and classification of each sequence (Couto et al., 2018;
Rutanga et al., 2018). The application of shotgun metagenomics
(SMg) to clinical samples to recover information of clinical
relevance is emerging and it is known as clinical metagenomics
(Forbes et al., 2018).
Shotgun-metagenomics has a huge potential, particularly in
areas where conventional diagnostic methods have limitations
such as in prosthetic joint infection (PJI) (Thoendel et al.,
2018). It is a promising approach opening huge opportunities for
detecting, identifying and characterizing all potential pathogens,
providing at the same time additional inputs on important
characteristics for clinical management, such as antibiotic
resistance determinants, virulence factors, and bacterial evolution
(Wilson et al., 2019).
To date, several studies have provided evidence of the
potential and successful applications of clinical metagenomics in
a variety of clinical specimens including urine (Hasman et al.,
2014; Schmidt et al., 2017), respiratory secretions (Nakamura
et al., 2009; Bogaert et al., 2011; Schlaberg et al., 2017; Langelier
et al., 2018), cerebrospinal fluid (Schlaberg et al., 2017; Miller
et al., 2019), stool (Zhou et al., 2016), blood (whole blood, serum,
and plasma), and tissue (Ruppé et al., 2017). Several reviews
have summarized the advances, limitations and challenges in
the field (Padmanabhan et al., 2013; Simner et al., 2018;
Chiu and Miller, 2019).
There are many issues that need to be addressed before
performing clinical metagenomics in real time directly from
clinical samples as an integral part of routine diagnostic testing.
Among them are the technical challenges related to sample
preparation protocols, to process and analyze clinical specimens.
In this regard, it is important to consider that different specimen
types present their unique and specific challenges reflecting
their matrix and concentrations of the target pathogen(s) and
normal (resident) flora (Bachmann et al., 2018). Therefore,
when performing sequencing directly from a clinical sample,
special attention has to be paid to (1) contamination of host
DNA and other microorganisms, (2) low abundance of the
target organism present in the sample and (3) the presence of
DNA amplification inhibitors and other sample variables (i.e.,
sample type, matrix) (Mulcahy-O’Grady and Workentine, 2016;
Bachmann et al., 2018).
Prosthetic joint infection (PJI) is a serious complication after
joint implantation, occurring in 1–2% of primary arthroplasties
and 4% in revision arthroplasties (Ong et al., 2009; Corvec
et al., 2012; Izakovicova et al., 2019). The infection is associated
with high morbidity rates and diagnosis is challenging due to
Abbreviations: ATCC, American type culture collection; BCBs, Blood culture
bottles; ENA, European Nucleotide Archive; IQR, Interquartile ranges; MALDI-
TOF, Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry;
mNGS, metagenomic next-generation sequencing; PJI, Prosthetic joint infection;
PJT, Periprosthetic joint tissue; SMg, Shotgun-metagenomics; WGS, Whole
genome sequencing.
imperfect definition and imperfect diagnostic techniques (Tande
and Patel, 2014; Park and Patel, 2018). Undiagnosed PJI cases due
to culture-negatives have been estimated to a proportion of 10–
30%, for example due to ongoing empirical antibiotic treatment
(Tande and Patel, 2014; Peel et al., 2016). Culturing the causative
pathogen takes longer time and is problematic in less virulent,
fastidious and slow growing organisms (Schafer et al., 2008).
The diagnosis of PJI is not standardized (Parvizi et al., 2011).
However, the microbiological assessment of periprosthetic tissue
is the most important method and to date the gold standard
for diagnosing PJI (Parvizi et al., 2011; Yan et al., 2018). Due
to low sensitivity and specificity, rapid and accurate diagnosis
is still a challenge. Additionally, methods for rapid pathogen
identification directly on clinical samples such as multiplex
PCR, MALDI-TOF and whole genome sequencing (WGS) have
been developed (Greenwood-Quaintance et al., 2014; Patel, 2015;
Tagini and Greub, 2017). However, they are still dependent
on pure microbial culture in addition to the fact that some
of them do not give information beyond species identification
(Török et al., 2013). Research and development of new diagnostic
methods that overcome these limitations are required.
In a previous study, we assessed the use of a BacT/Alert R©
Virtuo blood culture system for culturing periprosthetic tissue
specimens (Sanabria et al., 2019). The blood culture bottle
(BCB) method was found to detect a wider range of bacteria
more rapidly than the conventional microbiological method.
Furthermore, previous studies have demonstrated the potential
of microbiological detection using BCBs for culturing specimens
related to PJI, such as synovial fluid (Hughes et al., 2001; Font-
Vizcarra et al., 2010), sonication fluid (Portillo et al., 2015; Shen
et al., 2015; Janz et al., 2016; Dudareva et al., 2018), and prosthetic
joint tissue (PJT) (Velay et al., 2010; Minassian et al., 2014; Peel
et al., 2016, 2017; Dudareva et al., 2018). The evaluation of SMg
in the diagnosis of PJI remains limited (Zhang et al., 2019). To
date, studies have investigated the application of SMg on tissue
specimens (Ruppé et al., 2017), synovial fluid (Ivy et al., 2018) and
sonication fluid (Thoendel et al., 2016, 2017, 2018; Street et al.,
2017; Sanderson et al., 2018; Yan et al., 2019), where the main
obstacle has been a high background of genetic material mainly
derived from the host, hampering the detection of pathogens
(Zhang et al., 2019).
So far, there are no studies about SMg on BCBs inoculated with
any specimens related to PJI. We believe that the combination
of inoculation of BCBs with PJT specimens followed by direct
DNA sequencing may be a beneficial strategy. Here, we developed
a proof of concept study with the aim of evaluating the use of
SMg on BCBs inoculated with PJT for pathogen identification
in diagnosis of PJI. Our study was conducted as a laboratory
method development, including PJT specimens and appropriate
controls. The aim was to test if SMg technology works on
this specific type of specimens, and for this purpose develop a
method for preparation of high-quality bacterial DNA from PJT
for downstream SMg, establish a bioinformatics pipeline, and
compare SMg results with conventional culture method results.
SMg was performed to investigate if it was possible to obtain an
acceptable high number of bacterial reads, genome coverage and
genome sequencing depth for identification of PJI pathogens.
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MATERIALS AND METHODS
Ethics Statement
This study was performed in accordance with the ethical
guidelines established by The Arctic University of Norway (UiT).
The project has been evaluated by the Regional Committee
for Medical and Health Research Ethics, Rec North, Norway
(document no. 2016/1247/REK nord), concluding that ethical
approval was not required. There were no ethical issues
to consider due to use of anonymous clinical samples and
development of methodological procedures.
Sample Collection
A sample collection of positive BCBs was obtained from a
previous study, where we evaluated the use of Bact/Alert R© BCBs
(bioMérieux, Marcy l’Etoile, France) for culturing PJT (Sanabria
et al., 2019). In brief, three different types of BCB samples were
obtained during that study: BCBs inoculated with PJT clinical
samples from patients with suspicion of PJI, BCBs inoculated
with tissue spiked with bacterial species reported as common
microbiological causes of PJI and a negative control which was
prepared by inoculating sterilized tissue (irradiated to 25 Gy)
from a crushed native femoral head. For further details on the
BCB sample preparation method, see Sanabria et al. (2019).
Bact/Alert R© BCBs were enriched with 4 mL of horse
blood, which has previously been shown to produce high
positivity rates and shortening of time to detection (Nylén
et al., 2013) and the PJT was analyzed in parallel with the
conventional diagnostic method. Bacterial identification was
performed using matrix-assisted laser desorption ionization-
time of flight mass spectrometry (MALDI-TOF R© MS Bruker
Daltonics – microflexTM).
In this study, 25 positive aerobic BCBs (BacT/Alert FA Plus)
inoculated with PJT were used initially to test two different
DNA sample preparation methods. Subsequently, DNA from
nine BCBs were selected for SMg. Selection criteria included:
samples with presence of a single species of microorganism
(monomicrobial) reported as common microbiological cause of
PJI and high quality/quantity of total DNA concentration of
at least 1 ng/µL bacterial DNA. Samples sequenced included:
samples with Staphylococcus aureus (n = 6), Staphylococcus
epiderimidis (n = 2), Enterococcus faecalis (n = 1), negative control
(NC, n = 1), and spiked samples (positive controls, PC1-3)
(n = 3). The negative control contained DNA extracted from a
BCB enriched with horse blood and inoculated with sterilized
tissue (irradiated to 25 Gy) from a donor with no suspicion
of infection. The three spiked samples were BCBs inoculated
with tissue spiked with a suspension of approximately 90–150
CFU/mL of Escherichia coli ATCC 25922, S. aureus ATCC 25923,
or S. aureus ATCC 25923, and Cutibacterium acnes (clinical
sample), respectively.
In addition, DNA from one of the nine clinical samples was
sequenced three times (sample 1: S1a, S1b, S1c) in order to
evaluate the impact of the sample preparation method on the
metagenomic results, and to determine a suitable number of
samples that could be multiplexed in one lane on the flow cell
during the sequencing process.
Figure 1 gives an overview of the number of samples and the
sample types included in each step of the process. An overview
of all the samples sequenced through SMg, including the controls
and their features are listed in Table 1.
DNA Preparation
Total gDNA was extracted from the blood culture bottles
using the QIAamp BiOstic Bacteremia DNA Kit (Qiagen,
Hilden, Germany). Samples were pre-treated using MolYsisTM
Basic5 kit (Molzym, Bremen, Germany) to deplete human
DNA from the samples before DNA extraction. In order to
find the most suitable procedure for extracting DNA from
BCBs, DNA was extracted with or without pretreatment with
the MolYsis5 kit. Sample pre-treatment and DNA extraction
methods were according to the manufacturer’s instructions and
the procedures were evaluated on the basis of DNA quantity
and quality. Total DNA concentration was measured using
a Qubit dsDNA HS Assay Kit (Life Technologies, Carlsbad,
CA, United States) and DNA quality (OD260/OD280 and
OD260/OD230) determined by Nanodrop.
qPCR
Each DNA sample was fold diluted 1:100 and 1:1000 after
determining these as suitable dilution factors to avoid inhibition
during amplification. Bacterial DNA concentration was
calculated by qPCR targeting the 16S rDNA gene. The standard
curve consisted of a 10-fold dilution series of a mix of gDNA
from bacterial species common to PJI: S. aureus ATCC25923,
E. coli ATCC25922 and S. epidermidis ATCC 12228. The primers
and the probe used were as follows: forward primer 5′-CGA AAG
CGT GGG GAG CAA A-3′; reverse primer 5′-GTT CGT ACT
CCC CAG GCG G-3′; probe 5′-(FAM)-ATT AGA TAC CCT
GGT AGT CCA-(MGB)-3′ (Bogaert et al., 2011). The 20-µL
PCR master mix consisted of 2X TaqMan Universal master mix
II with UNG, 10 µM of each primer (0.8 µL), 5 µM MGB probe
(0.8 µL), 2.6 µL DNA free water, and 5 µL of template DNA
(Cremers et al., 2014).
Before adding the DNA template, 1M DTT and dsDNase
(0.5 µL) from PCR decontamination kit (ArcticZymes, Tromsø,
Norway) were added. Samples were then decontaminated by
incubation at 37◦C for 20 min followed by 60◦C for 20 min
to inactivate the dsDNase. Amplification was preformed using
a 7300 Real-time PCR system (Applied Biosystems, Foster City,
CA 94404 USA) under the following conditions: 50◦C for 2 min,
95◦C for 10 min, 50 cycles of 95◦C for 15 s and 60◦C for 1 min.
The gDNA samples were stored at−20◦C until further use.
Metagenomic Sequencing
Sequencing libraries were prepared using the ThruPLEX R©
DNA-seq Kit (Rubicon Genomics, United States) following the
manufacturer’s instructions. Approximately 100 ng of DNA was
used as input for library preparation from the clinical and spiked
samples, while for the negative control, a little more than 1 ng was
used. The sequencing process was performed at the Norwegian
Sequencing Centre, Oslo, using a MiSeq sequencer (Illumina Inc.,
San Diego, CA, United States) with v2 chemistry and 500 cycles
for 250 bp paired-end sequencing. Samples were multiplexed
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FIGURE 1 | Overview of the number of samples included in each step of the process. aDNA from a BCB sample untreated with molYsis5. Treated: BCB samples
pre-treated with MolYsis5 before DNA extraction. Untreated: BCB samples with no pretreatment with MolYsis5 before DNA extraction.
TABLE 1 | Description of samples sequenced through SMg.
Sample Sample type inoculated in BCB DNA preparation method Microorganism identified Laboratorya (MALDI-TOF)
No Code BCB Conventional
1 S1a PJT (clinical sample) MolYsis5 + BiOstic S. aureus S. aureus
S1b PJT (clinical sample) MolYsis5 + BiOstic S. aureus S. aureus
S1c PJT (clinical sample) BiOstic S. aureus S. aureus
2 S2 PJT (clinical sample) MolYsis5 + BiOstic S. aureus S. aureus
3 S3 PJT (clinical sample) MolYsis5 + BiOstic S. aureus S. aureus
4 S4 PJT (clinical sample) MolYsis5 + BiOstic S. aureus S. aureus
5 S5 PJT (clinical sample) MolYsis5 + BiOstic S. aureus S. aureus
6 S6 PJT (clinical sample) MolYsis5 + BiOstic E. faecalis E. faecalis
7 S7 PJT (clinical sample) MolYsis5 + BiOstic S. aureus No growth
8 S8 PJT (clinical sample) MolYsis5 + BiOstic S. epidermidis No growth
9 S9 PJT (clinical sample) MolYsis5 + BiOstic S. epidermidis No growth
10 PC1 Tissue spiked with S. aureus MolYsis5 + BiOstic S. aureus NA
11 PC2 Tissue spiked with E. coli MolYsis5 + BiOstic E. coli NA
12 PC3 Tissue spiked with S. aureus and C. acnes MolYsis5 + BiOstic S. aureus NA
13 NC Tissue sterile BiOstic NA NA
aResults from our previous study (Sanabria et al., 2019) including BCB method and conventional method. S1–S9, clinical samples; PC1-3, spiked samples (positive
controls); NC, negative control; NA, not applicable.
with 3 or 4 samples per lane. To estimate how many samples
could be multiplexed in one MiSeq lane, one of the samples was
run on a single lane in a pilot assay.
Bioinformatic Data Analysis
The bioinformatic analysis can be summarized in two main
steps: reads preprocessing (Figure 2A) and taxonomic
analyses (Figure 2B).
Obtained raw reads were checked for quality using FastQC
software v0.11.81. Optical duplicates in fastq files were removed
using the program Clumpify v38.36 from BBTools suite2 with
default parameters. Adapter sequences were trimmed off and
the poor-quality reads were removed using BBDuk of BBTools
1http://www.bioinformatics.babraham.ac.uk/projects/fastqc/
2https://jgi.doe.gov/data-and-tools/bbtools/
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FIGURE 2 | Workflow summarizing the bioinformatic analysis in this study. (A) Reads preprocessing. (B) Taxonomic classification and sample composition
estimation.
suite. The minimal length and Phred score were set to 50 and
20 nucleotides, respectively. Contaminant DNA was identified
and removed by mapping all reads against the reference
genomes of human GRCh38.p13 (GCF_000001405.39), horse
(GCF_002863925.1) and the PhiX phage (Escherichia virus
phiX174, GCF_000819615.1) using Bowtie2 aligner in FastQ
Screen v0.13.0 (Wingett and Andrews, 2018).
Preprocessed PE reads were classified using two established
tools for taxonomic profiling of metagenomic samples: Kraken
(Salzberg and Wood, 2014), which is based on exact alignments
of genomic k-mers, and MetaPhlAn2 which is based on clade-
specific marker genes (Segata et al., 2012). However, in this work
we have chosen to focus more on the Kraken analyses.
Taxonomic classification with MetaPhlAn2 v2.7.7 was
executed with default parameters and using the database
provided by the tool, as of July 2019. Taxonomic classification
with Kraken v1.1.1 was performed using default parameters
against the 8 GB dustmasked miniKraken database constructed
from bacterial, archaeal, and viral genomes in Refseq, as
of Oct. 18, 2017. Re-estimation of abundance was done
using Bracken (Lu et al., 2017). The same pipeline for
taxonomical assignment and species abundance estimation
was applied to all the samples after downsizing the number
of reads by randomly sampling (using SeqKit v0.11.0.)
a proportion of reads from the full dataset. Subsamples
from 10 to 100% of the reads were extracted and analyzed.
In addition, the effect of setting a threshold for species
detection level when using Kraken classifier, was evaluated
by setting different threshold values (0, 10, 100, 500, 1000,
1500, 2500, 3000, 3500, and 4000 reads) on the spiked and
clinical samples.
Finally, as a control to test false taxonomic assignments by
Kraken, sequence reads belonging to the spiked samples and
the negative control were aligned against reference genomes
belonging to the top species hits from Kraken classification,
using Burrows–Wheeler aligner-maximum exact matches (BWE-
MEM) v0.7.17 (Li and Durbin, 2009).
Statistical Analysis
Descriptive statistics for categorical variables were
based on percentages and frequencies, while continuous
variables were based on means, standard deviations
(SDs), medians and interquartile ranges (IQRs). In
addition, Wilcoxon rank sum test was used to evaluate
if the differences between the DNA sample preparation
methods were statistically significant. The differences
were considered statistically significant with P-values
lower than 0.05. Data were analyzed utilizing GraphPad
Prism software, version 8.3.0 (GraphPad Software Inc.,
CA, United States).
Classification results from the metagenomics experiments
were explored using the Pavian R package version 0.8.4
(Breitwieser and Salzberg, 2019) by using their data tables,
heatmaps, and Sankey flow diagrams.
RESULTS
Establishment of Method for Bacterial
DNA Isolation From BCBs Inoculated
With PJT
Since there is no standard procedure for the isolation of DNA
from BCBs inoculated with PJT, we initially examined the
performance of QIAamp BiOstic Bacteremia DNA Kit pre-
treated and untreated with the MolYsis basic5 kit.
DNA from 25 positive BCBs (BacT/Alert R© FA Plus, aerobic
bottles) were isolated using the BiOstic kit with or without
pretreatment with MolYsis5. Comparison between the two
methods was based on the total DNA yield and the DNA
quality (Supplementary Table S1). DNA concentration
measurements showed that samples treated with MolYsis5
yielded a higher mean DNA concentration (DNA 84.23
ng/µL, p = 0.0069), than untreated samples (65.28 ng/µL)
(Supplementary Tables S2, S3). Both procedures yielded
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relatively pure DNA with median absorbance ratios of 1.81
(IQR = 1.67–1.90) and 1.88 (IQR = 1.8–2.02), respectively
(Supplementary Figures S1A,B).
In order to evaluate the level of bacterial DNA within
total DNA, qPCR was performed. Amplification on undiluted
DNA extracts failed to amplify in all the cases, while
amplification of DNA diluted 1:100 and 1:1000, revealed
that the average bacterial DNA concentration was 21.35
ng/µL in untreated samples and 28.53 ng/µL in the MolYsis
treated samples (Supplementary Figures S1C,D). All DNA
samples contained at least 1 pg bacterial DNA/µL meeting
the requirements needed to be considered eligible for SMg.
DNA from negative controls contained 0.79% (3.6 pg/µL)
and 0.04% (0.2 pg/µL) bacterial DNA without and with
MolYsis treatment, respectively. The percentage of bacterial
DNA was significantly different between the pre-treated and
the untreated samples (p = 0.0207) (Supplementary Table S4).
In conclusion, these studies reveal that high quality microbial
gDNA was obtained from PJT on BCB samples pre-treated and
untreated with MolYsis5.
SMg Pilot Study – DNA Sample
Preparation Method for Further Assays
Two DNA samples (from the same BCB inoculated with a PJT
clinical sample) extracted using each of the two DNA sample
preparation methods [pre-treated (S1b) and untreated (S1c)],
were sequenced using illumina MiSeq sequencing technology.
In total, 14,785,194 and 14,078,494 raw reads were obtained
from the DNA pre-treated and untreated with MolYsis5,
respectively. The two samples were analyzed for the presence
of contaminant DNA from human and horse sources in
order to determine the proportion of contaminant reads. After
preprocessing raw reads, we mapped the remaining reads against
a set of human and horse reference genomes. We detected
a 16-fold increase in the number of reads mapping to horse
and a 19-fold increase in the number of reads mapping
to human in the sample untreated with MolYsis5 (Table 2
and Figure 3).
One of the key issues in clinical metagenomics is to remove the
host DNA without a substantial loss of bacterial DNA. Samples
treated with MolYsis5 before DNA extraction with QIAamp
BiOstic seemed to be a suitable DNA preparation method to
continue with SMg from BCB.
Shotgun-Metagenomics
Shotgun-metagenomics sequencing of DNA from clinical
samples resulted in a mean number of 10,277,311 reads per
sample (range 7,236,776–16,172,074). Sequencing of DNA
from spiked samples produced a mean number of 9,831,669
(range 6,857,300–11,884,076) reads, and 11,192,852 total reads
were obtained from sequencing the negative control (DNA
without MolYsis5 treatment) (Supplementary Table S5). An
additional negative control pre-treated with MolYsis5 was
sent for sequencing, but no good library preparation could be
obtained due to low DNA yield (results not shown). Thus, only
the untreated negative control was used in the analyses.
Extracting Sufficient Bacterial DNA While
Removing DNA From Other Sources
In this study, raw reads were screened for the presence of reads
from the host, from the horse blood (added to the bottles to
enrich the BCB media), and from PhiX phage used as control
during the sequencing process.
Overall, DNA from clinical samples presented a mean
proportion of reads classified as human (0.07%), horse (0.61%),
and PhiX (0.08%) lower than one percent. Similar results
were observed when analyzing DNA from the spiked samples,
where the mean proportion of reads mapping to the reference
genomes of human were 0.26%, horse 0.56%, and to the PhiX
phage 0.10%. For both cases, more than 99% of the reads
did not map to any of the reference genomes used during
the alignment (Figure 3). A different pattern was observed
when analyzing the negative control, the mean proportion of
reads mapped to human (1.4%) and horse (87.6%), while for
the PhiX phage, no difference was observed (0.01%). Two
percent of the reads did not map to any of the reference
genomes (horse, human and PhiX) and were then used for
taxonomical analyses (Figure 3 and Supplementary Table S5).
Overall, samples untreated with MolYsis5 (NC and S1C)
presented more reads mapping to the horse and human
genomes. In addition, the proportion of reads mapping to the
horse genome is higher than the human genome in all the
samples (Figure 3).
After preprocessing the raw data, we obtained a mean
number of 9,510,050 (92.86%) reads from the clinical samples,
and 7,936,436 (86.80%) from the spiked samples, while from
the negative control only 187,094 reads (1.67%) remained for
taxonomical analyses (Supplementary Table S5).
Kraken was used to assign a taxonomic label to each read for
estimating the relative proportion of species in the samples and
to determine the relative amount of sequences that came from the
known bacteria identified in the sample. Taxonomic classification
by Kraken when analyzing data from clinical samples identified
a median of 96.08% (IQR, 93.85–97.07%; range 85.7–98.6%)
bacterial reads. Spiked samples presented a median of 98.7%
(IQR, 96.90–98.70) bacterial reads, while for the negative control,
the proportion of bacterial reads was 30% (28,058 reads)
(Supplementary Table S6). In addition, when comparing the
pre-treated (sample S1b) and the untreated sample (sample S1c)
more reads were classified as bacterial reads (95.74%) for the pre-
treated sample than for the untreated sample (86.89%). Overall,
two percent more bacterial reads were obtained from the spiked
samples than in the clinical samples. Additionally, treatment of
the sample with MolYsis5 prior to DNA extraction resulted in
a higher proportion of bacterial reads when compared with an
untreated sample.
When estimating the number of reads classified at the genus
and species level (inferring the abundance of the number of
individuals from each taxon by correction for genome length
into abundance estimates by Bracken), it was on average higher
than 97.7% for both taxonomic levels (genus and species) and for
both sample types (DNA from spiked and clinical specimens).
In the negative control, 30.1% of the reads were classified to
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TABLE 2 | Reads affiliated to human and horse genomes when sample was treated (1b) and untreated with MolYsis5 (1c).
Sample code DNA preparation method Reads analyzed Human reads (%) Horse reads (%)
Treated (1b) MolYsis5 + BiOstic 13,417,582 14,521 (0.01) 135,751 (0.9)
Untreated (1c) BiOstic 12,698,920 249,520 (0.1) 2,365,316 (16.7)
FIGURE 3 | Proportion of the contaminant reads that mapped to PhiX, horse and human reference genomes or to multiple genomes. S1–S9, clinical samples;
PC1-3, spiked samples (positive controls); NC, negative control. aSamples untreated with Molysis5.
the genus and species level while the rest remained unclassified
(Supplementary Table S7).
Identification of Bacterial Species
Reported as Common Cause of PJI by
SMg
Nine of the PJT clinical samples in this study had previously been
analyzed using a conventional and a BCB method (Sanabria et al.,
2019). Bacterial identification for both methods was done using
MALDI-TOF. According to the results obtained from the BCB
method, S. aureus was identified in sample 1 (S1b), 2 (S2), 3 (S3),
4 (S4), and 7 (S7). Enterococcus faecalis was identified in sample 6
(S6), while in sample 8 (S8) and 9 (S9) Staphylococcus epidermidis
was found (Table 3).
All bacterial species identified from the BCB culture method
were detected by Kraken and MetaPhlAn, and they were
found to be the most abundant species present in the sample
(Supplementary Figure S2). The mean rate of the most abundant
bacteria in the clinical samples were 97.9 and 99.2% for the spiked
samples when using Kraken/Bracken. Similar results were found
using MetaPhlAn2, with 99.2 and 96.9% mean rates for clinical
and spiked samples, respectively.
The conventional culture results were all negative in
samples S7–S9, while the BCB method and the SMg were
consistent concerning bacterial species found (Table 3).
Bacteria detected by the conventional methods and by
SMg (Kraken/Bracken and MetaPhlan2) are listed in
Table 3. The taxonomic classification results for each
sample type excluding the negative control as estimated
by Kraken/Braken are presented in Figure 4. Similarly,
a heat map representing the relative abundance at the
species level as estimated by MetaPhlAn2 can be found in
Supplementary Figure S3.
Additionally, we tested the influence of downsizing the
number of reads (by subsampling reads) in the estimation
of abundance of species present in both the clinical and
spiked samples. We observed that the number of species
detected is higher at increasing sequencing depths and
that the taxonomical distribution did not change. The
potential pathogen species found in culture could still
be detected even if a smaller proportion of reads were
subsampled (10%). A rarefaction curve was used as a
qualitative method to estimate the species abundance as a
function of sequencing depth (Supplementary Figure S4).
Rarefaction curve reaches plateau just for a few samples
suggesting that saturation in sequencing was not achieved
and deeper sequencing is required to detect all the species
present. However, estimating the diversity is not the end point
in PJI diagnoses.
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TABLE 3 | Microorganisms identified in the samples using laboratory and SMg methods.
Sample Microorganism identified
Laboratorya (MALDI-TOF) SMg
No Code BCB Conventional Kraken/Bracken MetaPhlAn2
1 S1b S. aureus S. aureus S. aureus (99.6%) S. aureus (100%)
2 S2 S. aureus S. aureus S. aureus (99.5%) S. aureus (100%)
3 S3 S. aureus S. aureus S. aureus (99.9%) S. aureus (100%)
4 S4 S. aureus S. aureus S. aureus (89.8%) S. aureus (100%)
5 S5 S. aureus S. aureus S. aureus (99.8%) S. aureus (100%)
6 S6 E. faecalis E. faecalis E. faecalis (99.9%) E. faecalis (99.9%)
7 S7 S. aureus No growth S. aureus (99.9%) S. aureus (100%)
8 S8 S. epidermidis No growth S. epidermidis (95.8%) S. epidermidis (99.9%)
9 S9 S. epidermidis No growth S. epidermidis (97.7%) S. epidermidis (99.9%)
10 PC1 S. aureus NA S. aureus (99.9%) S. aureus (100%)
11 PC2 E. coli NA E. coli (99.7%) E. coli (90.7%)
12 PC3 S. aureus NA S. aureus (97.3%) S. aureus (100%)
aResults from our previous study (Sanabria et al., 2019), BCB method and conventional method. PJT, Periprosthetic joint tissue; BCB, Blood culture bottle; SMg,
shotgun-metagenomics; S1–S9, clinical samples; PC1-3, spiked samples (positive controls); NC, negative control; NA, not applicable.
FIGURE 4 | Stacked bar plot displaying relative abundance of bacteria at the species level as estimated by Kraken/Bracken in positive BCBs with PJT. Y-axis is split
in two parts, and each part with their own linear scale. From 0 to 0.2 the scale highlights the small values of species relative abundance. S1-S9, clinical samples;
PC1-3, spiked samples (positive controls).
Reads belonging to spiked samples were mapped against the
reference genomes of the respective strains used for spiking. For
S. aureus and E. coli, more than 98% of the genome was covered
with at least 4× depth. We obtained a genome coverage depth of
775X for the sample spiked with S. aureus (PC1) and 209X for
the sample spiked with E. coli (PC2). In the sample spiked with
S. aureus and C. acnes, no reads were observed when mapping
against C. acnes reference genome; instead 99.98% of the reads
mapped to the S. aureus reference genome, covering 99.5% of its
genome (Supplementary Table S11).
Other Bacteria and Possible
Contaminants Detected by SMg
In addition to the metagenomic reads belonging to the same
bacteria found by the conventional methods, reads belonging
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to other bacterial species were also found by Kraken. Their
respective abundance was estimated by Bracken in the clinical
samples (mean: 1.98%; range 0.07–10.21%), and in the spiked
samples (mean: 0.12%; range 0.06–0.23%). For each of the sample
types, we provide the respective Sankey flow diagram with the
classification results from Kraken (Supplementary Figure S5).
Reads belonging to Staphylococcus argenteus were found
in samples, S1(a, b, c), S3 S4, S5, and S7 always at the
same relative abundance (0.02%) and in samples S8 and S9
at a lower abundance (0.000422 and 6.043e-05, respectively).
This bacterial species was not found in the negative control
(Figure 5). The most abundant bacterial species found by
Kraken/Bracken in the negative control were Bacillus cereus
(81.5%), S. aureus (10.3%), Bacillus weihenstephanensis (1.2%),
and E. coli (0.88%) (Figure 5). MetaPhlAn did not identify
B. cereus and B. weihenstephanensis, but instead identified
the yeast Saccharomyces cerevisiae as the most abundant
microorganism found in the negative control (72.5%). S. aureus
was also found by MetaPhlAn2 at a relative abundance of
14.7%. E. coli was not detected but instead we found Escherichia
unclassified (4.1%) which means “an unknown species in the
genus Escherichia.”
When analyzing the clinical and spiked samples, we found
B. cereus in all the samples in a very low abundance (mean,
0.0016%). It was 12-fold more abundant (0.02%) in the
sample untreated with MolYsis5 (sample S1c), supporting that
it is a contaminant in this study. S. aureus was found by
Kraken/Bracken in the negative control (10.3%), as well as in
samples S6, S8, S9 and in the sample spiked with E. coli with a
very low occurrence (mean, 0.58%; range, 0.03–1.2%).
DISCUSSION
Here we demonstrate proof of concept that it is possible to
perform SMg directly on PJT from BCBs with the potential of
pathogen identification in PJI diagnosis. Culturing of PJT on BCB
was the starting point for our study, and we validated our findings
by comparison with conventional culturing methods, where we
already knew the outcome, i.e., complete microbiological data
from culturing were available for all samples.
To the best of our knowledge, this is the first study applying
SMg to Bact/Alert R© BCBs (bioMérieux) inoculated with PJT.
Sample type greatly influences the composition of sequencing
reads, and due to the complexity of both the BCBs and the
PJT specimens, sample preparation and bacterial enrichment
methods need to be specifically adapted.
It is well-known that the success of metagenomics is highly
dependent on the quality and quantity of DNA extracted from
a given specimen (Schlaberg et al., 2017). Therefore, sample
preparation methods need to be developed and improved to
effectively reduce the amount of host nucleic acids, lyse host
cells to release intracellular organisms and lyse different types
of microbial cells to release nucleic acids, without affecting the
quantity of targeted nucleic acid in the sample (Forbes et al.,
2018; Vijayvargiya et al., 2019). Here we demonstrated that the
use of MolYsis5 kit together with BiOstic kit is an effective sample
preparation method for performing SMg directly from BCBs
inoculated with PJT. Our DNA preparation method resulted in
high quality microbial DNA from all samples, both with and
without human DNA depletion, allowing downstream SMg.
Thus, we conclude that preanalytical reduction of the human
DNA load improved the output of targeted sequence reads.
This is important since DNA samples overwhelmed with human
DNA sequences affect the sensitivity for the detection of
bacteria that occur in low abundance in clinical specimens.
In addition, we screened the samples and removed reads
belonging to the horse genome, since horse blood was used
as enrichment supplement for the BCB, which may affect the
sensitivity for bacterial detection as such. Moreover, this makes
the method more expensive, creates the need of subtracting
the human and horse sequences during the bioinformatic
analysis, which delays the analyses, and it requires a significant
computational power (Hasan et al., 2016). Overall, our method
consistently generated high DNA yield quantity/quality, removed
efficiently human/horse DNA (<1%) and there was no inhibition
observed during the SMg library preparation, allowing further
sequencing process.
In order to select samples suitable for sequencing, one of
the main criteria that was considered, was the bacterial DNA
concentration measured by qPCR. We observed that samples had
to be diluted to get amplification signals. qPCR results could not
be considered as selection criteria. In addition, the concentration
of bacterial DNA from qPCR did not correlate with the bacterial
rate obtained from the classification of the sequencing reads
(median of 96.08%). This result was not surprising since there
are several factors that can affect the qPCR amplification,
among them: the presence of amplification inhibitors commonly
found in BCBs formulations (e.g., the anticoagulant, sodium
polyaneththolesulfonate SPS) (Mäki, 2015), unspecific primer
binding to host DNA which decreases the sensitivity and
specificity, and the less likely in this case, due to an overload of
eukaryotic DNA (since low horse and human DNA were found
in the sequencing reads). However, the DNA preparation tool
MolYsis which eliminates the human background, also removes
other PCR-inhibiting substances contained in BCBs, like SPS
(Gebert et al., 2008).
Methods for the preparation of bacterial DNA from BCBs (BD
BACTEC, Becton Dickinson Sparks, MD) using SMg have been
reported earlier but for bloodstream infection diagnosis (Anson
et al., 2018). However, the methods included a pre-treatment
by differential centrifugation to remove human cells and DNA
purification with SPRI beads prior to sequencing. In their study,
the use of BiOstic kit provided a higher DNA yield than Molysis
Plus (430× greater), and the mean DNA yield obtained was lower
(E. coli, 39.3 ng/µL and S. aureus, 11.5 ng/µL) than the DNA yield
obtained in our study (Mean DNA concentration: 84.23 ng/µL
for MolYsis5 treated samples and 65.28 ng/µL for untreated
samples). These differences in result may be due to the type of
clinical specimen inoculated into the BCBs, the effectiveness of
the pre-processing and purification step, in addition to the fact
that the BCBs belong to different brands.
Our results showed that MolYsis5 kit together with BiOstic
kit was an effective DNA sample preparation method for the
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FIGURE 5 | Sankey visualization of the absolute read counts as estimated by Kraken/Bracken from the negative control sample. D, Domain; P, Phylum; F, family; G,
genus; D, domain.
detection of the PJI related species tested here. Many bacterial
and fungal species have been reported as being detectable after the
use of MolYsis (Horz et al., 2010; Thoendel et al., 2016; Schmidt
et al., 2017; Krohn et al., 2018). However, we are aware about
potential limitations that should be taken into consideration
when using MolYsis in the clinical diagnostics. Sample pre-
treatment with MolYsis involves lysis of human cells prior to
degradation of bacterial cell walls, allowing digestion of human
DNA by DNAse treatment (Thoendel et al., 2016). The use of
MolYsis provides a solution for the removal of host DNA and
enrichment of intact microorganisms (Votintseva et al., 2017).
However, free floating DNA is removed. This raises a question
about which bacterial DNA is removed during the MolYsis
treatment. Bacteria with weak or absent cell walls will be removed
by the use of Molysis prior to DNA extraction. Among them,
Mycoplasma, Ureaplasma, or Chlamydia, although unusual, are
among the many organisms capable of causing PJIs (Geipel, 2009;
Rieber et al., 2019). In addition, bacteria previously exposed to
cell wall-targeting antibiotics will also be lysed and removed by
the Molysis (Horz et al., 2010). This in turn raises some concerns
about the proposed usefulness of MolYsis for the diagnosis of
PJI when these bacteria are causing the infection. In these cases,
sample pre-treatment with MolYsis should be avoided. DNA
extraction with BiOstic without MolYsis pre-treatment can be
used instead since good results were also obtained when using
this approach in our study (sample S1c, untreated with MolYsis).
SMg for diagnosing PJI directly from tissue specimens has
been tested (Ruppé et al., 2017). However, from a huge cohort
of samples collected (n = 179), only few (n = 24) could
be sequenced due to insufficient amounts of bacterial DNA
recovered from the samples. SMg directly from sonication fluid
(from orthopedic devices), has been tested as well, and this
is the specimen related to PJI most extensively studied in
metagenomics approaches (Thoendel et al., 2016, 2017, 2018;
Street et al., 2017; Sanderson et al., 2018). Despite all these
promising efforts on metagenomics for diagnosing PJI, direct
sequencing of nucleic acids obtained from biological samples
results in a high background of DNA, mainly derived from the
host, hindering the detection of pathogens causing PJI. Thus, all
these studies support clearly that the main challenge has been
recovering enough bacterial DNA. Our approach was therefore
to test the use of SMg directly on BCBs inoculated with PJT to
try to solve the limitations observed when using SMg directly
on PJI specimens.
In our study, predominant bacterial species in PJT from BCBs
determined by SMg, were 100% concordant with the results
obtained from the BCB culture method. Results were consistent
with respect to both the genus and species levels. We were able
to detect S. aureus, S. epidermidis, E. faecalis, and E. coli in the
samples, indicating the potential of the method for detection of
species commonly related to be the cause of PJI. The predominant
species (mean rate: 97.9%), reads belonging to other bacterial
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species were also found by the taxonomical classifier in a very low
proportion (mean rate: 1.98%).
Apart from the development and/or improvement in the DNA
sample preparation methods, one of the greatest challenges in
the use of SMg for identification of pathogens is the type of
controls (Couto et al., 2018). Positive controls should represent
the range of organisms that can be encountered in the clinical
specimen (Greninger and Naccache, 2019). In this study, three
spiked samples were included as positive controls. Two of them
spiked with one bacterial species (S. aureus or E. coli) and one
with two bacterial species (S. aureus and C. acnes). High breadth
and depth coverage were obtained when mapping the SMg reads
to S. aureus or E. coli reference genomes, respectively. However,
C. acnes was not found in the SMg taxonomical analyses of the
spiked control sample. It could be several reasons for this, but we
believe that it was due to mistakes in the experimental design.
S. aureus and C. acnes were spiked into the BCB at the same
time and we know from our previous study (Sanabria et al., 2019)
that C. acnes grows slower (mean time to detection: 8.7 days)
than S. aureus in the Bact/Alert R© BCBs. The positive control was
incubated in an aerobic BCB until positive, i.e., in this case 10.3 h
after incubation. We believe that the absence of reads belonging
to C. acnes is due to the fact that the bacterium did not have
enough time to grow. In addition, S. aureus might be a strong
competitor. Another possible explanation could be incomplete
lysis of C. acnes during the DNA sample preparation and the lack
of sensitivity of the SMg to detect the anaerobic C. acnes.
For the case of the negative control, we used a BCB medium
enriched with horse blood and inoculated with sterilized tissue
from a donor without suspicion of infection. We consider that
this negative control adequately reflects the contaminant or
background microorganisms originating from tissue specimens,
BCB media, horse blood, reagents, the environment and other
sources as from other samples and sequencing runs (Eisenhofer
et al., 2019; Huang et al., 2019). Results showed that from 93,502
reads, only 28,194 could be classified (30%).
In the negative control, we found taxa reported as common
contaminants (DNA extraction blank controls and no-template
controls) (Eisenhofer et al., 2019), e.g., Bacillus, Staphylococcus,
Enterococcus and Streptococcus. We also found some reads
classified as B. cereus in several of the clinical samples (in a
very low abundance, mean: 0.0016%) and this bacterium was
found 12-fold more abundant (0.02%) in the sample not treated
with Molysis5 (sample S1c). Bacillus spp. is often considered
a contaminant when it is isolated from BCBs and in negative
controls (Doern et al., 2020). However, the significance of this in
SMg on samples from BCBs is unknown.
We also found some reads assigned to S. aureus (10.3%)
and E. coli (0.88%) in the negative control. Since these bacteria
are among the most common causes of PJI (Tande and Patel,
2014; Izakovicova et al., 2019), these reads were evaluated by
aligning the reads against the reference genomes of the strain with
the highest assignment number of reads. When visualizing the
mapping results, reads mapped with genetic areas belonging to
coding sequences annotated as RNAs with a very low coverage
depth, and they were not distributed all over the genomes.
These may be reads originating from laboratory, in silico or kit
contaminants. Contamination is one of the main concerns in PJI
diagnostics and even more in metagenomic sequencing.
Reports have demonstrated that even the commercial kits
for DNA extraction and library preparation are potential for
contamination leading to misinterpretation of sequencing data
from clinical specimens (Salter et al., 2014; Eisenhofer et al.,
2019). It is therefore recommended to include and sequence
negative controls when performing SMg studies.
The spectrum of organisms defined as reportable by SMg
assays should be defined, and organisms determined to be
background contaminants or clinically insignificant should be
described (Gu et al., 2019). Defining a contaminant is not clear
for blood cultures in the laboratory and present a challenge for
SMg (Greninger and Naccache, 2019). Many factors should be
considered when interpreting the results from SMg especially
because the results are highly dependent on the database used
for the analysis, which could be incomplete for rare pathogens
or biased toward certain organisms, in addition to the fact
that contamination with normal flora and reagents are a
common occurrences that can limit specificity (Gu et al., 2019).
Consequently, it is very important to be careful when analyzing
the clinical significance of the results.
The most common in silico decontamination method in
practice is the removal of sequences below a determined
detection threshold (Davis et al., 2018). Usually, software used
for taxonomical classification such as Kraken can predict a lot
of species. Although we have limited clinical data to distinguish
between true PJI and contamination, we tested the effect of
several thresholds on the estimation of species abundance in the
samples. We observed that the number of species detected in the
samples are highly dependent on the threshold value used during
the analyses (Supplementary Figure S6 and Supplementary
Table S10). The results presented here prove that for species
detection, thresholds may often lead to different inferences while
interpreting the diagnostic results. Consequently, when using
SMg, thresholds need to be validated in each specific case for
an accurate interpretation of the results (Schlaberg et al., 2017).
In our case, unfortunately we cannot allow to give an exact cut-
off value, due to limited access to clinical data of our samples.
However, others have set optimal thresholds for differentiating
low-level contaminations from true PJI when using SMg on
sonication fluid (Street et al., 2017; Ivy et al., 2018).
There is no standard method for interpreting metagenomic
sequencing results. Contaminant DNA in SMg is a challenge
for clinical interpretation of metagenomics data (Peel et al.,
2016; Thoendel et al., 2016; Ruppé et al., 2017; Street et al.,
2017; Thoendel et al., 2017; Ivy et al., 2018; Simner et al.,
2018; Thoendel et al., 2018). We cannot exclude the possibility
of contamination in our study. As in most studies, all our
samples contained read identifications for microorganisms other
than known or suspected pathogens. In order to determine if
the bacterial species found are infection inducing pathogens,
background contaminants or noise, we observed that there
are several aspects that can help to differentiate them, among
them: (i) The proportion of reads assigned to the species
present. The possibility of obtaining quantified abundances
of microorganisms is important for distinguishing causative
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pathogens (Greninger and Naccache, 2019). In our case, we
considered that a high proportion of reads belonging to the
most abundant bacteria present in the samples (97.9% mean
rate) could be an indicator of the bacterium causing the
infection. (ii) Genome coverage and the proportion of the
genome covered, higher depth and breadth coverage expected
for the pathogen species with respect to other species detected
by the taxonomical classifier. For pathogen detection it is even
more important because sequencing depth also affects analytic
sensitivity (Schlaberg et al., 2017; Couto et al., 2018). (iii)
Comparison with respect to the species and to the proportions
of reads found in the negative control and in the spiked samples,
and (iv) To set an appropriate threshold, for pathogen detection.
Regarding this, it is important to limit the number of species
identified, for minimizing false-positive results, increasing the
detection rate of potential true pathogens and reducing the
misclassification of other species related signals as potential
pathogens (Couto et al., 2018). It is important to consider
that setting up cut-off values for pathogen detection may result
in decreased sensitivity. Therefore, it is better to rely on the
relative abundance of bacterial species in addition to the genome
coverage and the proportion of the genome covered.
It is important to predict the level at which samples should
be sequenced to prevent excessive sequencing and to answer our
biological question (Sims et al., 2014). The relatively high cost for
metagenomic sequencing is a major limitation for application in
the clinical setting (Ruppé et al., 2017). Significant reduction in
the cost of metagenomic sequencing is required for moving up in
the diagnostic pipeline (Greninger, 2018). Multiplexing samples
offers the possibility of decreasing the costs by decreasing the
number of reads per sample. The question is how many reads
are needed to answer a particular question (Mulcahy-O’Grady
and Workentine, 2016). In this study, we wanted to assess the
potential of SMg for the detection of bacterial species known
as common causes of PJI. We analyzed the effect of reduction
in sequencing depth (expressed as proportion of reads) for the
detection of potential PJI pathogens and, we observed that even
while using the minimal proportion of reads subsampled (10%)
we were able to detect S. aureus (Supplementary Figure S7).
This result suggests that presumably less sequencing depth is
needed for detection of common PJI pathogens, more samples
can be multiplexed in a sequencing lane, accomplishing a lower
cost per sample. However, it is important to be aware that
the impact of a lower sequencing depth to provide additional
information beyond pathogen detection was not considered in
this study. Nevertheless, the results obtained in this study open
the possibility for studying antibiotic resistance determinants and
virulence genes at further stages.
Our study has the following technical limitations: (1) Low
total number of clinical samples analyzed trough shotgun-
metagenomics (n = 9) and just one sample per patient. (2)
Limited clinical data about the patients making it difficult to
define a sample selection criterion to distinguish between true
PJI and contamination; (3) Negative samples by conventional and
BCB culture methods were not included. (4) Only aerobic BCBs
were included. (5) Absence of polymicrobial samples (all samples
tested were monomicrobial by culture). (6) In comparison with
the conventional and the BCB culture methods, the application of
SMg is limited by the expensive equipment and operational costs.
The use of clinical metagenomics approaches will increase
during the next years in research and in medical microbiology
laboratories (Deurenberg et al., 2017). The application in
clinical microbiology is still in its infancy, which encourage
further research on alternative and complementary tools for PJI
diagnosis. There are ongoing discussions about the obstacles
associated with the adoption of metagenomics in diagnostics and
their clinical utility (Greninger, 2018; Chiu and Miller, 2019; Han
et al., 2019). However, we do not believe that SMg can replace
conventional culturing, but it can be a potential diagnostic tool
to support conventional culture in cases when PJI diagnosis
is challenging, e.g., with fastidious organisms, discrepancies
between conventional methods, or in culture negative cases.
In conclusion, our DNA preparation method resulted in high
quality microbial DNA from all PJT samples, both with and
without human DNA depletion, allowing downstream SMg. By
SMg we were able to identify relevant PJI pathogens, and all
bacteria identified by culture were also identified through SMg.
A high enough sequencing depth was obtained indicating that it
is possible to multiplex samples reducing costs considerably. We
achieved a high sequencing quality, low human DNA content,
high number of reads and complete genome coverage of sufficient
depth that technically can be used for AMR prediction, virulence
gene detection and bacterial typing.
We consider this an essential step in further studies for solving
the challenges presented in PJI diagnosis, e.g., when bacteria are
not detected by the laboratory methods but there is still clinical
signs of the presence of infection (Peel et al., 2016). It is still
possible to extract DNA from a negative BCB and analyze if
pathogenic bacteria are present. In fact, the results of SMg can
also be valuable even when concordant with laboratory results,
not only providing a guarantee that the laboratory diagnosis
is correct, but also allowing extra information, e.g., detecting
coinfections and/or predicting antimicrobial susceptibility. Our
results can be useful for further validation and standardization
for the use of SMg on BCBs inoculated with clinical samples
for routine diagnostics of pathogens. It is still a long way until
SMg can be used in the clinical microbiology laboratory, but
this SMg approach presents an alternative tool in PJI diagnosis,
complementing the currently available tools.
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Supplementary Figure S5. Sankey flow diagram of Kraken reports from all the BCBs with PJT evaluated. S1-S9: clinical samples, PC1-3: spiked 
samples (positive controls), NC: negative control. 
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Supplementary Table S1. DNA Extraction results obtained from the two sample preparation 
methods tested.  
Sample 
No 
DNA sample preparation methods 




















 DNA ng/µl 
1 27,6 23,5 1,88 1,85 0,22 75,4 81 1,8 1,97 4,2 
2 5,8 6,5 2,06 1,04 1,7 27 45,8 1,94 2,22 7,8 
3 94,6 70,3 1,86 2,17 0,058 114 213 1,7 1,4 4,26 
4 80 103,5 1,83 2,11 4,57 62 111 1,68 1,49 60,15 
5 110 104,4 1,77 1,85 19 98 103,8 1,77 1,81 45 
6 110 101,6 1,8 1,95 49 116 484,6 2,04 2,29 50 
7 59,2 42,5 1,86 2,21 17,3 99,8 433,6 2,08 2,3 16,3 
8 94,4 81,9 1,87 2,32 51 114 109,7 1,82 1,97 43 
9 83,4 540,1 2,06 2,27 66 94,8 610 1,98 2,18 74,1 
10 52,2 272,7 2,09 2,2 25 75,4 259,8 1,96 2,03 45,2 
11 62,6 494,6 2,07 2,26 27,1 74,6 151,3 1,85 1,99 30,9 
12 55 218,6 1,99 2,27 29 68 138,4 1,88 1,96 20,61 
13 55,6 383,8 2,09 2,27 3,19 74,4 134,7 1,83 2,04 30,3 
14 66,8 472,9 2,1 2,33 33 78,4 162,2 1,85 2,01 50,8 
15 17,1 62,7 1,91 1,77 7,2 16,6 34,8 1,66 1,23 13,7 
16 65,2 178,4 1,93 2,38 25,93 78,4 295,1 1,81 1,96 29,8 
17 66,8 191,2 1,95 2,4 29 77,2 298,9 1,79 1,96 0,54 
18 86,8 82,2 1,7 1,21 11,7 100 149,2 1,78 1,42 17,2 
19 51,6 100,2 1,36 0,85 24,2 49 143,2 1,68 1,32 23,73 
20 66,8 115,6 1,79 1,8 22 47 106,9 1,56 1,07 55,47 
21 60,6 65,1 1,82 2,03 13,8 47,8 65,1 1,36 0,85 21,5 
22 36 16,8 1,8 1,59 1,88 110 67,4 1,92 1,92 5,82 
23 91 65,4 1,85 2,04 7,39 245 193,3 1,81 1,63 41,3 
24 118 216,7 1,9 2,23 63,7 104 110,5 1,49 0,98 6 
25 15 32,4 1,65 0,95 0,78 59 65 1,67 1,56 15,6 
 
Supplementary Table S3. Results from the statistical test (Wilcoxon rank sum test) applied 
to the total DNA concentration results obtained, for evaluating the statistical significance 
amongst the two sample preparation methods tested. 
 
Table Analyzed DNA concentration 
    
Column B MolYsis5 + BiOstic 
vs. vs. 
Column A BiOstic 
    
Wilcoxon matched-pairs signed rank test   
    P value 0,0069 
    Exact or approximate P value? Exact 
    P value summary ** 
    Significantly different (P < 0.05)? Yes 
    One- or two-tailed P value? Two-tailed 
    Sum of positive, negative ranks 260.5 , -64.50 
    Sum of signed ranks (W) 196 
    Number of pairs 25 
    Number of ties (ignored) 0 
    
Median of differences   
    Median 13 
    
How effective was the pairing?   
    rs (Spearman) 0,6837 
    P value (one tailed) <0.0001 
    P value summary **** 
    Was the pairing significantly effective? Yes 
Supplementary Table S4. Results from the statistical test (Wilcoxon rank sum test) applied 
to the bacterial DNA concentration results obtained by qPCR, for evaluating the statistical 
significance amongst the two sample preparation methods tested. 
 
Table Analyzed qPCR_Bacterial_DNA 





Column A BiOstic 
    
Wilcoxon matched-pairs signed rank 
test   
    P value 0,0207 
    Exact or approximate P value? Exact 
    P value summary * 
    Significantly different (P < 0.05)? Yes 
    One- or two-tailed P value? Two-tailed 
    Sum of positive, negative ranks 247.5 , -77.50 
    Sum of signed ranks (W) 170 
    Number of pairs 25 
    Number of ties (ignored) 0 
    
Median of differences   
    Median 5,5 
    
How effective was the pairing?   
    rs (Spearman) 0,4493 
    P value (one tailed) 0,0121 
    P value summary * 









Supplementary Table S6. Descriptive statistics from the Taxonomic classification by Kraken when analyzing data from all type of samples. 







Parameter Bacterial reads all (%) Bacterial reads CS (%) Bacterial reads PC (%) Viral reads_all (%) Viral reads_CS (%) Viral reads_PC (%)
Number of values 15 9 3 15 9 3
Minimum 30,01 85,73 96,9 5,88E-05 5,88E-05 0,0001127
25% Percentile 93,82 93,85 96,9 0,0001429 0,0001111 0,0001127
Median 96,08 96,08 98 0,006226 0,001229 0,001836
75% Percentile 97,24 97,07 98,7 0,1168 0,1384 0,006226
Maximum 98,7 98,6 98,7 0,5857 0,5857 0,006226
Range 68,69 12,87 1,8 0,5856 0,5856 0,006113
Mean 90,72 94,95 97,87 0,1007 0,09688 0,002725
Std. Deviation 17,23 3,783 0,9074 0,1895 0,1929 0,003152
Std. Error of Mean 4,449 1,261 0,5239 0,04893 0,06432 0,00182
Coefficient of variation 18.99% 3.984% 0.9272% 188.1% 199.2% 115.7%
Sum 1361 854,6 293,6 1,511 0,872 0,008175
Supplementary Table S7. Kraken and Bracken general classification results (number of reads and proportion of reads classified). S1-S9: 










Supplementary Table S8. Number of Species and genera determined by Kraken when no 
threshold was considered. S1-S9: clinical samples, PC1-3: spiked samples (positive controls), 


























Sample  Number of species Number of genera 
S1b 98 36 
S2 113 51 
S3 64 23 
S4 105 33 
S5 82 32 
S6 75 37 
S7 99 55 
S8 71 34 
S9 53 18 
PC1 126 62 
PC2 121 53 
PC3 71 27 
NC 107 78 
Supplementary Table S9. Descriptive statistics from the Number of Species and genus 
determined by Kraken when no threshold was considered. CS: clinical samples, all: clinical 
samples and spiked samples (positive controls). 
 
  
Number of  
species_all 






Number of values 13 13 9 9 
          
Minimum 53 18 53 18 
25% Percentile 71 29,5 67,5 27,5 
Median 98 36 82 34 
75% Percentile 110 54 102 44 
Maximum 126 78 113 55 
Range 73 60 60 37 
          
Mean 91,15 41,46 84,44 35,44 
Std. Deviation 23,24 17,15 20,36 11,76 
Std. Error of Mean 6,447 4,758 6,787 3,92 
          
Coefficient of variation 25.50% 41.37% 24.11% 33.18% 
          
Sum 1185 539 760 319 
Supplementary Table S10. Estimated number of species related reads when using different 
detection thresholds (expressed as number of reads). S1-S9: clinical samples, PC1-3: spiked 




Supplementary Table S11. Results from mapping of spiked sample reads against reference 









































GCF_000756205.1 5 203 440 8 030 844 8 029 324 1 440 2 806 345 99,5 583X 
a Total number of covered bases with a coverage depth bigger or equal to 4X. PC1-3: spiked 
samples (positive controls). 
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